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Adipokines, soluble factors produced by adipocytes, may help to connect diabetes 
and obesity; one such adipokine is visfatin.  Previous research has linked visfatin and 
visfatin gene (PBEF1) polymorphisms with glucose and obesity-related conditions; 
however, less is known regarding visfatin’s response to an aerobic exercise training 
intervention, and no one, to our knowledge, has examined whether polymorphic variation 
in the PBEF1 gene affects aerobic exercise training-induced changes in glucose and 
obesity-related variables.   
Thus, this retrospective study investigated whether 6 months of aerobic exercise 
training reduced plasma visfatin levels in individuals with impaired glucose tolerance 
(IGT) or normal glucose tolerance (NGT).  In addition, we examined the influence of 
common PBEF1 gene polymorphisms (-4689 G>T, -1543 C>T, -1001 T>G, -948 G>T, 
  
and SER301SER) and haplotypes on glucose and obesity-related variables and their 
responses to aerobic exercise training. 
Following the completion of 6 weeks of dietary stabilization, 116 healthy, 
sedentary, middle-aged, Caucasian men and women underwent 6 months of aerobic 
exercise training.  Glucose total area under the curve (AUC), insulin AUC, and insulin 
sensitivity were measured via oral glucose tolerance tests.  Plasma visfatin was measured 
using an enzyme immunoassay in 67 of the participants (22 with IGT, 45 with NGT), and 
standard techniques were used to assess lipoprotein-lipid and body composition variables.  
Restriction fragment length polymorphism techniques and TaqMan assays were used to 
determine PBEF1 genotypes.   
We found that plasma visfatin levels were comparable in IGT and NGT 
individuals at baseline and increased similarly in both groups in response to aerobic 
exercise training.  We also found associations at baseline between glucose and obesity-
related variables and PBEF1 gene variants, with -4689, -1001, -948, and SER301SER 
variant allele groups and PBEF1 variant allele-containing haplotypes having higher 
insulin sensitivity.  Last, PBEF1 genetic variation influenced the aerobic exercise 
training-induced change in glucose and obesity-related variables.  Moreover, the -948 
polymorphism, TCGTT haplotype, and TCGGT haplotype were associated with 
lipoprotein-lipid changes with training, and the SER301SER polymorphism influenced 
changes in BMI and body fat.  Future studies need to address the functional significance 
of PBEF1 polymorphisms and haplotypes and clarify mechanisms connecting visfatin to 
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Chapter 1: Introduction 
The prevalence of diabetes is reaching epidemic proportions in the United 
States and throughout the World with estimates predicting that over 360 million 
people will be afflicted by the year 2030 (124).  Associated with type 2 diabetes 
(T2D) are insulin resistance and obesity, risk factors that often precede the 
development of the disease.  Consequently, the prevalence of obesity is also reaching 
epidemic status in the United States, with over 65 % of American adults reportedly 
overweight or obese (101).  Furthermore, adipose tissue is a metabolically active 
organ and adipokines, soluble factors produced by adipocytes, may further link 
obesity and insulin resistance; one such adipokine is visfatin. 
Visfatin History 
In 2004, Fukuhara and colleagues reported the isolation of an adipokine 
prevalent in the visceral fat of humans and mice, which they termed visfatin (35).  
Previously isolated in lymphocytes and also found to be expressed in skeletal muscle, 
liver, and bone marrow, visfatin was first identified in 1994 as a cytokine-like 
molecule, enhancing the effects of interleukin-7 and stem cell factor on pre-B-
lymphocyte colony formation, known as pre-B cell colony-enhancing factor (PBEF) 
(102).  Additionally, Jia and colleagues reported that PBEF was an inflammatory 
cytokine since it was upregulated in neutrophils and acted to inhibit/delay neutrophil 
apoptosis in experimental inflammation and sepsis (54).  PBEF also was reported to 




in nicotinamide adenine dinucleotide (NAD) salvage pathways and suggested to be a 
regulator of mammalian health and longevity (127). 
Visfatin & Metabolism 
Fukuhara and colleagues, via their series of experiments involving cell 
culture, rodent models, and humans, extended the realm of PBEF/Nampt/visfatin to 
include glucose metabolism and obesity, asserting its insulin-like effects (35).  Until 
its retraction in 2007 (36), Fukuhara and colleagues’ paper was considered seminal in 
this area, and although Xie and colleagues (126) reported similar insulin-mimetic 
actions for visfatin in osteoblasts, other researchers have not been able to replicate the 
earlier findings of Fukuhara’s group (97).  Furthermore, Revollo and colleagues have 
proposed that visfatin’s connection to glucose and obesity-related variables is via its 
role as Nampt.  Moreover, they proposed a mechanism linking Nampt to NAD 
biosynthesis and metabolism through the maintenance of nicotinamide 
mononucleotide (NMN) and NAD levels and subsequent activation of NAD-
dependent factors such as the sirtuin family (95; 97).   
Briefly, the pathway proposed by Revollo and colleagues begins with 
nicotinamide absorption from the diet and distribution to the body’s tissues.  If taken 
up by cells, nicotinamide’s conversion to NMN would be mediated by intracellular 
Nampt.  If not removed from the circulation, extracellular Nampt could convert 
nicotinamide to NMN, which would then be transported to the tissues for uptake.  
Once inside of cells, NMN adenylyltransferase (Nmnat) would complete the reaction 
to produce NAD.  Then, via its involvement in transcriptional regulation, NAD would 




One such target of NAD is the sirtuin family, as NAD cleavage is required for 
their deacetylase and ADP-ribosylation reactions.  There are 7 mammalian sirtuins 
(SIRT1-7), and SIRT1 has been shown to regulate genes involved in pancreatic beta 
cell insulin secretion (14; 80), beta cell survival (60), adipogenesis (91), lipolysis (38; 
91; 99), gluconeogenesis (98; 99), and cholesterol degradation (99).  SIRT3 may also 
be involved, as it reportedly activates acetyl-coenzyme A synthetase (47), an enzyme 
important in the formation of acetyl coenzyme A, which is involved in the citric acid 
cycle, cholesterol synthesis, and fatty acid synthesis.  Finally, SIRT4 has been linked 
to amino acid-stimulated insulin secretion (46).  Thus, visfatin may be 
mechanistically linked to metabolic processes via its function as Nampt.   
Regardless of the mechanism, numerous investigators have examined 
visfatin’s potential role in glucose and obesity-related conditions.  Although the 
results have not been entirely consistent (Tables 1-1 and 1-2), most studies have 
found increased circulating levels of visfatin in type 1 diabetes [T1D; (43; 74)], T2D 
(22; 29; 31; 74; 94; 104), gestational diabetes [GDM;(68; 72)], obesity (7; 25; 37; 41; 
45; 56; 76; 131), polycystic ovary syndrome [PCOS; (19; 66; 113)], advanced chronic 
kidney disease [CKD; (9; 130)], and metabolic syndrome (7; 32; 133) patients as 
compared to healthy or less-diseased individuals.  As shown in Table 1-3, several 
studies have also found significant correlations between circulating visfatin and 
glucose and obesity-related variables including fasting insulin (69; 72; 74; 113; 131), 
insulin sensitivity [assessed via homeostasis model assessment-insulin resistance; 
HOMA-IR; (69; 113; 120)], fasting glucose (32; 131), visceral fat (7; 120), body 




have also been correlations reported between the surgical weight loss-related change 
in visfatin levels and the change in fasting insulin (45; 69) and insulin sensitivity (45; 
69).  However, these relationships have not always been consistent (Table 1-3). 
The disparity in previous visfatin studies may be partly due to study designs 
that have failed to account for the effects of diet and/or exercise.  Furthermore, only 
10 studies have mentioned some sort of subject dietary and/or physical activity 
criteria.  Of these, 5 studies included dietary information/exclusion criteria (17; 40; 
56; 69; 88), 4 included physical activity information (25; 43; 77; 89), and 1 included 
both dietary and physical activity information (110).  In addition, very few of the 
studies involving female participants reported menopausal status or hormone 
replacement therapy usage, either of which could also have influenced many of the 
outcome variables.  Thus, studies assessing visfatin levels that also account for the 
effects of diet, physical activity, and/or female menopausal status may help to clarify 
some of the discrepant findings from previous reports. 
Visfatin & Genetics 
The visfatin gene (PBEF1) is located on chromosome 7q22.  This 
chromosomal region has previously been reported to have linkage with the insulin 
response to aerobic exercise training in Caucasians (70), insulin resistance syndrome 
phenotypes in Mexican-Americans (8), and BMI in the National Heart, Lung, and 
Blood Institute’s Family Blood Pressure Program (125).  Thus, based on its 
chromosomal location, the visfatin gene may be a candidate for glucose and obesity-
related phenotypes.  Furthermore, over 52 single nucleotide polymorphisms have 




diseases, including glucose and obesity-related conditions.  Two such polymorphisms 
are the -1001 T>G and -948 G>T.  Moreover, the -1001 polymorphism has been 
associated with fasting glucose (11), fasting insulin (11), and waist-to-hip ratio (64), 
whereas the -948 variant has been associated with T2D (132), fasting insulin (11; 16), 
2-hour oral glucose tolerance test (OGTT) glucose (16), lipoprotein-lipids (11), and 
diastolic blood pressure (64).  Both of these SNPs occur at a relatively common 
frequency in the population, with reports ranging from 0.25-0.26 (9; 11; 64) and 0.12-
0.19 (11; 16; 64; 132), respectively.   
An additional promoter polymorphism, the -1543 C>T (also known as -1535), 
has been found to have a functional effect, reducing transcription in human lung 
microvascular endothelial cells (129), but a more recent study reported no alteration 
in transcription in mouse adipocytes (115).  The -1543 C>T polymorphism has not 
been studied in connection with glucose and obesity-related traits in Caucasians, 
although in Japanese individuals it was associated with differences in HDL-
cholesterol and triglyceride levels, but not with T2D, glucose, insulin, or insulin 
sensitivity (115).  Its frequency has been reported as ~ 0.31 (129).   
Along with these 3 SNPs, the -4689 G>T polymorphism covers much of the 
variation in the promoter region of the PBEF1 gene.  Moreover, Bailey and 
colleagues reported a weak association for this polymorphism and fat mass and 
apolipoprotein B levels in a French Canadian population, and the frequency of the T 
allele was 0.41 (11).   
Last, based on the linkage disequilibrium structure of the gene, one additional 




rs2302559 (SER301SER).  This exon 7 polymorphism results in a synonymous amino 
acid change at position 301 (serine) and has a minor allele frequency of ~ 0.41.  
However, no one has examined this polymorphism in connection with glucose or 
obesity-related traits.   
Thus, variation within the visfatin gene can be marked by 5 polymorphisms, 
some of which have been previously associated with glucose and obesity-related 
conditions.  However, the majority of genotype association studies have failed to 
account for the effects of diet, physical activity, and/or female menopausal status.  
Thus, a study that accounts for these factors may help to clarify some of the 
discrepant findings from previous reports. 
Visfatin & Exercise   
Many beneficial physiological changes occur with aerobic exercise training, 
including improvements in glucose tolerance and insulin sensitivity.  Furthermore, 
adipokines such as adiponectin are responsive to exercise training.  However, the 
response of visfatin to acute exercise and to aerobic exercise training has only been 
investigated minimally. 
Acute Exercise 
Only one study, thus far, has examined visfatin’s response to acute exercise in 
humans.  Frydelund-Larsen and colleagues studied visfatin mRNA expression in 15 
healthy men, approximately 25 yrs of age, with a BMI of ~ 25 kg/m2.  The 15 men 
were divided into an exercise group (n = 8) and a control group (n = 7).  The exercise 




consumption (VO2max) and then underwent 6 hours of recovery.  In contrast, the 
control group rested for 9 hours.  The researchers found that as compared to the 
control participants and as compared to baseline, abdominal adipose tissue visfatin 
mRNA expression increased 3-fold in response to exercise, with significant increases 
at the 3, 4.5, and 6 hours time points.  However, skeletal muscle visfatin mRNA 
expression and plasma visfatin levels did not significantly change with acute exercise.  
(34) 
Exercise Training 
Three studies, thus far, have examined visfatin’s response to aerobic exercise 
training in humans.  Haider and colleagues examined the effects of aerobic exercise 
training on plasma visfatin levels in 18 (11 women and 7 men, 42 ± 10 yrs of age) 
T1D patients.  The participants were compared to healthy, non-exercising controls (7 
women and 7 men, 29 ± 5 yrs of age).  The exercise training program consisted of 4 
months of stationary cycling for 1 hour, at an intensity of 60-70 % of heart rate 
reserve.  At baseline, the T1D patients had greater fasting plasma glucose and visfatin 
levels than the controls.  Moreover, there was no correlation between visfatin and 
BMI or age at baseline.  After both 2 and 4 months of exercise training, visfatin levels 
decreased significantly in the T1D patients (from 64.1 ± 12 ng/mL to 27.8 ± 2.6 
ng/mL and 17.5 ± 3.4 ng/mL, respectively) and remained lower 8 months after the 
cessation of exercise training.  However, BMI, fasting glucose, glycosylated 
hemoglobin, and lipoprotein-lipid levels were unchanged with the exercise training 
program.  In addition, the researchers did not measure VO2max or a similar training 




of the exercise sessions.  Thus, it is difficult to ascertain whether an actual aerobic 
exercise training effect occurred.  Lastly, the researchers did not assess diet, and 
differences in diet could have influenced the outcome measures.  (43) 
Choi and colleagues evaluated the effect of a combined aerobic and resistance 
exercise training program on plasma visfatin levels in non-diabetic Korean women.  
Healthy, overweight or obese women (n = 48) aged 30-55 yrs were recruited for the 
study.  The participants had to be sedentary (< 20 minutes of exercise twice per wk) 
and could not be taking laboratory test result-altering medications.  The 12 wk 
exercise training intervention consisted of ~ 45 minutes of aerobic exercise and ~ 20 
minutes of resistance exercise, 5 times per week.  At baseline, the obese women had 
higher plasma visfatin levels than the overweight women.  Furthermore, plasma 
visfatin levels were associated with body weight, BMI, and waist circumference in 
simple regression analyses and BMI in multiple regression analyses.  After 12 wks of 
exercise training, the participants lost 4-5 kg of weight, decreased BMI, waist 
circumference, blood pressure, percent body fat, fasting glucose, HOMA-IR, and 
visfatin levels.  Thus, a combined aerobic and resistance exercise training program 
with weight loss significantly decreased plasma visfatin levels and improved glucose 
and obesity-related variables in healthy, overweight or obese Korean women.  
However, diet was not assessed in the study and part of the weight loss was likely due 
to dietary changes since the caloric cost of the exercise training was estimated by the 
researchers as ~ 400 kcal per session.  Thus, it is difficult to assess whether the 




Finally, Brema and colleagues compared plasma visfatin levels in 15-30 yr old 
Caucasian age- and BMI-matched obese and T2D patients before and after the 
completion of an aerobic exercise training intervention.  The training program lasted 
12 weeks and consisted of 4 supervised sessions per week at an intensity of 75 % 
VO2max and a duration of 1 hour.  Dietary intake reportedly remained unchanged 
during the program, as did nearly every physiological variable measured, with the 
exception of waist circumference in the T2D group and VO2max in the obese group.  
Furthermore, visfatin levels were comparable in the obese and T2D patients before 
the intervention and decreased in both groups with training, with a greater decease 
occurring in the T2D patients.  Also, in the T2D patients, visfatin was correlated with 
percent body fat (r = -0.933) and HDL-cholesterol (r = -0.893) at baseline.  As 
VO2max did not change in the T2D patients and most outcomes did not change with 
the program, it is difficult to assess if a training effect occurred.  Furthermore, there 
was no indication made as to whether the participants were sedentary before the 
program started.  In addition, gender was not accounted for and differences between 
the groups could have affected many of the outcome variables.  (17) 
Summary: Visfatin & Exercise 
In sum, acute exercise seems to increase visfatin mRNA expression but not 
visfatin plasma levels in healthy, young men.  In contrast, plasma visfatin levels seem 
to decrease in response to exercise training.  However, no research has been reported 
regarding the independent effects of 6 months of aerobic exercise training on plasma 
visfatin levels in normal or impaired glucose tolerant individuals.  In addition, 




not provided evidence that an actual training effect occurred and was responsible for 
the reported visfatin changes.  The study involving T1D patients and Korean women 
also failed to control for the effects of diet.  Thus, studies taking these factors into 
account would help to further elucidate the effects of aerobic exercise training on 
plasma visfatin levels. 
Aerobic Exercise Training Responses & Their Genetic Link  
Coincidentally, the response of many variables to aerobic exercise training 
tends to be highly variable.  In fact, part of the variation in the response of glucose 
and obesity-related phenotypes to aerobic exercise training has been attributed to 
common genetic polymorphisms (93).  With its links to glucose and obesity-related 
phenotypes, its polymorphisms associated with glucose and obesity-related 
phenotypes, and its responsiveness to exercise training, visfatin is a candidate gene 
for aerobic exercise training-induced changes in glucose and obesity-related 
phenotypes.  However, this avenue of research has not currently been investigated. 
Specific Aims & Hypotheses 
Thus, the purpose of this study was to investigate the response of visfatin to 6 
months of aerobic exercise training in generally healthy, normal glucose tolerant 
(NGT) and impaired glucose tolerant (IGT) individuals.  In addition, common 
polymorphisms in the visfatin gene, and their corresponding haplotypes, were 
examined for their potential involvement in the response of glucose and obesity-




Hypothesis 1: As compared to baseline values, plasma visfatin concentration 
will decrease with aerobic exercise training in overall healthy, normal glucose 
tolerant individuals and impaired glucose tolerant individuals.  Moreover, there will 
be no differences in the magnitude of aerobic exercise training-induced change 
between the normal and impaired glucose tolerance groups.   
Hypothesis 2: The visfatin -948 G>T, -1001 T>G, -1543 C>T, -4689 G>T, 
and SER301SER gene polymorphisms will be associated with plasma visfatin levels 
and glucose and obesity-related phenotypes at baseline.  Specifically, -948 T allele 
carriers will have greater plasma visfatin levels, greater OGTT glucose total area 
under the curve (AUC), greater OGTT insulin total AUC, and lower insulin 
sensitivity than CC homozygotes.  Carriers of the -1001 G allele will have lower 
plasma visfatin levels, lower OGTT glucose total AUC, lower OGTT insulin total 
AUC, and higher insulin sensitivity than TT homozygotes.  Lastly, for the PBEF1 -
1543 C>T, -4689 G>T, and SER301SER polymorphisms, analyses will be carried out 
to determine the direction of association between genotypes and plasma visfatin 
levels, OGTT glucose total AUC, OGTT insulin total AUC, and insulin sensitivity.     
Hypothesis 3: The visfatin -948 G>T, -1001 T>G, -1543 C>T, -4689 G>T, 
and SER301SER gene polymorphisms will influence aerobic exercise training-
induced changes in glucose and obesity-related phenotypes, including dyslipidemia.  







Table 1-1. Circulating visfatin in diabetes-related conditions. 
  Sample Comparison Result Source 
plasma T1D vs healthy ↑ (43) 
serum T1D vs non-diabetic ↑ (74) T1D 
serum T1D vs T2D ↑ (74) 
plasma T2D vs healthy ND (112) 
plasma T2D vs healthy ↑ (29) 
plasma T2D vs healthy ↑ (22) 
serum T2D vs non-diabetic ↑ (74) 
serum T2D vs non-diabetic ↑ (94) 
serum T2D vs non-diabetic ↑ or ND (104) 
serum T2D newly diagnosed vs NGT ↑ (31) 
plasma T2D vs NGT ↓ (73) 
serum T2D vs NGT ND (55) 
serum T2D vs IGT ND (55) 
plasma T2D vs IGT ND (29) 
T2D 
 
serum T2D newly diagnosed vs IFG/IGT ↑ (31) 
serum  GDM vs healthy ↑ (72) 
plasma GDM vs healthy pregnant ↓ (40) 
? GDM vs healthy pregnant ↑ (68) 
GDM 
 
plasma GDM vs healthy pregnant ↓ (20) 
plasma IGT vs healthy ND (29) 
serum IGT vs NGT ND (55) IGT 
plasma IGT vs NGT ND (73) 
Results are statistically significant unless indicated otherwise.  T1D, type 1 
diabetes; T2D, type 2 diabetes; GDM, gestational diabetes mellitus; IGT, 
impaired glucose tolerance; ?, not clearly stated; ↑, higher; ND, no 
difference; ↓, lower; vs, versus; NGT, normal glucose tolerance, IFG, 








Table 1-2.  Circulating visfatin in obesity and other related conditions. 
  Sample Comparison Result Source
serum Obese vs normal weight ↓ (55) 
serum Obese vs normal weight ↑ (131) 
plasma Obese vs normal weight ↓ (88) 
 plasma Obese vs normal weight ↑ (76) 
serum Obese vs normal weight ↑ (56) 
plasma Obese vs healthy ↑ (41) 
plasma Obese vs healthy ↑ (45) 
plasma Obese vs non-obese ↑ (7) 
serum Obese vs overweight ↓ (55) 
plasma Obese vs overweight ↑ (25) 
plasma Severely obese vs healthy ↑ (37) 
plasma Severely obese w/NGT vs healthy ND (37) 
plasma Severely obese w/IFG or T2D vs healthy ↑ (37) 
serum Subcutaneous obese, visceral obese, lean ND (65) 
serum Overweight vs normal weight ND (55) 
plasma Overweight T2D, lean T2D, overweight 





plasma Obese vs obese w/T2D ND (17) 
plasma PCOS vs healthy ↑ (19) 
serum PCOS vs healthy ↑ (66) 
serum Lean PCOS vs healthy ↑ (66) 
PCOS 
plasma PCOS vs healthy w/infertility ↑ (113) 
serum CKD stage 5 vs CKD stage 3-4 ↑ (9) 
serum CKD stage 5 vs healthy ↑ (9) 
serum CKD stage 3, 4, or 5 vs healthy ↑ (130) 
serum CKD stage 1 or 2 vs healthy ND (130) 
CKD 
serum CKD diabetics vs CKD non-diabetics ND (9) 
plasma Metab. syndrome vs w/o metab. syndrome ↑ (32) 
serum Metab. syndrome vs w/o metab. syndrome ↑ (133) 
plasma Obese w/metab. syndrome vs obese ↑ (7) 
plasma Obese w/metab. syndrome vs non-obese ↑ (7) 
plasma FCHL family members vs FCHL spouses ND (120) 
Other  
plasma Hypertensive vs healthy ND (30) 
Results are statistically significant unless indicated otherwise.  PCOS, polycystic 
ovary syndrome; CKD, chronic kidney disease; vs, versus; w/, with; NGT, normal 
glucose tolerance; IFG, impaired fasting glucose; T2D, type 2 diabetes; metab., 
metabolic; w/o, without; FCHL, familial combined hyperlipidemia; ↓, lower; ↑, 











Fasting insulin (72; 113; 131)  (69; 74) 
Acute insulin response to glucose   (74) 
30-minute OGTT insulin   (74) 
2-hour OGTT insulin (72)   
Insulin sensitivity (74) (66) 
Insulin resistance (HOMA-IR) (113) (69; 120) 
Fasting glucose (32; 131)   
2-hour OGTT glucose   (73) 
Glycosylated hemoglobin  (74) (73) 
Visceral fat (7) (120) 
Percent body fat (13) (17)  
Body mass index (13; 19; 73) (22; 88) 
Waist to hip ratio (73)   
Waist circumference (32)   
Triglyceride levels (32) (69; 120) 
Subcutaneous fat visfatin mRNA (88; 113) (13) 
Omental fat visfatin mRNA (113)   
Visceral fat visfatin mRNA (13)   
Visfatin protein levels (113)   
Change in fasting insulin   (45; 69) 
Change in HOMA-IR   (45; 69)  
Change in body mass index (45)   
Change in weight (45)   
Change in waist circumference   (45) 
Waist reduction percentage   (37) 
Studies included in the table reported statistically significant correlations.  










Chapter 2: Methods 
This study was a retrospective analysis of data collected from participants in 
the Gene Exercise Research Study (GERS) at the University of Maryland, College 
Park.  The main purpose of the GERS was to investigate the effects of genetic 
polymorphisms on aerobic exercise training-induced changes in plasma lipoprotein 
lipids and/or blood pressure.  In contrast, this study examined relationships between 
visfatin, visfatin gene polymorphisms, glucose and obesity-related phenotypes, and 
the response of these variables to aerobic exercise training.  Visfatin levels and 
visfatin gene polymorphisms were assessed from banked plasma and DNA samples.  
All other variables were previously assayed by the GERS staff.  Last, before this 
retrospective study was conducted, written approval was obtained from the University 
of Maryland Institutional Review Board via an addendum to the original approved 
GERS Institutional Review Board application. 
Participants & Screening 
Participants in the GERS were sedentary volunteers, aged 50-75 yrs, living in 
the vicinity of the College Park campus (Washington, D.C. metropolitan area) and 
were recruited via media advertisements.  All were screened initially via telephone 
and then through a series of laboratory screening visits to verify eligibility.  During 
the first laboratory visit, potential participants met with study personnel, were 
informed of the study requirements, provided written informed consent, and 
completed health history and physical activity questionnaires.  During subsequent 




chemistry tests, a 2-hour OGTT to assess diabetes status, blood pressure, height, 
weight, and BMI measurements, a general physical examination, and a maximal 
graded treadmill exercise test using the Bruce protocol, to screen for signs and 
symptoms of cardiovascular disease (6).  A study physician conducted the general 
physical examination and oversaw the maximal graded treadmill exercise test, which 
included blood pressure, electrocardiogram, and heart rate recordings.   
 Briefly, participants had to be ≥ 50 yrs of age but ≤ 75 yrs of age, sedentary 
(< 20 minutes of physical activity ≤ twice per week), non-diabetic (fasting glucose 
concentration < 126 mg/dL and 2-hour glucose concentration < 200 mg/dL), non-
smoking, have no history or characteristics of cardiovascular disease, have no history 
or characteristics of lung, liver, or kidney disease, have a BMI < 37 kg/m2, have a 
hematocrit value > 35, and have no physical or orthopedic conditions that would 
preclude exercise.  In addition, female participants had to be postmenopausal for at 
least 2 years and willing to maintain their hormone therapy status, either receiving or 
not receiving hormone replacement therapy (HRT), throughout the duration of the 
study.  Furthermore, subjects had to qualify for either the GERS apolipoprotein-E 
gene (APO-E) and/or angiotensin converting enzyme gene (ACE) projects.  Thus, for 
APO-E, subjects had to additionally have at least 1 National Cholesterol Education 
Program (NCEP) lipid abnormality (total cholesterol > 200 mg/dL, LDL-cholesterol 
> 130 mg/dL, HDL-cholesterol < 35 mg/dL, or triglyceride levels > 200 mg/dL but < 
400 mg/dL) (2) and be normotensive or have blood pressure controlled with non-lipid 
and non-glucose altering medication.  For the ACE project, participants had to have 




mmHg even after dietary stabilization classes and physician approved hypertension 
medication tapering (as described below). 
Dietary Stabilization and ACE Study Medication Tapering 
 After screening into the study, participants were required to attend dietary 
stabilization classes twice a week for 6 weeks.  A registered dietician provided 
instructional sessions on the principles of the American Heart Association Step 1 diet, 
similar to the American Heart Association Dietary Guidelines for the General 
Population (1), which emphasized the consumption of 55-60 % of dietary calories 
from carbohydrates, < 30 % of dietary calories from fat, < 6 grams of salt per day, 
and alcohol in moderation.  Participants maintained the diet throughout the study’s 
duration, with periodic dietary recalls and food frequency checks to ensure adherence.  
In addition, before the start of aerobic exercise training and during week 24 of the 
exercise training intervention, participants recorded 7 day dietary logs which were 
analyzed by the dietician using Computrition dietary software (Computrition, Inc., 
Chatsworth, CA).  
Furthermore, if a participant enrolled in the ACE study had been taking blood 
pressure medication, he/she was gradually tapered off of the medication during the 
dietary stabilization period, provided that his/her physician granted approval.  If 
physician approval was not received for medication tapering, the participant did not 
undergo the medication taper and did not continue past the dietary stabilization 
portion of the study.   
Blood pressure measurements were taken and recorded during each dietary 




monitors were available for home blood pressure measurement by the participants.  
Moreover, resting blood pressure measurements had to remain > 120/80 mmHg but < 
160/100 mmHg for the participant to continue to take part in the ACE study.  If a 
participant’s blood pressure dropped below this range for 3 consecutive weeks, he/she 
was excluded from the ACE study.  In addition, if a participant’s blood pressure 
exceeded this range for 3 consecutive weeks, he/she was excluded from further 
participation in the ACE study and referred to his/her physician. 
Testing Procedures 
 Following the completion of the dietary classes, participants underwent 
baseline testing before beginning the aerobic exercise training intervention.  The 
baseline assessments determined main outcome variables in the GERS and included 
fasting blood draws, a 2-hour OGTT, body composition scans, and a maximal oxygen 
consumption (VO2max) test.  Final testing commenced following the completion of 
24 weeks of aerobic exercise training.  Final testing procedures were similar to 
baseline testing procedures except all final testing took place 24-36 hours after an 
exercise training bout.  This time frame ensured measurement of training rather than 
acute exercise effects. 
Lipoprotein-Lipid Levels 
 Following a 12-hour overnight fast on at least 2 separate occasions, venous 
blood samples were drawn from the antecubital region into 10 and/or 15 mL tubes 
containing 15 % potassium EDTA.  Blood samples were placed on ice until 




Plasma was separated from the centrifuged whole blood and analyzed for 
conventional plasma lipoprotein-lipid levels at the Baltimore Veteran’s Affairs 
Medical Center Clinical Chemistry Laboratory.  Plasma total cholesterol, 
triglycerides, LDL-cholesterol, and HDL-cholesterol were measured using standard 
procedures (5; 33; 103; 122).  The lipoprotein-lipid values from the separate blood 
draws were then averaged according to the GERS protocol. 
OGTT 
Following a 12-hour overnight fast, a 2-hour OGTT began between the hours 
of 6:30 and 9:00 AM.  A 20- or 22-gauge indwelling catheter was placed into a vein 
in the antecubital region, and blood sampling occurred before and every 30 minutes 
after the ingestion of a 75 gram D-glucose solution, for 2 hours.  The blood samples 
were immediately transferred into 10 and 15 mL tubes containing 15 % potassium 
EDTA.  Blood samples were placed on ice until centrifuged at 4 degrees Celsius, for 
20 minutes, at 3000 revolutions per minute.  Plasma was separated from the 
centrifuged whole blood and stored at -80 degrees Celsius until assayed for glucose 
and insulin levels.  In addition, extra fasting plasma samples (from the OGTT and 
from the lipoprotein-lipid fasting blood draws) were stored for assessment of other 
variables, including plasma visfatin levels.   
Glucose & Insulin 
 The glucose oxidase method was used to determine plasma glucose 
concentration via a glucose analyzer (YSI 2300 Stat Plus, YSI, Inc., Yellow Springs, 




did not differ by > 2 mg/dL.  If measurements differed by > 2 mg/dL, the sample was 
reanalyzed.   
A competitive radioimmunoassay (kit HI-14K, Linco Research, St. Charles, 
MO) was used to determine plasma insulin concentration.  Each sample was 
measured in duplicate and averaged, provided that the coefficient of variation for the 
sample duplicates was ≤ 10 %.  However, if the coefficient of variation for the sample 
duplicates was > 10 %, the sample was reanalyzed in duplicate. 
Glucose & Insulin-Related Variables 
Glucose total AUC was calculated via the trapezoidal method using fasting, 
30, 60, 90, and 120 minute glucose concentrations from the OGTT.  The formula was 
as follows: glucose total AUC = (fasting glucose * 15) + (30 minute glucose * 30) + 
(60 minute glucose * 30) + (90 minute glucose * 30) + (120 minute glucose * 15).  
Insulin total AUC was calculated in a similar manner, except using OGTT insulin 
concentrations.  An insulin sensitivity index (ISI) was calculated using the method of 
Matsuda and DeFronzo where ISI = 10,000 / square root of [(fasting glucose * fasting 
insulin) * (mean of fasting, 30, 60, 90, and 120 minute OGTT glucose * mean of 
fasting, 30, 60, 90, and 120 minute OGTT insulin)] (78). 
Participants were classified as having impaired glucose tolerance (IGT) or 
normal glucose tolerance (NGT) based on their 120 minute OGTT glucose 
concentration.  Glucose concentrations ≥ 140 mg/dL but < 200 mg/dL were classified 
as IGT, and glucose concentrations < 140 mg/dL were classified as NGT (3).  
Individuals with a 120 minute glucose concentration ≥ 200 mg/dL were excluded 





A commercially available competitive enzyme immunoassay (EIA) kit 
(Phoenix Pharmaceuticals, Inc., Burlingame, CA, catalog number: EK-003-80, lot 
number 600508) was used to determine plasma visfatin concentration.  Briefly, 50 µL 
of standard, plasma sample, or control was added to an assigned microplate well, 
followed by 25 µL of primary antiserum and 25 µL of biotinylated peptide.  Then, the 
microplate was sealed and incubated at room temperature for 2 hours with orbital 
shaking throughout the incubation period.  Following the completion of the first 
incubation, the microplate was washed 4 times with assay buffer.  Next, 100 µL of 
streptavidin-horseradish peroxidase was added to each well.  The microplate was 
sealed again and incubated at room temperature for 1 hour with orbital shaking 
throughout the incubation.  Following the completion of the second incubation, 100 
µL of substrate solution was added to each well, but only after the microplate had 
been washed 4 times with assay buffer.  The microplate was again sealed, incubated 
at room temperature for 1 hour, and orbitally shaken.  During this step, the microplate 
was also protected from light.  After the third incubation was completed, 100 µL of 
2N hydrochloric acid was added to each well to terminate the reaction.  Then, the 
absorbance of the wells was read at 450 nm using a microplate reader, and curve-
fitting software was used to calculate the standard curve and sample concentrations. 
The only deviation from the manufacturer’s recommendations was that 
manual washing was used in lieu of a plate washer, and this contributed to a higher 
intra-assay coefficient of variation (12.5 %) than the manufacturer’s reported < 5 %.  




stored for 2-8 years at -80 degrees Celsius, and this may have affected their 
measurement.  Moreover, only one study has examined the influence of storage on 
visfatin levels, and the researchers found that storage at -25 degrees Celsius for 1 
month resulted in measurement of 92.7 ± 31.1 % of the initial value (83).  Despite 
this potential limitation, we found no relationship between plasma sample age and the 
baseline or final visfatin concentration (data not shown, both p > 0.05). 
Each sample was measured in duplicate and averaged, with reanalysis of 
sample duplicates having a coefficient of variation > 20 %.  The inter-assay 
coefficient of variation was approximately 18 % versus the manufacturer’s reported < 
14 %.  
Plasma C-Reactive Protein 
 As previously reported (84), an enzyme-linked immunosorbent assay (Alpha 
Diagnostic International, San Antonio, TX) was used to measure plasma C-reactive 
protein. 
Body Composition  
Body composition was measured at the Baltimore Veteran’s Affairs Medical 
Center.  Total percent body fat was measured via dual-energy x-ray absorptiometry 
(DPX-L or DPX-IQ, Lunar Corporation, Madison, WI), whereas visceral and 
subcutaneous adipose tissue intra-abdominal fat were measured using single slice 
computed tomography (GE Hi-Light CT scanner).  Standard procedures were used as 




Maximal Graded Treadmill Exercise Test 
VO2max and heart rate were measured during a maximal graded treadmill 
exercise test, as previously described (28). A physician presided over the test, and 
electrocardiogram and blood pressure measurements were recorded throughout the 
test.  Standard criteria were used to ensure that VO2max was achieved (6), and the 
resting and maximum heart rates measured from the electrocardiogram recording 
during the test were used in the aerobic exercise training prescription. 
Genotyping 
 A 10 mL blood sample was collected during the screening process and DNA 
extracted and stored for later genotyping projects.  The 5 PBEF1 polymorphisms of 
interest in this project [-948 G>T, -1001 T>G, -1543 C>T, -4689 G>T, and 
SER301SER] were genotyped in the Functional Genomics Laboratory in the 
Department of Kinesiology at the University of Maryland School of Public Health, 
College Park, MD, using restriction fragment length polymorphism techniques (-
1543, -4689, SER301SER) or a TaqMan allelic discrimination assay (-948, -1001).   
For the PBEF1 -1543 polymorphism, the primer sequences were: forward 
primer, 5’-AGCGAGACTCCGTCTCAAAA-3’; reverse primer, 5’-
GGCAAAGATCATGGAAGTGG-3’.  Microplate wells containing a total reaction 
volume of 25 µL, consisting of 2.5 µL of 10X Taq PCR Buffer with ammonium 
sulfate ((NH4)2SO4), 4.0 µL of 1.25 mM 2'-deoxynucleoside 5'-triphosphate (dNTP) 
mix, 1.0 µL of 25 mM magnesium chloride (MgCl2), 0.4 µL of 20 mM forward 
primer, 0.4 µL of 20 mM reverse primer, 0.2 µL of Taq polymerase, 1.0 µL of 




genomic DNA, underwent the polymerase chain reaction (PCR).  The thermal cycling 
conditions for the PCR involved: 1) initial denaturation at 95 degrees Celsius for 5 
minutes, 2) 30 cycles of denaturation (95 degrees Celsius for 30 seconds), annealing 
(54 degrees Celsius for 30 seconds), and elongation (72 degrees Celsius for 30 
seconds), and 3) final extension at 72 degrees Celsius for 5 minutes.  Ten µL of each 
PCR product was then amplified using gel electrophoresis.  Following the 
amplification check, the remaining 15 µL of PCR product was digested overnight at a 
temperature of 60 degrees Celsius with BstNI (New England Biolabs, Inc., Beverly, 
MA).  The digestion mixture included 15 µL of PCR product, 0.5 µL of enzyme, 2.3 
µL of distilled deionized water, 2.0 µL of manufacturer provided buffer 2, and 0.2 µL 
of manufacturer provided bovine serum albumin (BSA).  Following the digestion, 5 
µL of Orange G running buffer was added to each sample, and 10 µL of the total 
volume was transferred into the wells of a 3 % agarose gel (9 g agarose in 300 mL 
Tris-acetate-EDTA buffer).  The agarose gel contained 5 µL of ethidium bromide for 
every 100 mL of Tris-acetate-EDTA buffer.  The gel then underwent electrophoresis 
for approximately 75-90 minutes and was visualized under ultraviolet light.  The 
typical gel patterns for genotyping the -1543 polymorphism were: homozygous TT 
with 1 band at 206 bp; homozygous CC with 2 bands, 1 at 174 bp and 1 at 32 bp; and 
heterozygous CT with 3 bands, 1 at 206 bp, 174 bp, and 34 bp.  For quality control 
and genotype assignment purposes, genotype-known controls (obtained via direct 
sequencing) were included in each run. 
The procedures for genotyping the -4689 polymorphism were similar to those 




forward primer, 5’-TGCTGTTTTCACATCCTCCA-3’; reverse primer, 5’-
GTTTCCTCAGACCTGCTTGC-3’.  Furthermore, the restriction endonuclease used 
was Alu I, the digestion mixture included 15 µL of PCR product, 0.6 µL of enzyme, 
2.4 µL of distilled deionized water, and 2.0 µL of manufacturer provided buffer 2, 
and the overnight digestion required a temperature of 37 degrees Celsius.  The -4689 
polymorphism banding patterns were: homozygous GG with 1 band at 188 bp; 
homozygous TT with 2 bands, 1 at 143 bp and 1 at 45 bp; and heterozygous GT with 
3 bands, 1 at 188 bp, 143 bp, and 45 bp. 
Slightly different PCR and digestion conditions were used for the 
SER301SER polymorphism.  First, the primer sequences for the SER301SER 
polymorphism were: forward primer, 5’-TTGGGTGAAGTCATCAGACG-3’; 
reverse primer, 5’-GTATTGCCGGGAAGGAAAAG-3’.  Next, the PCR reaction 
mixture contained 2.5 µL of 10X Taq PCR Buffer, 4.0 µL of 1.25 mM dNTP mix, 1.0 
µL of 25 mM MgCl2, 0.4 µL of 20 mM forward primer, 0.4 µL of 20 mM reverse 
primer, 0.2 µL of Taq polymerase, 14.5 µL of distilled deionized water, and 2.0 µL of 
genomic DNA, equaling a 25 µL total volume.  The annealing step of the PCR also 
involved a different temperature, 56 degrees Celsius.  Overnight digestion of the PCR 
product occurred using the Taq I enzyme and a temperature of 65 degrees Celsius.  
The digestion mixture included 15 µL of PCR product, 0.6 µL of enzyme, 2.2 µL of 
distilled deionized water, 2.0 µL of manufacturer provided buffer 3, and 0.2 µL of 
BSA.  Gel electrophoresis remained as previously described.  The bands visualized 




361 bp; homozygous CC with 2 bands, 1 at 204 bp and 1 at 157 bp; and heterozygous 
CT with 3 bands, 1 at 361 bp, 204 bp, and 157 bp. 
Custom TaqMan SNP genotyping assays (Applied Biosystems, Foster City, 
CA) were developed for genotyping the PBEF1 -948 and -1001 polymorphisms based 
on a previously published report (64).   The primers and reporters for the -948 
polymorphism were: forward primer, 5’-GCCCGTTGCCTTTTCCTT-3’; reverse 
primer, 5’-GGTGGAATTCAGTCCTCACAGATAA-3’; VIC reporter, 
CCTAATTGAACCGAGTATT; FAM reporter, CCTAATTGAACAGAGTATT.  
The primers and reporters for the -1001 polymorphism were: forward primer, 5’-
CCAACTCGTTTCCCAGGATTTAAAG-3’; reverse primer, 5’-
ACGGGCCAAGCCTTTGA-3’; VIC reporter, CAGTGTCGCACCCTG; FAM 
reporter, CAGTTTCGCACCCTG.  All reactions were carried out using an Applied 
Biosystems 7300 Real Time PCR System and optical reaction plates.  Plate wells 
contained a total reaction volume of 12.5 µL consisting of 6.25 µL of 2X TaqMan 
Universal PCR Master Mix (Perkin-Elmer, Applied Biosystems Division), 0.625 µL 
of 20X diluted SNP mix, 1.5 µL of genomic DNA, and 4.125 µL of nuclease free 
water.  The PCR cycling protocol consisted of 2 minutes at 50 degrees Celsius; 10 
minutes at 95 degrees Celsius (for AmpliTaq Gold DNA polymerase activation); and 
50 cycles of 92 degrees Celsius for 15 seconds (for melting/denaturation) and 60 
degrees Celsius for 1 minute (for annealing and extending).  Fluorescence (via allele 
specific VIC and FAM dyes) was measured and genotypes were determined using the 




purposes, each plate contained 4 no template controls and 4 positive control samples 
of known genotype (determined previously via direct sequencing).  
Haplotype Estimation 
 The computational inference program PHASE, version 2.1 (108; 109) was 
used to construct haplotypes from the 5 PBEF1 polymorphisms investigated in this 
study.  A dataset containing the genotypes for the study participants was input into 
the PHASE program as described in the program’s documentation.  Resulting 
haplotypes with a frequency ≥ 5 % were used in exploratory analyses involving 
glucose and obesity-related variables.     
Aerobic Exercise Training 
Following the completion of baseline testing, subjects initiated 24 weeks of 
supervised aerobic exercise training.  Briefly, a participant’s resting and maximum 
heart rate data, obtained during the baseline maximal graded treadmill test, were used 
in the Karvonen (heart rate reserve) formula to determine his/her exercise training 
heart rates.  A heart rate range was determined for each participant corresponding to 
the percent intensity desired ± 5 %.  During the exercise training sessions, Polar heart 
rate monitors were used to assess heart rate.  Training equipment available to the 
participants included stair climbers, stationary bicycles, recombinant bicycles, rowing 
ergometers, treadmills, elliptical machines, and cross country ski machines.  To 
gradually acclimatize the sedentary participants to exercise, the first week of training 
involved 20 minutes of activity at 50 % intensity for 3 days per week.  Exercise 




exercise intensity increased gradually, 5 % per week, until 70 % was attained.  Thus, 
from week 9 through week 24, participants exercised for 40 minutes at an intensity of 
70 %.  In week 10, participants were also asked to add in an unsupervised home 
workout.  Participants recorded resting and exercise heart rates and blood pressure 
measurements in training logs provided by the GERS.   
Statistical Analysis 
All statistical analyses were performed using SAS (version 9.1) and SPSS 
(version 14.0) software.  Before any statistical analyses were conducted, the 
assumptions for each procedure were examined, and as a result, transformation using 
the common logarithm was required for visfatin, triglycerides, intra-abdominal fat, 
insulin AUC, ISI, and C-reactive protein in order to meet the assumption(s) of 
normality and/or homogeneity of variance.  Chi-square tests were used to assess 
Hardy-Weinberg equilibrium, pairwise linkage disequilibrium, and to compare 
differences in categorical variables between groups.  However, a Fisher’s Exact 
Probability Test was used when the frequency of categorical data in a cell was ≤ 5.  
Pearson correlation coefficients were used to examine relationships between potential 
covariates and between plasma visfatin levels and glucose and obesity-related 
variables. Analysis of variance (ANOVA) and analysis of covariance (ANCOVA) 
techniques were used to compare baseline and after aerobic exercise training 
concentrations of plasma visfatin between normal glucose tolerant (NGT) and 
impaired glucose tolerant (IGT) individuals.  BMI was used as a covariate in the 
baseline visfatin analysis, and BMI and the baseline plasma visfatin level were 




as a potential moderating factor.  Paired t-tests were used to determine significant 
changes within the IGT and NGT groups with aerobic exercise training.  ANCOVA 
was also used to compare differences in glucose and obesity-related variables 
between PBEF1 genotype groups and haplotype groups at baseline and in response to 
aerobic exercise training.  When appropriate, covariates for the baseline analyses 
included age and BMI, and covariates for the after aerobic exercise training analyses 
included age, BMI, and the baseline value of the outcome variable.  Gender was also 
included as a potential moderating factor in all of the analyses.  When significant 
genotype, haplotype, or interaction effects were detected, Bonferroni adjusted post-
hoc multiple comparisons were undertaken.  Paired t-tests were used to determine 
significant changes within groups with aerobic exercise training.  Statistical 




Chapter 3: Results 
Hypothesis 1: Plasma Visfatin Concentration 
Baseline  
Sixty seven participants with an average age of 59 ± 1 yr had viable plasma 
samples available for analysis of fasting visfatin concentration.  Furthermore, 22 of 
the participants (14 men, 8 women) had impaired glucose tolerance (IGT) at baseline, 
whereas 45 participants (21 men, 24 women) were classified with normal glucose 
tolerance (NGT).  Hormone replacement therapy (HRT) use among women in the 
study was 63 % in the IGT group and 54 % in the NGT group and was not 
significantly different between the groups (p > 0.999).  Table 3-1 displays baseline 
characteristics for the IGT and NGT groups.  Besides having lower insulin sensitivity 
(via ISI) and elevated fasting glucose, glucose total area under the curve (AUC), and 
insulin AUC, the IGT group also had higher body mass index (BMI; p = 0.032) and 
intra-abdominal fat measurements (p = 0.020) than the NGT group.  As the BMI and 
intra-abdominal fat measurements were correlated (r = 0.599, p < 0.001), and BMI 
data were available on all 67 participants as compared to 65 participants with intra-
abdominal fat measurements, BMI was used as a covariate in the analyses involving 
visfatin.   
Correlations involving plasma visfatin concentration and glucose and obesity-
related variables are displayed in Table 3-2.  Although the variables examined were 




tendency towards a negative relationship between insulin AUC and baseline visfatin 
(r = -0.242, p = 0.070).  However, insulin AUC was not included as a covariate 
because of its relatedness to the 120 minute OGTT glucose concentration (used to 
determine IGT/NGT status; r = 0.487, p < 0.001).  There were also no significant 
correlations involving plasma visfatin concentration and glucose and obesity-related 
variables when the IGT and NGT groups were analyzed separately (data not shown).  
One-way ANOVA techniques were used to examine the influence of plasma sample 
age, study qualification (APO-E, ACE, both), cardiovascular disease risk factor 
quantity, and HRT usage on baseline levels of visfatin.  However, these factors were 
not statistically related to the baseline visfatin concentration (p = 0.156, p = 0.522, p 
= 0.744, and p = 0.217, respectively).  
After including BMI as a covariate and gender as a potentially moderating 
factor in the analysis, baseline plasma visfatin levels did not differ between the IGT 













Table 3-1. Characteristics of visfatin study participants at baseline. 
 IGT 
(n = 17-22) 
NGT 
(n = 40-45) 
P-value 
Men/Women 14/8 21/24 0.192 
HRT use (Yes/No) 5/3 13/11 1.000 
Age (yrs) 59 ± 2 59 ± 1 0.851 
VO2max (mL/kg/min) 25.8 ± 1.1 26.2 ± 0.7 0.750 
Weight (kg) 84.2 ± 3.2 79.1 ± 2.4 0.216 
BMI (kg/m2) 29.0 ± 0.9 26.6 ± 0.6 0.032* 
Intra-abdominal fat (cm2) 144 (119-175) 110 (97-125) 0.020* 
Subcutaneous fat (cm2) 310 ± 21 294 ± 19 0.624 
Total fat (%) 35.8 ± 2.1 34.7 ± 1.4 0.654 
Total cholesterol (mg/dL) 192 ± 7 196 ± 4 0.615 
Triglycerides (mg/dL) 133 (117-151) 126 (108-148) 0.660 
HDL-cholesterol (mg/dL) 43 ± 3 47 ± 2 0.242 
LDL-cholesterol (mg/dL) 122 ± 6 119 ± 4 0.665 
Fasting glucose (mg/dL) 95 ± 2 90 ± 1 0.039* 
Fasting insulin (pmol/L) 84 ± 7 72 ± 4 0.116 
ISI 2.5 (2.0-3.0) 4.2 (3.6-4.8) < 0.001*
Glucose AUC (mg/dL x 120 min) 19913 ± 561 14632 ± 431 < 0.001*





C-reactive protein (mg/L) 22 (12-40) 14(11-19) 0.150 
Data are expressed as mean ± SE with the exception of intra-abdominal fat, 
triglycerides, ISI, insulin AUC, and C-reactive protein, which are presented as 
geometric mean (95 % confidence interval), and categorical data, which are 
presented as count.  HRT, hormone replacement therapy; IGT, impaired glucose 
tolerance; NGT, normal glucose tolerance; VO2max, maximal oxygen consumption; 
BMI, body mass index; ISI, insulin sensitivity index; AUC, total area under the 
curve; n, sample size.  Sample sizes are varied due to the inability to obtain all 
measurements on all participants.   P-values are from χ2 or Fisher Exact tests 
(categorical variables) and ANOVA (continuous variables).  * indicates significant 















Table 3-2. Correlations between plasma visfatin concentration and glucose 
and obesity-related variables at baseline. 
 N Pearson’s correlation P-value 
Weight (kg) 67 -0.056 0.654 
    
BMI (kg/m2) 67 -0.100 0.421 
    
Intra-abdominal fat (cm2) 65 -0.160 0.202 
    
Subcutaneous fat (cm2) 65 -0.125 0.323 
    
Total fat (%) 66 -0.109 0.383 
    
Total cholesterol (mg/dL) 67 -0.170 0.170 
    
Triglycerides (mg/dL) 67 -0.031 0.802 
    
HDL-cholesterol (mg/dL) 67 -0.052 0.676 
    
LDL-cholesterol (mg/dL) 67 -0.149 0.228 
    
Fasting glucose (mg/dL) 67 -0.034 0.788 
    
Fasting insulin (pmol/L) 58 -0.076 0.573 
    
ISI 57 0.182 0.175 
    
Glucose AUC (mg/dL x 120 min) 66 -0.056 0.657 
    
Insulin AUC (pmol/L x 120 min) 57 -0.242 0.070 
    
C-reactive protein (mg/L) 57 -0.003 0.985 
    
Intra-abdominal fat, triglycerides, ISI, insulin AUC, C-reactive protein, and 
visfatin were transformed using the common logarithm prior to analysis.  
BMI, body mass index; ISI, insulin sensitivity index; AUC, total area under 
the curve; n, sample size.  Sample sizes are varied due to the inability to 




























Figure 3-1. Plasma visfatin concentration at baseline and after aerobic exercise 
training, grouped by glucose tolerance status.  IGT, impaired glucose tolerance; NGT, 
normal glucose tolerance.  Values are geometric mean + 95 % confidence interval.  * 
indicates statistically significant difference between groups. † indicates significant 






After Aerobic Exercise Training 
Table 3-3 displays participant characteristics following the completion of 24 
weeks of aerobic exercise training, and fasting insulin (p = 0.012), glucose AUC (p < 
0.001), insulin AUC (p = 0.014), and ISI (p = 0.004) still differed between the IGT 
and NGT groups.  In general, aerobic exercise training adherence for the IGT and 
NGT groups did not differ (p = 0.716), averaging 89.5 ± 1.6 and 90.3 ± 1.3 %, 
respectively.  Furthermore, the IGT and NGT groups similarly and significantly 
improved VO2max (both p < 0.001), HDL-cholesterol (p = 0.001, p < 0.001), and 
insulin AUC (p = 0.014, p = 0.003) with training.  In contrast, changes in weight, 





Correlations involving the aerobic exercise training-induced change in plasma 
visfatin concentration and the aerobic exercise training-induced change in glucose 
and obesity-related variables are displayed in Table 3-4.  However, none of the 
variable changes were significantly correlated with the aerobic exercise training-
induced change in plasma visfatin concentration.  Similar results were also found for 
correlations involving the NGT group (data not shown).  However, in the IGT group, 
there was a weak correlation between the aerobic exercise training-induced increase 
in plasma visfatin and the non-significant decrease in C-reactive protein levels (r = 
0.547, p = 0.043).  But after accounting for gender, this relationship was no longer 
significant (r = 0.531, p = 0.062). 
Although the IGT and NGT groups both significantly increased plasma 
visfatin levels with training (Figure 3-1, p = 0.028, p = 0.027), the changes were 
similar, resulting in no difference between the groups after training [Figure 3-1; 23 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3-4. Correlations between aerobic exercise training-induced change in 
plasma visfatin concentration and glucose and obesity-related variables. 
 N Pearson’s correlation P-value 
Weight (kg) 67 -0.089 0.475 
    
BMI (kg/m2) 67 -0.073 0.555 
    
Intra-abdominal fat (cm2) 59 -0.146 0.271 
    
Subcutaneous fat (cm2) 58 -0.093 0.487 
    
Total fat (%) 64 -0.137 0.280 
    
Total cholesterol (mg/dL) 64 -0.022 0.864 
    
Triglycerides (mg/dL) 63 0.025 0.844 
    
HDL-cholesterol (mg/dL) 63 0.126 0.325 
    
LDL-cholesterol (mg/dL) 63 -0.114 0.373 
    
Fasting glucose (mg/dL) 66 0.070 0.579 
    
Fasting insulin (pmol/L) 56 -0.149 0.272 
    
ISI 53 0.133 0.341 
    
Glucose AUC (mg/dL x 120 min) 63 -0.089 0.488 
    
Insulin AUC (pmol/L x 120 min) 53 -0.046 0.744 
    
C-reactive protein (mg/L) 51 0.150 0.294 
    
Intra-abdominal fat, triglycerides, ISI, insulin AUC, C-reactive protein, and 
visfatin were transformed using the common logarithm prior to analysis.  
BMI, body mass index; ISI, insulin sensitivity index; AUC, total area under 
the curve; n, sample size.  Sample sizes are varied due to the inability to 






Hypothesis 2: Baseline 
 Data from 116 participants (55 men, 61 women) were included in the PBEF1 
genotype analyses.  General baseline characteristics of this sample are presented in 
Table 3-5.  On average, the participants were overweight, had borderline-high risk 
levels of total cholesterol and LDL-cholesterol (2), and had below average VO2max 
values (6).  In addition, approximately 47.5 % of women used HRT while 
participating in the GERS.  Among the 116 participants, there were 80 who qualified 
only for the GERS APO-E study, 20 who qualified only for the GERS ACE study, 
and 16 who qualified for both studies.  Results from ANOVA analyses indicated 
significant differences in total cholesterol (p < 0.001), LDL-cholesterol (p < 0.001), 
and triglyceride (p = 0.001) levels between the groups.  Post-hoc multiple 
comparisons with Bonferroni correction identified that in all 3 instances, those 
individuals qualifying only for the ACE study had significantly different values than 
those qualifying for both studies (p < 0.001, p = 0.002, p = 0.032) or for only the 
APO-E study (p < 0.001, p < 0.001, p = 0.001).   Thus, only data from APO-E 
qualifiers were used in the analyses involving lipoprotein-lipid levels.  As blood 
pressure was not investigated in this project and other GERS entrance criteria were 
uniform between the ACE and APO-E studies, the groups were combined for the 
analyses involving glucose and obesity-related variables.  As suggested by correlation 
matrices, age and BMI were included as covariates, when appropriate, and gender 







Table 3-5. Characteristics of study participants at baseline. 
Gender (men/women) (n = 116) 55/61 
Age (yrs) (n = 116) 59 ± 1 
VO2max (mL/kg/min) (n = 116) 25.7 ± 0.4 
Weight (kg) (n = 116) 81.7 ± 1.4 
BMI (kg/m2) (n = 116) 27.9 ± 0.4 
Intra-abdominal fat (cm2) (n = 113) 124 (116-133) 
Subcutaneous fat (cm2) (n = 112) 307 ± 11 
Total fat (%) (n = 114) 36.2 ± 0.8 
Total cholesterol (mg/dL) (n = 96) 210 ± 3 
Triglycerides (mg/dL) (n = 96) 147 (134-161) 
HDL-cholesterol (mg/dL) (n = 95) 47 ± 1 
LDL-cholesterol (mg/dL) (n = 95) 131 ± 3 
Fasting glucose (mg/dL) (n = 85) 92 ± 1 
Fasting insulin (pmol/L) (n = 72) 80 ± 3 
ISI (n = 71) 3.3 (3.0-3.7) 
Glucose AUC (mg/dL x 120 min) (n = 82) 16495 ± 397 
Insulin AUC (pmol/L x 120 min) (n = 71) 49774 (44627-55514) 
Fasting visfatin (ng/mL) (n = 63) 20 (18-23) 
Data are expressed as mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as 
geometric mean (95 % confidence interval), and categorical data, which 
are presented as count.  VO2max, maximal oxygen consumption; BMI, 
body mass index; ISI, insulin sensitivity index; AUC, total area under 
the curve; n, sample size.  Sample sizes are varied due to the inability to 
obtain all measurements on all participants.  
 
PBEF1 -4689 G>T (rs2110385) 
 Genotypes for the PBEF1 -4689 polymorphism were available on 115 of the 
116 possible participants, and the genotype frequencies were 37 % GG, 47 % GT, and 
16 % TT.  The resultant T allele frequency was 39 %, which was consistent with a 
previous report (11).  In addition, the genotype frequencies did not vary from Hardy-
Weinberg equilibrium (χ2 = 0.023, p = 0.878), and gender (χ2 = 0.511, p = 0.774) and 




There were no significant genotype group differences at baseline for visfatin, 
lipoprotein-lipid, or body composition variables (Table 3-6).  However, there was a 
significant genotype effect for insulin AUC (p = 0.002), with the GG group having a 
significantly higher insulin AUC value than the TT group (p = 0.004) and the GT 
group (p = 0.021).  In addition, there was a significant gender by genotype interaction 
effect for ISI (Figure 3-2; p = 0.028), as women with the TT genotype had a 
significantly higher ISI value than women with the GG genotype (p = 0.001), men 
with the GG genotype (p = 0.025), or men with the GT genotype (p = 0.011).  The 
main effects for gender (p = 0.02) and genotype (p = 0.012) were also significant, 
with women having a higher ISI than men and the GG genotype group having a lower 
ISI than the TT genotype group (p = 0.010).   
As displayed in Figure 3-2, there were significant genotype by gender 
interaction effects for fasting glucose (p = 0.017) and fasting insulin (p = 0.041).  
Pairwise comparisons indicated that women with the TT genotype had a significantly 
lower fasting glucose concentration than men with the GG genotype (p = 0.001), GT 
genotype (p = 0.041), or TT genotype (p = 0.002) and a significantly lower fasting 
insulin concentration than men with the GT genotype (p = 0.032).  However, these 
findings should be viewed with caution as there were only 6 women in our study with 
the TT genotype.  For fasting glucose, the main effect of gender was also significant 







Table 3-6. Baseline characteristics of Gene Exercise Research Study participants 
genotyped for the PBEF1 -4689 polymorphism.  
 GG 
(n = 24-43) 
GT 
(n = 35-54) 
TT 
(n = 12-18) 
P-value 
Men/women 20/23 25/29 10/8 --- 
HRT use (Y/N) 11/12 12/17 5/3 --- 
Age (yrs) 58 ± 1 58 ± 1 60 ± 1 0.629 
VO2max 26.3 ± 0.5 25.9 ± 0.5 24.2 ± 0.8 0.103 
Weight (kg) 80.8 ± 2.1 82.6 ± 1.8 81.1 ± 3.2 0.796 
BMI (kg/m2) 28.0 ± 0.6 27.8 ± 0.6 27.9 ± 1.0 0.981 
IA fat (cm2) 129 (116-143) 128 (117-141) 108 (92-126) 0.140 
SC fat (cm2) 294 ± 16 308 ± 15 321 ± 25 0.644 
Total fat (%) 35.6 ± 1.0 35.9 ± 0.9 37.7 ± 1.5 0.458 
TC (mg/dL) 210 ± 5 208 ± 5 217 ± 9 0.684 
TG (mg/dL) 162 (140-188) 138 (122-157) 138 (107-177) 0.239 
HDL (mg/dL) 45 ± 2 46 ± 2 51 ± 4 0.348 
LDL (mg/dL) 129 ± 5 131 ± 4 131 ± 8 0.953 
Glucose (mg/dL) 94 ± 1 91 ± 1 90 ± 2 0.085 
Insulin (pmol/L) 84 ± 5 81 ± 4 66 ± 6 0.074 
ISI 2.9 (2.5-3.3) 3.4 (3.0-3.9) 4.2 (3.4-5.2) 0.012* 
Glucose AUC  17027 ± 619 16562 ± 544 15064 ± 941 0.221 







Visfatin (ng/mL) 20 (16-25) 19 (15-23) 23 (17-31) 0.621 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as 
geometric mean (95 % confidence interval), and categorical data which are 
presented as count.  HRT, hormone replacement therapy; Y, yes; N, no; 
VO2max, maximal oxygen consumption; BMI, body mass index; IA; intra-
abdominal; SC, subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, 
high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; 
ISI, insulin sensitivity index; AUC, total area under the curve; n, sample size.  
Sample sizes are varied due to the inability to obtain all measurements on all 
participants.  Measurement units: VO2max, mL/kg/min; glucose AUC, mg/dL x 
120 min; insulin AUC, pmol/L x 120 min.  P-value is for the main effect of 





Figure 3-2.  Interaction between gender and the PBEF1 -4689 polymorphism for A) 
fasting glucose (p = 0.017), B) fasting insulin (p = 0.041), and C) ISI (p = 0.028).  
Data are presented as adjusted mean ± SE except for ISI, which is presented as 


































































PBEF1 -1543 C>T 
 Genotypes for the -1543 polymorphism were available on 115 of the 116 
possible participants.  Genotype frequencies for the PBEF1 -1543 polymorphism 
were 54 % CC, 39 % CT, and 7 % TT.  The T allele frequency was approximately 27 
%, consistent with previous reports (9; 129).  In addition, the genotype frequencies 
were in Hardy-Weinberg equilibrium (χ2 = 0.002, p = 0.966), and both gender (p > 
0.999) and HRT use (p = 0.845) did not differ by genotype group.  Due to the low 
frequency of individuals with the TT genotype and non-statistically different CT and 
TT group means for the major outcome variables (all p > 0.398, data not shown), the 
CT and TT genotype groups were combined for analysis. 
 There were no significant genotype group differences at baseline for visfatin, 
lipoprotein-lipid, body composition, or OGTT variables (Table 3-7).  However, as 




ISI (p = 0.024), but after Bonferroni adjustment, none of the pairwise comparisons 
were significantly different. 
 
Table 3-7. Baseline characteristics of Gene Exercise Research Study participants 
genotyped for the PBEF1 -1543 polymorphism.  
 CC 
(n = 38-62) 
CT+TT 
(n = 33-53) 
P-value 
Men/Women 30/32 25/28 --- 
HRT use (Y/N) 16/16 12/16 --- 
Age (yrs) 59 ± 1 58 ± 1 0.563 
VO2max (mL/kg/min) 25.4 ± 0.4 26.0 ± 0.5 0.366 
Weight (kg) 81.1 ± 1.7 82.8 ± 1.8 0.506 
BMI (kg/m2) 27.8 ± 0.5 28.2 ± 0.6 0.575 
IA fat (cm2) 120 (110-131) 131 (119-144) 0.208 
SC fat (cm2) 308 ± 13 309 ± 15 0.965 
Total fat (%) 36.6 ± 0.8 35.7 ± 0.9 0.435 
TC (mg/dL) 214 ± 4 208 ± 4 0.376 
TG (mg/dL) 147 (129-167) 148 (130-168) 0.957 
HDL (mg/dL) 46 ± 2 47 ± 2 0.765 
LDL (mg/dL) 133 ± 4 129 ± 4 0.432 
Glucose (mg/dL) 91 ± 1 93 ± 1 0.162 
Insulin (pmol/L) 75 ± 4 86 ± 4 0.067 
ISI 3.5 (3.1-4.0) 3.1 (2.7-3.5) 0.139 
Glucose AUC  16511 ± 527 16549 ± 561 0.960 
Insulin AUC  46989 (41115-53703) 54325 (46989-62951) 0.145 
Visfatin (ng/mL) 21 (18-25) 18 (15-22) 0.271 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of genotype.  * indicates significant difference 






Figure 3-3.  Interaction between gender and the PBEF1 -1543 polymorphism for ISI 















PBEF1 -1001 T>G (rs9770242) 
 Genotypes for the PBEF1 -1001 polymorphism were available for all 116 
participants, and the genotype frequencies were approximately 8 % GG, 33 % GT, 
and 59 % TT, which were consistent with Hardy-Weinberg equilibrium (χ2 = 1.29, p 
= 0.256).  The G allele frequency of 24 % was congruent with previous reports (9; 
64), and both gender (p = 0.879) and HRT use (p = 0.845) did not differ between the 
PBEF1 -1001 genotype groups.  However, as there were few GG homozygotes in the 
study and baseline variables did not differ significantly between the GT and GG 
groups (all p > 0.120, data not shown), the GG genotype group was combined with 




Baseline characteristics of the participants grouped by -1001 genotype appear 
in Table 3-8.  The TT genotype group had significantly higher VO2max (p = 0.038), 
BMI (p = 0.017), and fasting insulin (p = 0.027) values and a significantly lower ISI 
value (p = 0.040) than the GG+GT group.  As depicted in Figure 3-4, there were also 
significant gender by genotype interaction effects detected for total cholesterol (p = 
0.024) and LDL-cholesterol (p = 0.025).  Furthermore, pairwise comparisons 
indicated that women with the G allele had significantly higher total cholesterol 
values than men with the G allele (p = 0.046), but for LDL-cholesterol, none of the 


















Table 3-8. Baseline characteristics of Gene Exercise Research Study participants 
genotyped for the PBEF1 -1001 polymorphism.  
 GG+GT 
(n = 32-47) 
TT 
(n = 38-69) 
P-value 
Men/Women 23/24 32/37 --- 
HRT use (Y/N) 13/11 16/21 --- 
Age (yrs) 58 ± 1 59 ± 1 0.560 
VO2max (mL/kg/min) 24.9 ± 0.5 26.3 ± 0.4 0.038* 
Weight (kg) 83.8 ± 1.9 80.3 ± 1.6 0.169 
BMI (kg/m2) 27.2 ± 0.5 28.8 ± 0.4 0.017* 
IA fat (cm2) 124 (112-137) 124 (115-135) 0.962 
SC fat (cm2) 329 ± 15 292 ± 13 0.061 
Total fat (%) 37.3 ± 0.9 35.4 ± 0.8 0.124 
TC (mg/dL) 209 ± 5 211 ± 4 0.782 
TG (mg/dL) 137 (119-158) 154 (137-174) 0.205 
HDL (mg/dL) 48 ± 2 46 ± 2 0.433 
LDL (mg/dL) 130 ± 4 132 ± 4 0.799 
Glucose (mg/dL) 91 ± 1 93 ± 1 0.175 
Insulin (pmol/L) 72 ± 5 86 ± 4 0.027* 
ISI 3.8 (3.2-4.4) 3.0 (2.6-3.5) 0.040* 
Glucose AUC  15370 ± 651 16996 ± 575 0.069 
Insulin AUC  45186 (38548-53088) 53827 (46666-62087) 0.113 
Visfatin (ng/mL) 22 (18-27) 19 (16-22) 0.296 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, No; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of genotype.  * indicates significant difference 








Figure 3-4.  Interaction between gender and the PBEF1 -1001 polymorphism for A) 
total cholesterol (p = 0.024) and B) LDL-cholesterol (p = 0.025).  Data are presented 































































PBEF1 -948 G>T 
 PBEF1 -948 G>T genotypes were available for all 116 participants.  The 
genotype frequencies were 71 % GG, 26 % GT, and 3 % TT, resulting in a T allele 
frequency of 16 %, similar to previous reports (11; 64; 132).  In addition, the 
genotype frequencies were in Hardy-Weinberg equilibrium (χ2 = 0.36, p = 0.547), 
and gender (p = 0.524) and HRT use (p = 0.883) were not different between the 
groups.  Due to the low frequency of the TT genotype and no statistical differences 
between the GT and TT groups at baseline (all p > 0.301, data not shown), the TT 
group was combined with the GT group for analysis. 
As displayed in Table 3-9, the GG genotype group had significantly higher 
glucose AUC (p = 0.030) and insulin AUC (p = 0.018) values and a significantly 
lower ISI value (p = 0.017) than the combined GT and TT group.  The GG group also 
tended to have a higher fasting insulin concentration than the T allele carriers (p = 
0.051).  Last, as shown in Figure 3-5, there was a significant gender by genotype 
interaction detected for the baseline visfatin concentration (p = 0.006), as women with 
the T allele had significantly higher baseline visfatin levels than women with the GG 
















Table 3-9. Baseline characteristics of Gene Exercise Research Study participants 
genotyped for the PBEF1 -948 polymorphism.  
 GG 
(n = 49-82) 
GT+TT 
(n = 19-34) 
P-value 
Men/Women 39/43 16/18 --- 
HRT use (Y/N) 20/23 9/9 --- 
Age (yrs) 59 ± 1 58 ± 1 0.323 
VO2max (mL/kg/min) 25.9 ± 0.4 25.3 ± 0.6 0.394 
Weight (kg) 81.4 ± 1.5 82.5 ± 2.3 0.695 
BMI (kg/m2) 28.4 ± 0.4 27.4 ± 0.6 0.150 
IA fat (cm2) 128 (118-138) 117 (104-131)  0.198 
SC fat (cm2) 310 ± 12 301 ± 18 0.678 
Total fat (%) 36.3 ± 0.7 36.0 ± 1.1 0.819 
TC (mg/dL) 213 ± 4 203 ± 6 0.156 
TG (mg/dL) 154 (138-171) 130 (109-154) 0.102 
HDL (mg/dL) 46 ± 2 49 ± 2 0.232 
LDL (mg/dL) 133 ± 3 125 ± 5 0.226 
Glucose (mg/dL) 92 ± 1 91 ± 2 0.586 
Insulin (pmol/L) 84 ± 4 70 ± 6 0.051 
ISI 3.1 (2.7-3.5) 4.0 (3.3-4.9) 0.017* 
Glucose AUC  16942 ± 515 14882 ± 759 0.030* 
Insulin AUC  54325 (47863-61518) 41020 (33884-49659) 0.018* 
Visfatin (ng/mL) 19 (16-22) 23 (18-30)  0.139 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of genotype.  * indicates significant difference 













Figure 3-5.  Interaction between gender and the PBEF1 -948 polymorphism for 
fasting plasma visfatin concentration (p = 0.006).  Data are presented as geometric 

























PBEF1 SER301SER C>T (rs2302559) 
 Genotypes for the PBEF1 SER301SER polymorphism were available on 113 
of the 116 participants.  Genotype frequencies for the PBEF1 SER301SER 
polymorphism were 42 % CC, 45 % CT, and 12 % TT.  The T allele frequency of 35 
% was slightly lower than previously reported (132).  However, the genotype 
frequencies met Hardy-Weinberg expectancies (χ2 = 0.006, p = 0.937), and both 
gender (χ2 = 0.697, p = 0.706) and HRT use (p = 0.931) did not differ by genotype 
group. 
 As presented in Table 3-10, intra-abdominal fat (p = 0.026), HDL-cholesterol 
(p = 0.039), fasting insulin (p = 0.018), insulin AUC (p = 0.002), and insulin 




and CT groups had significantly higher intra-abdominal fat (p = 0.037 and 0.029) and 
significantly lower insulin sensitivity (p = 0.003 and 0.037) than the TT group.  The 
CC group also had significantly higher fasting insulin (p = 0.014) and higher insulin 
AUC (p = 0.002) values than the TT group.  Pairwise comparisons for HDL-
cholesterol indicated no significant differences after Bonferroni adjustment.  Finally, 
there was a significant gender by genotype interaction effect for fasting glucose 
(Figure 3-6; p = 0.007) with a significant gender, but not a genotype, main effect 
(men > women, p < 0.001).  Pairwise comparisons indicated that women with the TT 
genotype had significantly lower fasting glucose levels than men with the CC (p = 
0.001) or TT (p = 0.004) genotype.  However, these results should be viewed with 
















Table 3-10. Baseline characteristics of Gene Exercise Research Study 




(n = 31-51) 
TT 
(n = 9-14) 
P-value 
Men/Women 24/24 23/28 8/6 --- 
HRT use (Y/N) 10/14 13/15 3/3 --- 
Age (yrs) 58 ± 1 59 ± 1 59 ± 1 0.757 
VO2max 26.4 ± 0.5 25.6 ± 0.5 24.5 ± 0.9 0.167 
Weight (kg) 82.1 ± 2.0 82.4 ± 1.9 80.0 ± 3.6 0.835 
BMI (kg/m2) 28.2 ± 0.6 27.8 ± 0.6 27.5 ± 1.1 0.760 
IA fat (cm2) 129 (117-143) 130 (119-143) 100 (84-119) 0.026* 
SC fat (cm2) 289 ± 15 316 ± 15 318 ± 28 0.393 
Total fat (%) 35.2 ± 0.9 36.4 ± 0.9 37.1 ± 1.7 0.515 
TC (mg/dL) 209 ± 5 212 ± 5 210 ± 10 0.841 
TG (mg/dL) 161 (140-185) 144 (126-164) 118 (88-159) 0.152 
HDL (mg/dL) 43 ± 2 48 ± 2 53 ± 4 0.039* 
LDL (mg/dL) 131 ± 4 131 ± 4 128 ± 9 0.949 
Glucose (mg/dL) 94 ± 1 91 ± 1 90 ± 2 0.265 
Insulin (pmol/L) 86 ± 4 79 ± 4 64 ± 7 0.018* 
ISI 2.9 (2.5-3.4) 3.3 (2.9-3.8) 4.6 (3.7-5.8) 0.004* 
Glucose AUC  16737 ± 589 16957 ± 564 14674 ± 975 0.123 







Visfatin (ng/mL) 19 (15-23) 20 (16-25) 22 (16-31) 0.633 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as 
geometric mean (95 % confidence interval), and categorical data, which are 
presented as count.  HRT, hormone replacement therapy; Y, yes; N, no; 
VO2max, maximal oxygen consumption; BMI, body mass index; IA; intra-
abdominal; SC, subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, 
high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; 
ISI, insulin sensitivity index; AUC, total area under the curve; n, sample size.  
Sample sizes are varied due to the inability to obtain all measurements on all 
participants.  Measurement units: VO2max, mL/kg/min; glucose AUC, mg/dL x 
120 min; insulin AUC, pmol/L x 120 min.  P-value is for the main effect of 











Figure 3-6.  Interaction between gender and the PBEF1 SER301SER polymorphism 






















 Pairwise linkage disequilibrium values for the PBEF1 -4689, -1543, -1001, -
948, and SER301SER polymorphisms appear in Table 3-11.  Moreover, a strong 
association was found for the PBEF1 -4689 and SER301SER polymorphisms (r2 = 
0.65, p < 0.001).  
PBEF1 haplotypes were inferred from the PBEF1 -4689, -1543, -1001, -948, 
and SER301SER genotype data using the program PHASE, version 2.1.  As shown in 
Table 3-12, 12 haplotypes were identified in our participant population, and 5 of these 
haplotypes occurred at a frequency > 5 %.  Furthermore, there were 14 individuals 
homozygous for the GCTGC haplotype, 7 homozygous for the GTTGC haplotype, 4 
homozygous for the TCGTT haplotype, and 1 homozygous for the TCTGT 




obesity-related variables were conducted by comparing haplotype carriers to non-
carriers for the 5 haplotypes present at a frequency > 5 % (GCTGC, GTTGC, 
TCGTT, TCTGT, and TCGGT). 
 
Table 3-11.  PBEF1 polymorphism pairwise linkage disequilibrium values. 
 -4689 -1543 -1001 -948 
-1543 0.04 
(p < 0.001) 
   
-1001 0.25 
(p < 0.001) 
0.06 
(p = 0.005) 
  
-948 0.25 
(p < 0.001) 
0.01 
(p = 0.143) 
0.16 
(p < 0.001) 
 
SER301SER 0.65 
(p < 0.001) 
0.04 
(p < 0.001) 
0.25 
(p < 0.001) 
0.32 
(p < 0.001) 
Values are r2.  P-values are from χ2 or Fisher Exact tests. 
  
Table 3-12. PBEF1 haplotypes and their frequencies.   
Haplotype Count Frequency 
GCTGC 80 34.5 % 
GTTGC 57 24.6 % 
TCGTT 35 15.1 % 
TCTGT 20 8.6 % 
TCGGT 19 8.2 % 
TCTGC 11 4.7 % 
GTTGT 3 1.3 % 
TTTGC 2 0.9 % 
TCTTT 2 0.9 % 
GCGGC 1 0.4 % 
TCGTC 1 0.4 % 
GCTGT 1 0.4 % 
 
Haplotype GCTGC 
 The GCTGC haplotype, comprised of common alleles for the 5 PBEF1 
polymorphisms, was present in 66 participants (14 homozygous).  Neither gender (χ2 




GCTGC haplotype carriers and non-carriers.  As shown in Table 3-13, baseline 
glucose AUC (p = 0.049) and insulin AUC (p = 0.048) differed between the GCTGC 
haplotype groups, with carriers having greater values than non-carriers. 
  
Table 3-13. Baseline characteristics of Gene Exercise Research Study participants 
grouped by PBEF1 GCTGC haplotype status.  
 GCTGC carriers 
(n = 40-66) 
GCTGC non-carriers 
(n = 31-50) 
P-value 
Men/Women 29/37 26/24 --- 
HRT use (Y/N) 17/20 12/12 --- 
Age (yrs) 58 ± 1 59 ± 1 0.553 
VO2max (mL/kg/min) 25.9 ± 0.4 25.5 ± 0.5 0.592 
Weight (kg) 81.1 ± 1.7 82.5 ± 1.9 0.570 
BMI (kg/m2) 27.8 ± 0.4 28.6 ± 0.5 0.244 
IA fat (cm2) 127 (117-138) 121 (109-133)  0.423 
SC fat (cm2) 299 ± 13 318 ± 15 0.356 
Total fat (%) 36.4 ± 0.8 36.0 ± 0.9 0.733 
TC (mg/dL) 211 ± 4 209 ± 5 0.766 
TG (mg/dL) 155 (137-175) 137 (119-157) 0.187 
HDL (mg/dL) 46 ± 2 48 ± 2 0.508 
LDL (mg/dL) 130 ± 4 132 ± 4 0.814 
Glucose (mg/dL) 93 ± 1 91 ± 1 0.343 
Insulin (pmol/L) 82 ± 4 77 ± 5 0.392 
ISI 3.0 (2.6-3.5) 3.7 (3.2-4.4) 0.055 
Glucose AUC  17015 ± 559 15299 ± 646 0.049* 
Insulin AUC  54828 (47643-63096) 44259 (37757-51761) 0.048* 
Visfatin (ng/mL) 20 (16-23) 21 (17-25)  0.718 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 





 The common alleles for the -4689, -1001, -948, and SER301SER 
polymorphisms and the variant allele for the -1543 polymorphism create haplotype 
GTTGC.  There were 50 carriers (7 homozygous) and 66 non-carriers of the GTTGC 
haplotype, and gender (χ2 = 0.070, p = 0.791) and HRT use (χ2 = 0.186, p = 0.666) 
did not differ between the groups.  In fact, the only variable that varied between the 
GTTGC carriers and non-carriers was BMI (p = 0.012), which was greater in the 
GTTGC carriers (Table 3-14). 
Haplotype TCGTT 
 The TCGTT haplotype contains the common allele for the -1543 
polymorphism and the variant alleles for the other 4 polymorphisms.  There were 31 
carriers (4 homozygous) and 85 non-carriers of the TCGTT haplotype, and gender (χ2 
= 0.016, p = 0.899) and HRT use (χ2 = 0.053, p = 0.819) did not differ between the 
groups.  Table 3-15 displays haplotype associations with glucose and obesity-related 
variables.  In the TCGTT haplotype carrier group, fasting insulin (p = 0.026), glucose 
AUC (p = 0.040), and insulin AUC (p = 0.040) values were all significantly lower 
than and the ISI (p = 0.020) value was significantly greater than the TCGTT 
haplotype non-carriers.  As shown in Figure 3-7, there were significant gender by 
haplotype interaction effects found for visfatin (p = 0.024) and total cholesterol (p = 
0.030), and although neither the gender nor the haplotype main effects were 
significant for visfatin, the gender main effect was significant for total cholesterol 
(women > men, p = 0.020).  Pairwise comparisons indicated that men with the 




non-carriers (p = 0.019), but there were no differences between the groups for visfatin 
after Bonferroni correction. 
 
Table 3-14. Baseline characteristics of Gene Exercise Research Study participants 
grouped by PBEF1 GTTGC haplotype status.  
 GTTGC carriers 
(n = 24-50) 
GTTGC non-carriers 
(n = 39-66) 
P-value 
Men/Women 23/27 32/34 --- 
HRT use (Y/N) 12/15 17/17 --- 
Age (yrs) 58 ± 1 59 ± 1 0.301 
VO2max (mL/kg/min) 26.2 ± 0.5 25.4 ± 0.4 0.215 
Weight (kg) 82.6 ± 1.9 81.0 ± 1.7 0.533 
BMI (kg/m2) 29.1 ± 0.5 27.4 ± 0.4 0.012* 
IA fat (cm2) 129 (117-142) 121 (111-132)  0.360 
SC fat (cm2) 307 ± 15 308 ± 13 0.947 
Total fat (%) 35.3 ± 0.9 36.9 ± 0.8 0.191 
TC (mg/dL) 207 ± 5 214 ± 4 0.288 
TG (mg/dL) 148 (129-169) 146 (129-166) 0.901 
HDL (mg/dL) 45 ± 2 48 ± 2 0.358 
LDL (mg/dL) 130 ± 4 131 ± 4 0.856 
Glucose (mg/dL) 92 ± 1 92 ± 1 0.668 
Insulin (pmol/L) 86 ± 5 75 ± 4 0.083 
ISI 3.1 (2.6-3.7) 3.5 (3.1-4.0) 0.250 
Glucose AUC  16463 ± 672 16142 ± 579 0.723 
Insulin AUC  53827 (45604-63680) 47098 (40926-54200) 0.232 
Visfatin (ng/mL) 19 (16-24) 20 (17-24)  0.701 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 






Table 3-15. Baseline characteristics of Gene Exercise Research Study participants 
grouped by PBEF1 TCGTT haplotype status.  
 TCGTT carriers 
(n = 19-31) 
TCGTT non-carriers 
(n = 49-85) 
P-value 
Men/Women 15/16 40/45 --- 
HRT use (Y/N) 8/8 21/24 --- 
Age (yrs) 58 ± 1 59 ± 1 0.411 
VO2max (mL/kg/min) 25.3 ± 0.6 25.9 ± 0.4 0.387 
Weight (kg) 82.5 ± 2.4 81.4 ± 1.5 0.681 
BMI (kg/m2) 27.2 ± 0.6 28.5 ± 0.4 0.093 
IA fat (cm2) 116 (103-132) 127 (118-137)  0.214 
SC fat (cm2) 300 ± 19 310 ± 12 0.659 
Total fat (%) 36.1 ± 1.1 36.2 ± 0.7 0.908 
TC (mg/dL) 201 ± 6 213 ± 4 0.105 
TG (mg/dL) 129 (107-154) 153 (138-170) 0.097 
HDL (mg/dL) 49 ± 3 46 ± 2 0.398 
LDL (mg/dL) 127 ± 6 132 ± 3 0.382 
Glucose (mg/dL) 91 ± 2 92 ± 1 0.575 
Insulin (pmol/L) 69 ± 6 84 ± 4 0.026* 
ISI 4.1 (3.3-4.9) 3.1 (2.7-3.5) 0.020* 
Glucose AUC  14926 ± 773 16886 ± 512 0.040* 
Insulin AUC  41783 (34356-50933) 53580 (47315-60674) 0.040* 
Visfatin (ng/mL) 22 (17-29) 19 (17-22)  0.312 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 












Figure 3-7.  Interaction between gender and the PBEF1 TCGTT haplotype for A) 
visfatin (p = 0.024) and B) total cholesterol (p = 0.030).  Data are geometric mean ± 
























































 The TCTGT haplotype, composed of the -4689 and SER301SER variant 
alleles and -1543, -1001, and -948 common alleles, was present in 19 participants (1 
homozygous).  Gender (χ2 = 1.001, p = 0.317) and HRT use (p = 0.260) did not differ 
between the groups.  Although age differed between the groups (p = 0.041), there 
were no other statistically significant TCTGT haplotype effects detected for any of 
the outcome variables (Table 3-16). 
Haplotype TCGGT 
 Haplotype TCGGT contains the variant alleles for the -4689, -1001, and 
SER301SER polymorphisms and the common alleles for the -1543 and -948 
polymorphisms.  In the study population, there were 19 carriers and 97 non-carriers 
of the TCGGT haplotype.  Although gender (χ2 = 0.257, p = 0.612) and HRT use (χ2 
= 0.264, p = 0.607) did not differ between the groups, the TCGGT haplotype carriers 
had significantly greater subcutaneous fat (p = 0.020) and significantly lower fasting 












Table 3-16. Baseline characteristics of Gene Exercise Research Study participants 
grouped by PBEF1 TCTGT haplotype status.  
 TCTGT carriers 
(n = 11-19) 
TCTGT non-carriers 
(n = 51-97) 
P-value 
Men/Women 11/8 44/53 --- 
HRT use (Y/N) 2/6 27/26 --- 
Age (yrs) 61 ± 1 58 ± 1 0.041* 
VO2max (mL/kg/min) 25.3 ± 0.8 25.8 ± 0.4 0.612 
Weight (kg) 77.1 ± 3.1 82.6 ± 1.4 0.110 
BMI (kg/m2) 29.2 ± 0.8 27.9 ± 0.4 0.146 
IA fat (cm2) 116 (99-136) 126 (117-135)  0.349 
SC fat (cm2) 293 ± 25 310 ± 11 0.543 
Total fat (%) 36.0 ± 1.5 36.2 ± 0.6 0.892 
TC (mg/dL) 219 ± 9 209 ± 3 0.307 
TG (mg/dL) 148 (115-191) 147 (132-162) 0.938 
HDL (mg/dL) 50 ± 4 46 ± 1 0.381 
LDL (mg/dL) 135 ± 8 130 ± 3 0.580 
Glucose (mg/dL) 92 ± 2 92 ± 1 0.942 
Insulin (pmol/L) 80 ± 8 79 ± 3 0.913 
ISI 3.3 (2.5-4.4) 3.3 (3.0-3.8) 0.952 
Glucose AUC  17454 ± 1161 16084 ± 465 0.280 
Insulin AUC  45290 (34041-60256) 50699 (45082-57016) 0.472 
Visfatin (ng/mL) 18 (14-25) 20 (18-24)  0.538 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, maximal 
oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 













Table 3-17. Baseline characteristics of Gene Exercise Research Study participants 
grouped by PBEF1 TCGGT haplotype status.  
 TCGGT carriers 
(n = 11-19) 
TCGGT non-carriers 
(n = 52-97) 
P-value 
Men/Women 8/11 47/50 --- 
HRT use (Y/N) 6/5 23/27 --- 
Age (yrs) 59 ± 1 58 ± 1 0.490 
VO2max (mL/kg/min) 25.3 ± 0.8 25.8 ± 0.4 0.572 
Weight (kg) 82.9 ± 3.1 81.5 ± 1.4 0.668 
BMI (kg/m2) 27.1 ± 0.8 28.3 ± 0.4 0.186 
IA fat (cm2) 126 (108-147) 124 (116-133)  0.843 
SC fat (cm2) 358 ± 24 297 ± 11 0.020* 
Total fat (%) 38.3 ± 1.4 35.8 ± 0.6 0.108 
TC (mg/dL) 219 ± 7 209 ± 3 0.222 
TG (mg/dL) 135 (109-167) 150 (135-166) 0.399 
HDL (mg/dL) 47 ± 3 47 ± 1 0.968 
LDL (mg/dL) 138 ± 6 129 ± 3 0.215 
Glucose (mg/dL) 87 ± 2 93 ± 1 0.010* 
Insulin (pmol/L) 66 (55-81) 78 (71-85) 0.132 
ISI 4.1 (3.2-5.2) 3.2 (2.8-3.6) 0.073 
Glucose AUC  15156 ± 1037 16524 ± 475 0.237 
Insulin AUC  42560 (33266-54450) 51761 (45920-58345) 0.159 
Visfatin (ng/mL) 21 (15-29) 20 (17-23)  0.800 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, insulin, ISI, insulin AUC, and visfatin, which are presented as 
geometric mean (95 % confidence interval), and categorical data, which are 
presented as count.  HRT, hormone replacement therapy; Y, yes; N, no; VO2max, 
maximal oxygen consumption; BMI, body mass index; IA; intra-abdominal; SC, 
subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin 
sensitivity index; AUC, total area under the curve; n, sample size.  Sample sizes 
are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 








Hypothesis 3: After Aerobic Exercise Training 
Average attendance for the 24 week aerobic exercise training intervention was 
90.8 ± 0.7 %.  Table 3-18 displays participant characteristics following the 
completion of the intervention.  Furthermore, some of the advantageous changes 
occurring with aerobic exercise training included improvements in insulin sensitivity 
[decreased fasting insulin (p = 0.001), decreased insulin AUC (p < 0.001), and 
increased ISI (p < 0.001)], lipoprotein-lipid levels [increased HDL-cholesterol (p < 
0.001) and reduced triglycerides (p = 0.001)], and a 15 % increase in VO2max (p < 
0.001).  Although slight, body composition changes were also favorable, with 
reductions in body weight (p < 0.001), intra-abdominal fat (p < 0.001), and total body 
fat (p < 0.001).  Moreover, weight loss averaged 1.0 ± 0.2 kg, or approximately 1.2 
%, a value consistent with the GERS requirement of body weight maintenance within 
























Table 3-18. Characteristics of study participants at baseline and following aerobic 
exercise training. 
 N Baseline After Training 
VO2max (mL/kg/min) 115 25.7 ± 0.4 29.6 ± 0.6* 
Weight (kg) 116 81.7 ± 1.4 80.7 ± 1.4* 
BMI (kg/m2) 116 27.9 ± 0.4 27.6 ± 0.4 
Intra-abdominal fat (cm2) 103 124 (116-133) 115 (107-124)* 
Subcutaneous fat (cm2) 101 303 ± 11 296 ± 10 
Total fat (%) 110 36.5 ± 0.8 35.0 ± 0.8* 
Total cholesterol (mg/dL) 92 211 ± 3 208 ± 3 
Triglycerides (mg/dL) 91 148 (134-163)  134 (122-148)* 
HDL-cholesterol (mg/dL) 90 47 ± 2 51 ± 2* 
LDL-cholesterol (mg/dL) 90 130 ± 3 128 ± 3 
Fasting glucose (mg/dL) 81 92 ± 1 93 ± 1 
Fasting insulin (pmol/L) 69 80 ± 3 72 ± 3* 
ISI 66 3.3 (2.9-3.7) 3.8 (3.4-4.2)* 
Glucose AUC 79 16355 ± 449 16061 ± 423 
Insulin AUC 68 50652 (45300-56637) 39976 (34261-46644)* 
Fasting visfatin (ng/mL) 63 20 (18-23) 23 (20-26)* 
Data are expressed as mean ± SE with the exception of intra-abdominal fat, 
triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric mean 
(95% confidence interval).  VO2max, maximal oxygen consumption; BMI, body 
mass index; ISI, insulin sensitivity index; AUC, total area under the curve; n, sample 
size.  Sample sizes are varied due to the inability to obtain all measurements on all 
participants.  Measurement units for glucose AUC are mg/dL x 120 min; 
measurement units for insulin AUC are pmol/L x 120 min.  * indicates significant 










PBEF1 -4689 G>T (rs2110385) 
 There were no significant differences between the PBEF1 -4689 genotype 
groups in any of the outcome variables with 24 weeks of aerobic exercise training 
(Table 3-19).  There were also no significant interactive effects involving the -4689 
polymorphism and gender or aerobic exercise training.  However, the GG, GT, and 
TT genotype groups all experienced significant increases in VO2max (p < 0.001) and 
significant decreases in intra-abdominal (p =0.009, p < 0.001, p = 0.020) and total 
body fat (p < 0.001, p < 0.001, p = 0.004) as a result of the training intervention.  In 
addition, both the GG and GT genotype groups significantly decreased weight (p = 
0.009, p < 0.001), BMI (p = 0.007, p < 0.001), and insulin AUC (p = 0.001, p < 
0.001), and significantly increased HDL-cholesterol (p = 0.001, p < 0.001) and ISI (p 
= 0.006, p < 0.001) values with training.  The exercise session attendance rates for the 
groups also did not differ (p = 0.690), averaging 90.3 ± 1.0, 91.4 ± 1.0, and 90.1 ± 1.9 
% for the GG, GT, and TT groups, respectively. 
PBEF1 -1543 C>T 
 Although there were no significant differences between the PBEF1 -1543 
genotype groups for any of the outcome variables following the completion of aerobic 
exercise training (Table 3-20), the CC and CT+TT genotype groups significantly 
increased VO2max (both p< 0.001), HDL-cholesterol (p = 0.002, p < 0.001), and ISI 
(p = 0.010, p = 0.004) and significantly decreased weight (both p = 0.001), BMI (both 
p = 0.001), total body fat (both p < 0.001), fasting insulin (p = 0.017, p = 0.021), and 
insulin AUC (both p < 0.001) with training.  There was also a significant gender by 




Bonferroni adjustment, none of the pairwise comparisons differed.  The average 
attendance for the CC and CT+TT genotype groups did not differ (p = 0.829) and was 
90.8 ± 0.9 and 90.5 ± 1.0 %, respectively. 
 
Table 3-19. After training characteristics of Gene Exercise Research Study 
participants genotyped for the PBEF1 -4689 polymorphism.  
 GG 
(n = 23-43) 
GT 
(n = 32-53) 
TT 
(n = 11-18) 
P-value 
VO2max 29.1 ± 0.4† 30.1 ± 0.4† 29.4 ± 0.7† 0.181 
Weight (kg) 80.8 ± 0.3† 80.4 ± 0.3† 80.9 ± 0.5 0.562 
BMI (kg/m2) 27.6 ± 0.1† 27.4 ± 0.1† 27.7 ± 0.2 0.394 
IA fat (cm2) 115 (108-122)† 118 (112-124)† 108 (99-118)† 0.251 
SC fat (cm2) 296 ± 7 294 ± 6 285 ± 11 0.664 
Total fat (%) 35.0 ± 0.3† 34.7 ± 0.3† 35.2 ± 0.5† 0.613 
TC (mg/dL) 203 ± 3 210 ± 3 209 ± 5 0.315 
TG (mg/dL) 132 (121-144)† 139 (129-150) 118 (101-138) 0.167 
HDL (mg/dL) 50 ± 1† 51 ± 1† 50 ± 2 0.595 
LDL (mg/dL) 124 ± 3 129 ± 3 135 ± 6 0.172 
Glucose 93 ± 2 94 ± 1 94 ± 2 0.864 
Insulin 72 ± 4† 74 ± 3 65 ± 5† 0.323 
ISI 3.7 (3.3-4.1)† 3.8 (3.5-4.2)† 4.0 (3.4-4.6) 0.718 
Glucose AUC  16375 ± 441 15923 ± 394 16889 ± 655 0.431 







Visfatin 22 (19-26) 24 (21-27)† 21 (17-26) 0.623 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95% confidence interval).  VO2max, maximal oxygen consumption; BMI, 
body mass index; IA; intra-abdominal; SC, subcutaneous; TC, total cholesterol; 
TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density 
lipoprotein cholesterol; ISI, insulin sensitivity index; AUC, total area under the 
curve; n, sample size.  Sample sizes are varied due to the inability to obtain all 
measurements on all participants.  Measurement units: VO2max, mL/kg/min; 
glucose, mg/dL; insulin, pmol/L; glucose AUC, mg/dL x 120 min; insulin AUC, 
pmol/L x 120 min; visfatin, ng/mL.  P-value is for the main effect of genotype.  * 
indicates significant difference between genotype groups.  † indicates significant 
change within genotype group with aerobic exercise training (via paired t-test).  




Table 3-20. After training characteristics of Gene Exercise Research Study 
participants genotyped for the PBEF1 -1543 polymorphism.  
 CC 
(n = 34-62) 
CT+TT 
(n = 32-53) 
P-value 
VO2max 29.6 ± 0.4† 29.5 ± 0.4† 0.879 
Weight (kg) 80.8 ± 0.3† 80.9 ± 0.3† 0.705 
BMI (kg/m2) 27.6 ± 0.1† 27.7 ± 0.1† 0.714 
IA fat (cm2) 114 (109-120)† 117 (111-124) 0.497 
SC fat (cm2) 296 ± 6 296 ± 7 0.990 
Total fat (%) 35.0 ± 0.3† 35.0 ± 0.3† 0.940 
TC (mg/dL) 208 ± 3 209 ± 3 0.729 
TG (mg/dL) 137 (127-149) 130 (121-141)† 0.325 
HDL (mg/dL) 50 ± 1† 51 ± 1† 0.101 
LDL (mg/dL) 128 ± 3 129 ± 3 0.663 
Glucose (mg/dL) 93 ± 1 94 ± 1 0.754 
Insulin (pmol/L) 69 ± 3† 75 ± 3† 0.144 
ISI 3.8 (3.5-4.2)† 3.7 (3.4-4.0)† 0.534 
Glucose AUC  16431 ± 373 16069 ± 383 0.503 
Insulin AUC  41495 (38019-45290)† 42658 (38994-46666)† 0.674 
Visfatin (ng/mL) 22 (19-25) 23 (20-27)† 0.431 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95% confidence interval).  VO2max, maximal oxygen consumption; BMI, 
body mass index; IA; intra-abdominal; SC, subcutaneous; TC, total cholesterol; 
TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density 
lipoprotein cholesterol; ISI, insulin sensitivity index; AUC, total area under the 
curve; n, sample size.  Sample sizes are varied due to the inability to obtain all 
measurements on all participants.  Measurement units: VO2max, mL/kg/min; 
glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 min.  P-value is for 
the main effect of genotype.  * indicates significant difference between genotype 
groups.  † indicates significant change within genotype group with aerobic 










Figure 3-8.  Interaction between gender and the PBEF1 -1543 polymorphism for 
VO2max (p = 0.043) following 24 weeks of aerobic exercise training.  Data are 
























PBEF1 -1001 T>G (rs9770242) 
 The aerobic exercise training intervention resulted in significant increases in 
VO2max (both p < 0.001) and HDL-cholesterol (both p < 0.001) and significant 
reductions in weight (p = 0.002, p < 0.001), intra-abdominal fat (p < 0.001, p = 
0.033), total body fat (both p < 0.001), triglyceride (p = 0.038, p = 0.006), and insulin 
AUC (p = 0.007, p = 0.004) values in the GG+GT and TT genotype groups.  
However, there were no significant differences between the PBEF1 -1001 genotype 
groups for any of the outcome variables after training, although fasting insulin neared 
significance (Table 3-21; p = 0.052).  There was a significant gender by genotype 
interaction detected for fasting glucose (Figure 3-9; p = 0.031), and pairwise 




values after 6 months of aerobic exercise training than women with the TT genotype 
(p = 0.037).  The exercise session adherence for the GG+GT and TT genotype groups 
was similar (p = 0.870), averaging 90.6 ± 1.1 and 90.8 ± 0.8 %, respectively.   
 
Table 3-21. After training characteristics of Gene Exercise Research Study 
participants genotyped for the PBEF1 -1001 polymorphism.  
 GG+GT 
(n = 34-62) 
TT 
(n = 32-53) 
P-value 
VO2max 29.7 ± 0.4† 29.5 ± 0.3† 0.716 
Weight (kg) 80.6 ± 0.3† 80.7 ± 0.3† 0.776 
BMI (kg/m2) 27.6 ± 0.6 27.6 ± 0.5 0.937 
IA fat (cm2) 112 (106-119)† 117 (111-123)† 0.265 
SC fat (cm2) 293 ± 7 297 ± 6 0.643 
Total fat (%) 34.9 ± 0.3† 35.0 ± 0.2† 0.888 
TC (mg/dL) 210 ± 3 206 ± 3 0.342 
TG (mg/dL) 132 (121-144)† 135 (126-145) † 0.694 
HDL (mg/dL) 51 ± 1† 50 ± 1† 0.372 
LDL (mg/dL) 131 ± 3 126 ± 3 0.243 
Glucose (mg/dL) 95 ± 1† 92 ± 1 0.087 
Insulin (pmol/L) 77 ± 3 68 ± 3† 0.052 
ISI 3.6 (3.3-4.0) 3.9 (3.6-4.3)† 0.282 
Glucose AUC  16227 ± 528 15928 ± 467 0.681 
Insulin AUC  43954 (36058-53456)† 37154 (31189-44157)† 0.215 
Visfatin (ng/mL) 23 (20-27) 22 (20-25)† 0.800 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95% confidence interval).  VO2max, maximal oxygen consumption; BMI, 
body mass index; IA; intra-abdominal; SC, subcutaneous; TC, total cholesterol; 
TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density 
lipoprotein cholesterol; ISI, insulin sensitivity index; AUC, total area under the 
curve; n, sample size.  Sample sizes are varied due to the inability to obtain all 
measurements on all participants.  Measurement units: VO2max, mL/kg/min; 
glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 min.  P-value is for 
the main effect of genotype.  * indicates significant difference between genotype 
groups.  † indicates significant change within genotype group with aerobic 






Figure 3-9.  Interaction between gender and the PBEF1 -1001 polymorphism for 
fasting glucose (p = 0.031) following 24 weeks of aerobic exercise training.  Data are 
























PBEF1 -948 G>T 
 Several advantageous changes occurred with aerobic exercise training in the 
PBEF1 -948 GG and GT+TT genotype groups, including increases in VO2max (both 
p < 0.001) and HDL-cholesterol (p < 0.001, p = 0.001) and decreases in intra-
abdominal fat (p = 0.007, p = 0.004) and total body fat (p < 0.001, p = 0.001) 
measurements.  However, total cholesterol (p = 0.002) and LDL-cholesterol (p = 
0.012) concentrations varied by genotype group with the GG group experiencing 
decreases (p = 0.005, p = 0.029) and the GT+TT group experiencing increases (p = 
0.022, p = 0.024) in both variables with training (Table 3-22).  As displayed in Figure 
3-10, there were significant gender by genotype interaction effects for subcutaneous 




indicated that men with the T allele had lower subcutaneous fat after aerobic exercise 
training than women with the GG genotype (p = 0.043) or T allele (p = 0.005).  
However, there were no group differences for HDL-cholesterol after Bonferroni 
adjustment.  For subcutaneous fat, the gender main effect was also significant 
(women > men; p = 0.001).  Last, exercise adherence did not differ between the GG 
and GT+TT genotype groups (p = 0.668, 90.5 ± 0.8 versus 91.2 ± 1.4 %). 
Table 3-22. After training characteristics of Gene Exercise Research Study 
participants genotyped for the PBEF1 -948 polymorphism.  
 GG 
(n = 45-81) 
GT+TT 
(n = 18-34) 
P-value 
VO2max 29.5 ± 0.3† 29.8 ± 0.5† 0.609 
Weight (kg) 80.5 ± 0.2† 81.1 ± 0.4 0.175 
BMI (kg/m2) 27.8 ± 0.4 27.1 ± 0.7 0.385 
IA fat (cm2) 117 (112-122)† 111 (104-118)† 0.194 
SC fat (cm2) 296 ± 5 292 ± 8 0.724 
Total fat (%) 34.9 ± 0.2† 35.1 ± 0.3† 0.641 
TC (mg/dL) 204 ± 2† 218 ± 4† 0.002* 
TG (mg/dL) 135 (126-144)† 130 (117-145) 0.573 
HDL (mg/dL) 50 ± 1† 52 ± 1† 0.115 
LDL (mg/dL) 125 ± 2† 137 ± 4† 0.012* 
Glucose (mg/dL) 92 ± 1 96 ± 2† 0.080 
Insulin (pmol/L) 71 ± 2† 72 ± 4 0.848 
ISI 3.9 (3.6-4.2)† 3.5 (3.1-4.0) 0.247 
Glucose AUC  15623 ± 404† 17064 ± 626 0.063 
Insulin AUC  37670 (32359-43752)† 46666 (36308-59979) 0.157 
Visfatin (ng/mL) 23 (21-26)† 22 (18-26) 0.664 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95% confidence interval).  VO2max, maximal oxygen consumption; BMI, 
body mass index; IA; intra-abdominal; SC, subcutaneous; TC, total cholesterol; 
TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density 
lipoprotein cholesterol; ISI, insulin sensitivity index; AUC, total area under the 
curve; n, sample size.  Sample sizes are varied due to the inability to obtain all 
measurements on all participants.  Measurement units: VO2max, mL/kg/min; 
glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 min.  P-value is for 
the main effect of genotype.  * indicates significant difference between genotype 
groups.  † indicates significant change within genotype group with aerobic 




Figure 3-10.  Interaction between gender and the PBEF1 -948 polymorphism for A) 
subcutaneous fat (p = 0.044) and B) HDL-cholesterol (p = 0.046) following 24 weeks 






















































PBEF1 SER301SER C>T (rs2302559) 
 Table 3-23 displays after training characteristics for the participants grouped 
by PBEF1 SER301SER genotype.  With aerobic exercise training, all 3 genotype 
groups significantly increased VO2max (p < 0.001) and decreased total body fat (p < 
0.001, p < 0.001, p = 0.030).  In addition, the CC and CT groups significantly 
increased HDL-cholesterol (p = 0.001, p < 0.001) and ISI (both p = 0.006) and 
significantly decreased weight (p = 0.003, p < 0.001), BMI (p = 0.002, p < 0.001), 
intra-abdominal fat (p < 0.001, p = 0.018), total body fat (both p < 0.001), triglyceride 
(p = 0.006, p = 0.016), and insulin AUC (both p < 0.001) measurements.  However, 
the magnitude of change in BMI and total body fat was not consistent between the 
groups, resulting in significant differences in BMI (p = 0.030) and total body fat (p = 
0.011) values by genotype.  Furthermore, the CT group decreased BMI significantly 
more than the TT group (p = 0.030) and decreased total body fat significantly more 
than the CC and TT groups (p = 0.037 and 0.046, respectively) [Figure 3-11].  
Overall, there were no significant interactive effects detected involving the 
SER301SER polymorphism and gender or aerobic exercise training, and exercise 
attendance did not differ (p = 0.689) between the groups, averaging 90.2 ± 1.0, 91.4 ± 









Table 3-23. After training characteristics of Gene Exercise Research Study 




(n = 31-51) 
TT 
(n = 8-14) 
P-value 
VO2max 29.3 ± 0.4† 30.1 ± 0.4† 29.4 ± 0.8† 0.365 
Weight (kg) 81.0 ± 0.3† 80.5 ± 0.3† 82.1 ± 0.6 0.054 
BMI (kg/m2) 27.6 ± 0.1† 27.4 ± 0.1† 28.0 ± 0.2 0.030* 
IA fat (cm2) 114 (108-121)† 116 (110-123)† 116 (104-128) 0.862 
SC fat (cm2) 297 ± 7 287 ± 6 300 ± 12 0.475 
Total fat (%) 35.2 ± 0.3† 34.2 ± 0.3† 35.6 ± 0.5† 0.011* 
TC (mg/dL) 205 ± 3 208 ± 3 215 ± 6 0.333 
TG (mg/dL) 135 (123-147)† 132 (122-144)† 145 (120-175) 0.702 
HDL (mg/dL) 49 ± 1† 51 ± 1† 51 ± 2 0.240 
LDL (mg/dL) 124 ± 3 130 ± 3 133 ± 7 0.242 
Glucose 93 ± 1 93 ± 1 96 ± 2 0.557 
Insulin 67 ± 3† 77 ± 3 67 ± 5 0.058 
ISI 3.9 (3.5-4.3)† 3.7 (3.4-4.1)† 3.7 (3.1-4.4) 0.838 
Glucose AUC  16380 ± 423 15862 ± 400† 17053 ± 684 0.315 







Visfatin 22 (19-25) 24 (20-27) 22 (18-28) 0.703 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as 
geometric mean (95% confidence interval).  VO2max, maximal oxygen 
consumption; BMI, body mass index; IA; intra-abdominal; SC, subcutaneous; 
TC, total cholesterol; TG, triglycerides; HDL, high density lipoprotein 
cholesterol; LDL, low density lipoprotein cholesterol; ISI, insulin sensitivity 
index; AUC, total area under the curve; n, sample size.  Sample sizes are varied 
due to the inability to obtain all measurements on all participants.  Measurement 
units: VO2max, mL/kg/min; glucose, mg/dL; insulin, pmol/L; glucose AUC, 
mg/dL x 120 min; insulin AUC, pmol/L x 120 min; visfatin, ng/mL.  P-value is 
for the main effect of genotype.  * indicates significant difference between 
genotype groups.  † indicates significant change within genotype group with 




























Figure 3-11.  Body composition variables grouped by PBEF1 SER301SER genotype.  
A) BMI and B) total body fat.  Data are adjusted mean ± SE.  * indicates significant 
difference between genotype groups.  † indicates significant difference within 




























































 Many advantageous changes occurred in the GCTGC haplotype carrier and 
non-carrier groups with 24 weeks of aerobic exercise training.  Furthermore, both 
haplotype groups significantly increased VO2max (both p < 0.001), HDL-cholesterol 
(both p < 0.001), and ISI (p = 0.021, p = 0.003) values and significantly decreased 
weight (p < 0.001, p = 0.006), intra-abdominal fat (p = 0.001, p = 0.023), total body 
fat (both p < 0.001), triglyceride (p = 0.005, p = 0.040), fasting insulin (p = 0.014, p = 
0.025), and insulin AUC (p = 0.009, p = 0.001) values.  As a result of these similar 
changes, there were no significant differences in glucose and obesity-related 
outcomes between the GCTGC haplotype groups following the completion of aerobic 
exercise training (Table 3-24), even though glucose AUC and insulin AUC were 
different at baseline.  Exercise adherence also did not differ (p = 0.657), averaging 
90.4 ± 0.8 % in the haplotype carrier group and 91.0 ± 1.1 % in the haplotype non-
carrier group.   
GTTGC 
 Table 3-25 displays the after aerobic exercise training values for glucose and 
obesity-related variables grouped by GTTGC haplotype.  With aerobic exercise 
training, VO2max (both p < 0.001), HDL-cholesterol (both p < 0.001), and ISI 
increased (p = 0.006, p = 0.014), whereas weight (p = 0.001, p < 0.001), total body fat 
(both p < 0.001), fasting insulin (p = 0.020, p = 0.017), and insulin AUC (p < 0.001, p 
= 0.014) values decreased in the GTTGC haplotype carrier and non-carrier groups, 




and 90.6 ± 0.9 %, there were no significant differences between the GTTGC 
haplotype groups after training. 
 
Table 3-24. After training characteristics of Gene Exercise Research Study 
participants grouped by PBEF1 GCTGC haplotype status.  
 GCTGC carriers 
(n = 35-66) 
GCTGC non-carriers 
(n = 28-50) 
P-value 
VO2max (mL/kg/min) 29.5 ± 0.4† 29.6 ± 0.4† 0.830 
Weight (kg) 80.5 ± 0.3† 80.9 ± 0.3† 0.373 
BMI (kg/m2) 27.4 ± 0.5 27.8 ± 0.6 0.661 
IA fat (cm2) 115 (110-121)† 115 (108-121)†  0.879 
SC fat (cm2) 294 ± 6 298 ± 7 0.614 
Total fat (%) 34.9 ± 0.2† 35.0 ± 0.3† 0.797 
TC (mg/dL) 207 ± 3 210 ± 3 0.426 
TG (mg/dL) 138 (129-149)† 128 (118-139)† 0.172 
HDL (mg/dL) 50 ± 1† 51 ± 1† 0.189 
LDL (mg/dL) 127 ± 3 131 ± 3 0.331 
Glucose (mg/dL) 93 ± 1 93 ± 1 0.913 
Insulin (pmol/L) 72 ± 3† 71 ± 3† 0.872 
ISI 3.7 (3.4-4.0)† 3.9 (3.5-4.2)† 0.543 
Glucose AUC  16125 ± 461 15980 ± 519 0.838 





Visfatin (ng/mL) 22 (20-25) 23 (20-27)  0.619 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  VO2max, maximal oxygen consumption; BMI, body mass index; IA; intra-
abdominal; SC, subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high 
density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, 
insulin sensitivity index; AUC, total area under the curve; n, sample size.  Sample 
sizes are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 
between haplotype groups.  † indicates significant change within haplotype group 









Table 3-25. After training characteristics of Gene Exercise Research Study 
participants grouped by PBEF1 GTTGC haplotype status.  
 GTTGC carriers 
(n = 24-50) 
GTTGC non-carriers 
(n = 38-66) 
P-value 
VO2max (mL/kg/min) 29.4 ± 0.4† 29.7 ± 0.4† 0.567 
Weight (kg) 80.8 ± 0.3† 80.6 ± 0.3† 0.650 
BMI (kg/m2) 28.0 ± 0.6 27.3 ± 0.5 0.379 
IA fat (cm2) 117 (111-124) 113 (108-119)†  0.341 
SC fat (cm2) 301 ± 7 292 ± 5 0.303 
Total fat (%) 35.1 ± 0.3† 34.9 ± 0.2† 0.595 
TC (mg/dL) 208 ± 3 208 ± 3 0.888 
TG (mg/dL) 131 (121-142)† 136 (126-147) 0.519 
HDL (mg/dL) 51 ± 1† 50 ± 1† 0.419 
LDL (mg/dL) 127 ± 3 129 ± 3 0.662 
Glucose (mg/dL) 94 ± 1 93 ± 1 0.822 
Insulin (pmol/L) 73 ± 3† 71 ± 3† 0.553 
ISI 3.7 (3.4-4.1)† 3.8 (3.5-4.1)† 0.773 
Glucose AUC  16114 ± 525 16021 ± 455 0.895 





Visfatin (ng/mL) 24 (20-28)† 22 (19-25)  0.441 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  VO2max, maximal oxygen consumption; BMI, body mass index; IA; intra-
abdominal; SC, subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high 
density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, 
insulin sensitivity index; AUC, total area under the curve; n, sample size.  Sample 
sizes are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 
between haplotype groups.  † indicates significant change within haplotype group 









 With aerobic exercise training, TCGTT haplotype carriers and non-carriers 
significantly increased VO2max (both p < 0.001) and HDL-cholesterol (p = 0.001, p < 
0.001) levels and significantly decreased intra-abdominal (both p = 0.005) and total 
body fat (p = 0.002, p < 0.001) measurements.  However, TCGTT haplotype carriers 
had significantly higher total cholesterol (p = 0.002) and LDL-cholesterol (p = 0.018) 
concentrations than haplotype non-carriers after the training intervention (Table 3-
26).  These differences were consistent with the changes that occurred with aerobic 
exercise training, as both total cholesterol and LDL-cholesterol increased in the 
haplotype carrier group (p = 0.017, p = 0.037), but decreased in the haplotype non-
carrier group (p  = 0.007, p = 0.046).  There were also significant gender by 
haplotype interaction effects detected for subcutaneous fat (p = 0.025), intra-
abdominal fat (p = 0.042), and HDL-cholesterol (p = 0.019) [Figure 3-12]. 
Furthermore, men with the TCGTT haplotype had significantly lower subcutaneous 
fat after 24 weeks of aerobic exercise training than women with the TCGTT 
haplotype (p = 0.003) or women without the haplotype (p = 0.027), but after 
Bonferroni adjustment, none of the group comparisons were different for intra-
abdominal fat or HDL-cholesterol.  Along with the interaction effects, the gender 
main effect was significant for subcutaneous fat (women > men, p < 0.001) and intra-
abdominal fat (women > men, p = 0.040), and the haplotype main effect was 
significant for HDL-cholesterol (carriers > non-carriers, p = 0.039).  Overall, there 
were no differences (p = 0.873) in exercise session adherence between the TCGTT 




Table 3-26. After training characteristics of Gene Exercise Research Study 
participants grouped by PBEF1 TCGTT haplotype status.  
 TCGTT carriers 
(n = 24-50) 
TCGTT non-carriers 
(n = 38-66) 
P-value 
VO2max (mL/kg/min) 29.7 ± 0.5† 29.5 ± 0.3† 0.684 
Weight (kg) 81.2 ± 0.4 80.5 ± 0.2† 0.144 
BMI (kg/m2) 27.1 ± 0.7 27.8 ± 0.4 0.407 
IA fat (cm2) 109 (102-117)† 117 (112-122)†  0.102 
SC fat (cm2) 292 ± 8 296 ± 5 0.694 
Total fat (%) 35.1 ± 0.4† 34.9 ± 0.2† 0.682 
TC (mg/dL) 219 ± 4† 205 ± 2† 0.002* 
TG (mg/dL) 129 (115-145) 135 (127-144)† 0.480 
HDL (mg/dL) 53 ± 1† 50 ± 1† 0.039* 
LDL (mg/dL) 137 ± 4† 126 ± 2† 0.018* 
Glucose (mg/dL) 96 ± 2† 92 ± 1 0.080 
Insulin (pmol/L) 72 ± 4 71 ± 2† 0.848 
ISI 3.5 (3.1-4.0) 3.9 (3.6-4.2)† 0.247 
Glucose AUC  17064 ± 626 15623 ± 404† 0.063 
Insulin AUC  46666 (36308-59979) 37670 (32359-
43752)† 
0.157 
Visfatin (ng/mL) 22 (18-26) 23 (21-26)†  0.609 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  VO2max, maximal oxygen consumption; BMI, body mass index; IA; intra-
abdominal; SC, subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high 
density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, 
insulin sensitivity index; AUC, total area under the curve; n, sample size.  Sample 
sizes are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 
between haplotype groups.  † indicates significant change within haplotype group 














Figure 3-12. Interaction between gender and the PBEF1 TCGTT haplotype for A) 
subcutaneous fat (p = 0.025), B) intra-abdominal fat (p = 0.042), and C) HDL-
cholesterol (p = 0.039) following 24 weeks of aerobic exercise training.  Data are 
presented as adjusted mean ± SE (subcutaneous fat, HDL-cholesterol) or geometric 














































































































 Both the TCTGT haplotype carrier and non-carrier groups increased VO2max 
(both p < 0.001) and ISI (p = 0.020, p = 0.004) and decreased weight (p = 0.020, p < 
0.001), total body fat (p = 0.002, p < 0.001), and insulin AUC (p = 0.007, p = 0.002) 
values with aerobic exercise training.  Thus, there were no significant differences in 
glucose or obesity-related variables between the TCTGT haplotype groups after 
training (Table 3-27).  There were also no differences (p = 0.143) in exercise 
adherence between the haplotype carrier and non-carrier groups, 93.0 ± 1.6 and 90.3 


















Table 3-27. After training characteristics of Gene Exercise Research Study 
participants grouped by PBEF1 TCTGT haplotype status.  
 TCTGT carriers 
(n = 11-19) 
TCTGT non-carriers 
(n = 55-97) 
P-value 
VO2max (mL/kg/min) 30.1 ± 0.7† 29.4 ± 0.3† 0.323 
Weight (kg) 80.6 ± 0.5† 80.7 ± 0.2† 0.785 
BMI (kg/m2) 26.6 ± 0.9 27.8 ± 0.4 0.258 
IA fat (cm2) 121 (110-133) 114 (109-119)†  0.284 
SC fat (cm2) 304 ± 11 294 ± 5 0.409 
Total fat (%) 35.0 ± 0.5† 35.0 ± 0.2† 0.999 
TC (mg/dL) 210 ± 5 208 ± 2 0.704 
TG (mg/dL) 136 (116-158) 133 (126-141)† 0.830 
HDL (mg/dL) 50 ± 2 51 ± 1† 0.646 
LDL (mg/dL) 132 ± 6 128 ± 2 0.510 
Glucose (mg/dL) 91 ± 2 94 ± 1 0.225 
Insulin (pmol/L) 71 ± 5 72 ± 2† 0.912 
ISI 4.1 (3.5-4.7)† 3.7 (3.5-4.0)† 0.335 
Glucose AUC  15316 ± 888 16194 ± 368 0.367 





Visfatin (ng/mL) 23 (18-28) 23 (20-25)†  0.947 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, ISI, insulin AUC, and visfatin, which are presented as geometric 
mean (95 % confidence interval), and categorical data, which are presented as 
count.  VO2max, maximal oxygen consumption; BMI, body mass index; IA; intra-
abdominal; SC, subcutaneous; TC, total cholesterol; TG, triglycerides; HDL, high 
density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; ISI, 
insulin sensitivity index; AUC, total area under the curve; n, sample size.  Sample 
sizes are varied due to the inability to obtain all measurements on all participants.  
Measurement units: glucose AUC, mg/dL x 120 min; insulin AUC, pmol/L x 120 
min.  P-value is for the main effect of haplotype.  * indicates significant difference 
between haplotype groups.  † indicates significant change within haplotype group 










 With 24 weeks of aerobic exercise training, TCGGT haplotype carrier and 
non-carrier groups significantly increased VO2max (both p < 0.001) and HDL-
cholesterol (p = 0.036, p < 0.001) values and significantly decreased weight (pp = 
0.004, p < 0.001), total body fat (both p < 0.001), and insulin AUC (p = 0.014, p = 
0.002) values.  However, total cholesterol decreased only in the haplotype carrier 
group with training (p = 0.017), which contributed to differing total cholesterol 
concentrations by haplotype group after training (Table 3-28; p = 0.021).  Exercise 
adherence did not differ (p = 0.815), averaging 91.1 ± 1.6 and 90.6 ± 0.8 % for the 

















Table 3-28. After training characteristics of Gene Exercise Research Study 
participants grouped by PBEF1 TCGGT haplotype status.  
 TCGGT carriers 
(n = 11-19) 
TCGGT non-carriers 
(n = 52-97) 
P-value 
VO2max (mL/kg/min) 29.5 ± 0.6† 29.6 ± 0.3† 0.890 
Weight (kg) 79.9 ± 0.5† 80.8 ± 0.2† 0.099 
BMI (kg/m2) 28.1 ± 0.9 27.5 ± 0.4 0.540 
IA fat (cm2) 117 (107-127) 115 (110-119)†  0.691 
SC fat (cm2) 292 ± 10† 296 ± 5 0.708 
Total fat (%) 34.6 ± 0.4† 35.1 ± 0.2† 0.327 
TC (mg/dL) 199 ± 4† 210 ± 2 0.021* 
TG (mg/dL) 139 (123-158) 132 (124-140)† 0.464 
HDL (mg/dL) 50 ± 1† 51 ± 1† 0.552 
LDL (mg/dL) 122 ± 5† 130 ± 2 0.145 
Glucose (mg/dL) 94 ± 2† 93 ± 1 0.777 
Insulin (pmol/L) 71 (63-80) 68 (64-72)† 0.526 
ISI 3.9 (3.4-4.6) 3.7 (3.5-4.0)† 0.500 
Glucose AUC  15144 ± 796 16276 ± 376 0.208 





Visfatin (ng/mL) 23 (18-28) 23 (20-25)†  0.968 
Data are expressed as adjusted mean ± SE with the exception of intra-abdominal 
fat, triglycerides, insulin, ISI, insulin AUC, and visfatin, which are presented as 
geometric mean (95 % confidence interval), and categorical data, which are 
presented as count.  VO2max, maximal oxygen consumption; BMI, body mass 
index; IA; intra-abdominal; SC, subcutaneous; TC, total cholesterol; TG, 
triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density 
lipoprotein cholesterol; ISI, insulin sensitivity index; AUC, total area under the 
curve; n, sample size.  Sample sizes are varied due to the inability to obtain all 
measurements on all participants.  Measurement units: glucose AUC, mg/dL x 120 
min; insulin AUC, pmol/L x 120 min.  P-value is for the main effect of haplotype.  
* indicates significant difference between haplotype groups.  † indicates 
significant change within haplotype group with aerobic exercise training (via 









Chapter 4: Discussion 
 
In a paper that was later retracted (36), Fukuhara and colleagues initially 
linked visfatin with glucose metabolism and obesity via its reported insulin-like 
abilities (activating the insulin receptor, increasing glucose uptake) (35).  However, 
other researchers have suggested that visfatin’s connection to glucose and obesity-
related variables may be through its role as the NAD biosynthetic enzyme Nampt and 
NAD’s involvement in transcriptional regulation, including that of the sirtuin family 
(95-97).  Regardless of the mechanism, researchers have examined the role of visfatin 
and visfatin gene (PBEF1) polymorphisms in glucose and obesity-related conditions 
and visfatin’s response to weight loss and medication interventions.  Aerobic exercise 
training has been shown to be an effective way to improve many health outcomes, 
including glucose tolerance and insulin sensitivity.  However, less is known regarding 
visfatin’s response to an aerobic exercise training intervention, and no one, to our 
knowledge, has examined whether polymorphic variation in the PBEF1 gene affects 
aerobic exercise training-induced changes in glucose and obesity-related variables.   
Thus, the present study sought to determine whether 6 months of aerobic 
exercise training reduced plasma visfatin levels in generally healthy, middle-to-older 
aged individuals with impaired glucose tolerance (IGT) or normal glucose tolerance 
(NGT).  In addition, this study investigated the influence of common polymorphisms 
in the PBEF1 gene on glucose and obesity-related variables and their responses to 
aerobic exercise training. 
The major findings were that 1) plasma visfatin levels were similar in IGT and 




aerobic exercise training, 2) there were significant associations at baseline between a 
number of glucose and obesity-related variables and PBEF1 gene polymorphisms and 
haplotypes, and 3) PBEF1 gene polymorphisms and haplotypes influenced the 
aerobic exercise training-induced change in several glucose and obesity-related 
variables.  
 Visfatin Levels 
 Our data indicate no significant differences in the baseline level of fasting 
visfatin in our generally healthy, but sedentary, middle-to-older aged IGT and NGT 
participants.  In addition, baseline visfatin levels were not significantly correlated 
with weight, BMI, intra-abdominal fat, subcutaneous fat, total body fat, total 
cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting glucose, fasting 
insulin, glucose AUC, insulin AUC, or insulin sensitivity (via ISI) in the combined 
study population, the IGT group, or the NGT group.  Despite previous reports 
suggesting ties between visfatin and inflammation (9; 54; 79; 86; 119), there were 
also no significant correlations with C-reactive protein levels at baseline 
Jian et al. (55), Li et al. (73), and Dogru et al. (29) have previously compared 
visfatin levels in IGT and healthy NGT individuals, and similar to our findings, 
reported no difference between the groups.  Also in concordance with our study, 
Dogru et al. found no significant correlations between visfatin and BMI, fasting 
insulin, fasting glucose, lipoprotein-lipids, insulin sensitivity (via HOMA-IR), or C-
reactive protein in either group (29).   Based on these data, circulating levels of 




Three previous studies have examined the visfatin response to aerobic 
exercise training.  Haider et al. reported a significant reduction in circulating visfatin 
levels after 2 and 4 months of aerobic exercise training in T1D patients (43).  
Similarly, Choi et al. reported significant decreases in plasma visfatin after 12 weeks 
of a combined aerobic and resistance exercise training program in overweight and 
obese Korean women (25).  Brema et al. also reported significant decreases in 
visfatin in young obese and T2D patients with 12 weeks of exercise (17).  In contrast 
to these studies, and to our hypothesis, we found a slight but significant increase in 
plasma visfatin levels with 6 months of aerobic exercise training in generally healthy, 
IGT and NGT individuals.  Furthermore, our data indicate that there were no 
differences in the magnitude of the aerobic exercise training induced-change in 
visfatin, as both groups increased levels of the adipokine by approximately 15-20 %. 
Weight loss is one explanation for the discrepancy in results between our 
study and the Choi et al. study.  Moreover, the participants in the Choi et al. study 
lost ~ 4-5 kg of body weight during the 12 week intervention (25), whereas our 
participants lost ~ 2 kg in the IGT group and ~ 0.5 kg in the NGT with 24 weeks of 
aerobic exercise training.  Thus, weight loss, independently or in combination with 
exercise training, may have been the cause of the decreased visfatin levels in the Choi 
et al. study.    
In contrast, participants in the Haider et al. study did not change their BMI, 
total cholesterol, LDL-cholesterol, HDL-cholesterol, or fasting glucose levels with 2 
or 4 months of aerobic exercise training or 8 months after the cessation of the training 




patients experienced a non-significant decrease in HDL-cholesterol (from 72 ± 17 to 
64 ± 13 mg/dL) and a non-significant increase in fasting glucose (from 151 ± 46 to 
192 ± 61 mg/dL) (43).  Based on the lack of improvement in HDL-cholesterol and 
since no training variable was measured (i.e.VO2max), it does not appear that a 
training effect took place.  Furthermore, it is possible that the T1D patients were 
already physically active before the aerobic exercise training intervention began, 
since regular exercise was only reported as an exclusionary factor in the non-
exercising control group.  Thus, the change in visfatin levels in the Haider et al. study 
may have been due to a factor other than exercise training.   
Participants in the Brema et al. study also did not experience improvement in 
many physiological outcomes with training.  In fact, the T2D patients did not change 
their VO2max with 12 weeks of training even though they were bicycling 4 times per 
week, 1 hour per session, at 75 % VO2max intensity (17).   It is also possible that the 
patients were regularly physically active before the aerobic exercise training 
intervention began, which may explain the lack of improvement.  At any rate, it does 
not appear that a training effect occurred and that the training effect was responsible 
for the visfatin decrease. 
Another possible explanation for the differing results may be the retrospective 
design of our study, including the analysis of visfatin from plasma samples stored for 
2-8 years at -80 degrees Celsius.  Although plasma sample age was not related to 
visfatin levels in our study, it is possible that the viability of this cytokine-like 
molecule may have been compromised by its time in storage.  Moreover, only one 




the researchers found that storage at -25 degrees Celsius for 1 month resulted in 
measurement of 92.7 ± 31.1 % of the initial value (83). 
An additional reason for the discrepancy in results may be due to the C-
terminal assay used in this study and in the Choi et al., Haider et al., and Brema et al. 
studies to measure circulating visfatin.  Moreover, Korner et al. compared serum 
visfatin measures from 3 immunoassays, the C-terminal competitive EIA we used, a 
competitive radioimmunoassay (RIA, Phoenix Pharmaceuticals), and a sandwich 
enzyme-linked immunosorbent assay (ELISA, AdipoGen Inc.) and found no 
correlation between the visfatin measurements (65).  The researchers also compared 
the ability of the assays to detect the visfatin dimer, previously measured at 100-150 
kDa, and using size exclusion chromatography serum fractions found that only the 
ELISA detected a peak in this area (65).  Another recent study reported a low 
correlation (r = 0.4121) between the EIA C-terminal assay and the full-length ELISA 
assay (94).  Thus, measurement of full-length visfatin with the newer ELISA may 
have provided a better indicator of physiologically circulating visfatin levels. 
It is also quite possible that the circulating visfatin concentration is not 
reflective of biologically relevant levels of visfatin.  Furthermore, visfatin occurs as 
an extracellular secreted protein and as an intracellular protein (97).  The importance 
of each of these sources to visfatin biology and to its downstream metabolic effects 
has not been determined.  In addition, Frydelund-Larson et al. found 3-fold increases 
in visfatin abdominal adipose tissue mRNA expression after 3 hours of acute cycling 
exercise, but found no differences in skeletal muscle mRNA expression or plasma 




exercise training effects.  Finally, adipose tissue is only one of the possible sources of 
visfatin as visfatin mRNA and protein levels have been found in a variety of tissues 
(97; 102).   Thus, the relative contribution of the differing production sites to the total 
circulating visfatin pool is also not known.   
Finally, in the present study, the change in visfatin levels with aerobic 
exercise training was not significantly correlated with the change in glucose and 
obesity-related variables in the total study population or in the NGT group.  However, 
in the IGT group, the aerobic exercise training-induced increase in visfatin was 
correlated with the non-significant decrease in CRP levels.  But after accounting for 
the effect of gender, this relationship was no longer significant.  Thus, the aerobic 
exercise training-induced change in visfatin does not appear to be related to training-
induced improvements in glucose and obesity-related variables. 
Influence of PBEF1 Polymorphisms & Haplotypes at Baseline 
 Genetic variation in the PBEF1 gene has previously been associated with a 
wide range of metabolic phenotypes (11; 16; 64; 115; 132).  In agreement with this 
and consistent with the theme of hypothesis 2, we found significant associations with 
glucose and obesity-related variables for the PBEF1 -4689, -1001, -948, and 
SER301SER polymorphisms and the GCTGC, GTTGC, TCGTT, and TCGGT 
haplotypes. 
 First, our data show an influence of the -4689 polymorphism on ISI and 
insulin AUC.  Furthermore, the TT genotype group, with lower insulin AUC and 
higher ISI values, was found to be more insulin sensitive than the GG genotype 




4689 G>T (rs2302559) polymorphism with fat mass, total apoB, LDL apoB, and 
LDL-cholesterol, but not with glucose or insulin levels, in the Quebec Family Study 
(11).  Last, the -4689 polymorphism could influence transcriptional activity of the 
PBEF1 gene, as it is located in the promoter region of the PBEF1 gene.  However, no 
studies, to our knowledge, have investigated this or other functional effects of the -
4689 polymorphism.  
 We found that the -1001 T>G (rs9770242) polymorphism was associated with 
VO2max, BMI, fasting insulin, and ISI.  Furthermore, the GG+GT group had lower 
VO2max, BMI, and fasting insulin, and higher ISI values than the TT genotype group.  
In concordance with these findings, Bailey et al. reported that the G allele was 
associated with lower fasting insulin and fasting glucose levels in the Quebec Family 
Study (11), and Korner et al. reported higher waist-to-hip ratios in healthy school 
children with the TT genotype (64).  However, Bottcher et al. did not find 
associations with T2D, body composition, or glucose-related variables in Germans 
(16).  Bottcher’s group also did not find an influence of the -1001 polymorphism on 
circulating visfatin levels or visfatin mRNA expression, but they found that subjects 
homozygous for the G allele had a lower visceral to subcutaneous visfatin mRNA 
expression ratio (16).  With regard to functional significance, a luciferase reporter 
gene assay found that the G allele did not alter PBEF1 gene expression in lung 
microvascular endothelial cells (129).  However, the PBEF1 -1001 polymorphism is 
reportedly in complete linkage disequilibrium with rs1319501, another PBEF1 




 The -948 G>T polymorphism has been associated with fasting insulin, total 
apoB, and LDL apoB in the Quebec Family Study (11), diastolic blood pressure in 
obese children (64), and inflammation (CRP and fibrinogen levels) in Italians (132).  
In addition, in case-control studies, Zhang et al. found that the T allele was associated 
with T2D (132), whereas Bottcher et al. found no association with T2D (16).   
Bottcher et al. also reported that non-diabetic German T allele carriers had 
significantly lower OGTT 2-hour plasma glucose, lower fasting insulin levels, and a 
lower visceral to subcutaneous visfatin mRNA expression ratio than those with the 
GG genotype (16).  In contrast to our hypothesis, but in agreement with Bottcher et 
al., we found lower fasting insulin, lower insulin AUC, lower glucose AUC, and 
higher ISI values in the -948 T allele carriers than in the GG homozygotes.  The -948 
G>T polymorphism is located in the promoter region of PBEF1, and to date, no one 
has examined whether the -948 T allele alters PBEF1 transcriptional activity. 
 To our knowledge, this is the first study to examine the SER301SER C>T 
(rs2302559) polymorphism in connection with glucose and obesity-related variables.  
We found that the TT genotype group had significantly lower intra-abdominal fat and 
significantly higher insulin sensitivity values than the CT and CC genotype groups.  
The TT genotype group also had lower fasting insulin and lower insulin AUC values 
than the CC genotype group.  As this polymorphism results in a synonymous amino 
acid change, its functional importance may be via linkage with another SNP. 
 Although we found significant associations for the PBEF1 -4689, -1001, -948, 
and SER301SER polymorphisms, we found no influence of the -1543 C>T 




findings, Jian et al. reported that the -1543 polymorphism was not associated with 
T2D, fasting glucose, 120 minute OGTT glucose, glucose AUC, total cholesterol, 
triglycerides, HDL-cholesterol, or LDL-cholesterol in a study involving Chinese 
NGT, IGT, and T2D patients (55).  In contrast, Tokunaga et al. reported an 
association with triglyceride and HDL-cholesterol levels in Japanese individuals; 
however, they did not adjust for or report the age or gender composition of the 
genotype groups (115).  Tokunaga’s group also did not assess diet, physical activity 
levels, or menopausal status, and differences in these factors could also have 
influenced the lipoprotein-lipid measures.  Ye et al. reported that the -1543 
polymorphism was functional, with ~ 1.8-fold decrease in luciferase reporter gene 
expression in human lung microvascular endothelial cells with the T allele promoter 
(129).  However, Tokunaga et al. found no differences in luciferase activity for the C 
versus T promoters in 3T3-L1 adipocytes (115). 
As the combination of polymorphisms is often more informative in 
determining the genetic contribution to phenotypes, we constructed haplotypes from 
the PBEF1 -4689 , -1543, -1001, -948, and SER301SER polymorphisms using the 
program PHASE, version 2.1 and investigated their association with glucose and 
obesity-related outcomes.  Overall, we found that 5 PBEF1 haplotypes were 
commonly occurring in our participant population: GCTGC, GTTGC, TCGTT, 
TCTGT, and TCGGT.  Moreover, carriers of the GCTGC haplotype, composed of the 
common alleles for the 5 PBEF1 polymorphisms, had higher glucose AUC and higher 
insulin AUC values than non-carriers.  Carriers of the GTTGC haplotype, comprised 




and the variant allele for the -1543 polymorphism, were found to have a higher mean 
BMI than non-carriers.   
In contrast, we found that TCGTT haplotype carriers had significantly lower 
fasting insulin, lower glucose AUC, lower insulin AUC, and higher ISI values than 
TCGTT haplotype non-carriers.  Furthermore, the TCGTT haplotype contains the 
variant alleles for the -4689, -1001, -948, and SER301SER polymorphisms and 
common allele for the -1543 polymorphism.   
Haplotype TCTGT, composed of the -4689 and SER301SER variant alleles 
and -1543, -1001, and -948 common alleles, was not associated with any glucose or 
obesity-related phenotypes.  Last, carriers of the TCGGT haplotype, made up of the 
variant alleles for the -4689, -1001, and SER301SER polymorphisms and the 
common alleles for the -1543 and -948 polymorphisms, had greater subcutaneous fat 
mass, but lower fasting glucose than haplotype non-carriers. 
Thus, genetic variations in the PBEF1 gene were found to influence glucose 
and obesity-related variables at baseline. 
Influence of PBEF1 Polymorphisms & Haplotypes After Aerobic  
Exercise Training 
No previous study has investigated the influence of PBEF1 polymorphisms 
and haplotypes on the response of glucose and obesity-related variables to aerobic 
exercise training.  Our data indicate no significant differences after training for any of 
the outcome variables by the PBEF1 -4689 G>T, -1543 C>T, and -1001 T>G 
genotype groups.  In the -4689 and -1001 groups this is due to the disadvantaged 




in no differences after training between the groups.  In contrast, there were no 
differences at baseline between the -1543 genotype groups, and the groups changed 
similarly with training.  However, we found that total cholesterol and LDL-
cholesterol levels varied by the -948 genotype after training due to the GG group 
decreasing and the GT+TT group increasing these variables with aerobic exercise 
training.  In addition, we found significant SER301SER genotype effects on BMI and 
total body fat after training.  Moreover, the CT group decreased BMI significantly 
more than the TT group and decreased total body fat significantly more than the CC 
and TT groups.   
In PBEF1 haplotype analyses, we found no significant differences in glucose 
and obesity-related exercise training outcomes between the GCTGC, GTTGC, and 
TCTGT haplotype carriers and non-carriers.  However, the TCGTT haplotype carriers 
had significantly higher after training total cholesterol, HDL-cholesterol, and LDL-
cholesterol levels than TCGTT haplotype non-carriers.  These differences were a 
result of significant increases in total cholesterol and LDL-cholesterol with aerobic 
exercise training in the TCGTT haplotype carrier group and significant decreases 
with training in the TCGTT haplotype non-carrier group.  In addition, HDL-
cholesterol increased in both the TCGTT haplotype carrier and non-carrier groups, 
but the magnitude of the increase was greater in the haplotype carrier group.  Finally, 
in the TCGGT haplotype group, total cholesterol decreased only in the haplotype 
carriers, resulting in differing total cholesterol levels by haplotype after training. 
The mechanism linking PBEF1 polymorphic variation to differential 




unknown.  The initial step may involve alterations in visfatin/Nampt mRNA and 
protein levels.  Moreover, there are hypoxia (10; 85; 105) and stress responsive 
elements (85) in the PBEF1 promoter region that may affect PBEF1 transcription in 
response to aerobic exercise training.  Furthermore, it is possible that one or more of 
the promoter polymorphisms examined in this study affects transcription factor 
binding at or near these sites, thereby altering PBEF1 transcription.  However, more 
research is needed to clarify these speculations. 
Thus, PBEF1 polymorphisms and haplotypes influence aerobic exercise 
training-induced changes in glucose and obesity-related variables. 
Gender & Genotype/Haplotype Interaction Effects 
In addition to the significant PBEF1 polymorphism and haplotype effects in 
the present study, numerous gender by genotype and gender by haplotype interaction 
effects were detected.  All of the women in our study were postmenopausal, and in all 
instances, HRT use did not differ by genotype group.  Furthermore, Ognjanovic et al. 
did not include any sex hormone specific response elements in their list of putative 
PBEF1 transcription factor binding sites (85).  Thus, it is unclear as to why the 
response of men and women differed by genotype.  Future studies investigating 
PBEF1 genetic variation must at least account for the moderating effect of gender and 
may want to consider analyzing men and women separately to avoid this variability. 
PBEF1 Genotype & Haplotype Results Summary 
Overall, we found that the variant allele group for the -4689, -1001, -948, and 




including greater insulin sensitivity, than the common allele group at baseline.  These 
similar results may be due to the moderate pairwise linkage disequilibrium between 
the polymorphisms.  However, the functional significance of the polymorphisms 
remains to be determined, as does the effect that leads to alterations in glucose and 
obesity-related phenotypes.  Thus, research in these areas is needed.   
Our data also show PBEF1 haplotype effects on glucose and obesity-related 
variables at baseline.  Consistent with the single SNP analyses, the TCGTT 
haplotype, composed of the variant alleles for the -4689, -1001, -948, and 
SER301SER polymorphisms and the -1543 common allele, was associated with 
higher insulin sensitivity measures.  Furthermore, the GCTGC haplotype (comprised 
of the polymorphism common alleles) and GTTGC haplotype (comprised of 
polymorphism common alleles and the -1543 variant allele) were both associated 
with more disadvantageous phenotypes.  Despite these interesting results, future 
research needs to clarify the functional impact of the different haplotypes and identify 
the mechanism responsible for alterations in glucose and obesity-related phenotypes.   
We also report, for the first time, significant influences of PBEF1 
polymorphisms and haplotypes on glucose and obesity-related variables following the 
completion of 24 weeks of aerobic exercise training.  Moreover, the PBEF1 -948 
variant, TCGTT haplotype, and TCGGT haplotype were associated with differential 
changes in lipoprotein-lipid levels with training.  In addition, the SER301SER 
polymorphism influenced changes in BMI and total body fat.  However, the reason 




Chapter 5: Conclusion 
 
 Adipokines, such as visfatin, may help to connect diabetes and obesity, and 
previous research has linked visfatin and visfatin gene polymorphisms with glucose 
and obesity-related conditions.  Furthermore, aerobic exercise training has often been 
used as an effective means to improve many health outcomes, including insulin 
sensitivity.  Although we report that plasma visfatin levels increased similarly in 
response to an aerobic exercise training intervention in IGT and NGT individuals, we 
found no relationships between the aerobic exercise training-induced change in 
circulating visfatin levels and the training-induced changes in glucose and obesity-
related variables.  Thus, alterations in circulating visfatin levels are likely not related 
to or responsible for the beneficial improvements in glucose and obesity-related 
variables with aerobic exercise training.  However, we found that polymorphic 
variation in the visfatin gene (PBEF1) influenced glucose and obesity-related 
outcomes at baseline and modulated their aerobic exercise training-induced 
responses.  The mechanism responsible for these differential changes is unknown.  
Thus, future studies need to address the functional significance of PBEF1 
polymorphisms and haplotypes, clarify mechanisms connecting visfatin to glucose 
and obesity-related phenotypes, and verify the influence of PBEF1 polymorphisms 





Chapter 6: Literature Review 
Visfatin History 
In 2004, Fukuhara and colleagues used the term visfatin to describe a 
seemingly novel adipokine that they had isolated from the visceral fat of humans and 
mice (35).  However, visfatin had previously been isolated from lymphocytes in the 
early 1990s and identified as pre-B cell colony-enhancing factor (PBEF) (102).  
Furthermore, PBEF was a cytokine-like molecule, enhancing the effects of 
interleukin-7 and stem cell factor on pre-B-lymphocyte colony formation, which was 
also present in skeletal muscle, liver, and bone marrow (102).  Additionally, Jia and 
colleagues reported that PBEF was an inflammatory cytokine since it was upregulated 
in neutrophils and acted to inhibit/delay neutrophil apoptosis in experimental 
inflammation and sepsis (54).  PBEF was also reported to function as a nicotinamide 
phosphoribosyltransferase (100) known as Nampt, active in nicotinamide adenine 
dinucleotide (NAD) salvage pathways and suggested to be a regulator of mammalian 
health and longevity (127).  Thus, visfatin, PBEF, and Nampt are the same enzyme.   
Protein Structure & Secretion 
 The human visfatin protein reportedly shares over 95 % sequence homology 
with rat and mouse visfatin (11).  Kim and colleagues reported on the crystal structure 
of rat visfatin in apo form, in complex with nicotinamide mononucleotide (NMN), 
and in complex with FK-866 (a nicotinamide phosphoribosyltransferase inhibitor) 




homodimer (59).  Furthermore, the researchers discovered that both of the monomers 
were needed for the formation of visfatin’s active site (located near the interface of 
the subunits) and nicotinamide phosphoribosyltransferase activity (59).  Khan and 
colleagues found similar results for mouse and human visfatin (58), and Wang and 
colleagues added that mouse visfatin was a type II phosphoribosyltransferase (121).  
Lastly, Takahashi and colleagues characterized the crystal structure of human visfatin 
in its free form and also found that it was dimeric (111).   
Visfatin mRNA and protein expression have been detected in a variety of 
tissues.  In fact, Revollo and colleagues found that mouse brown adipose tissue, liver, 
and kidney had the highest levels; mouse heart had intermediate levels; mouse white 
adipose tissue, lung, spleen, testis, and muscle had low levels; and mouse brain and 
pancreas had no visfatin protein expression levels (97).  Furthermore, Fukuhara and 
colleagues reported that visfatin also occurs as a secreted protein, detectable in the 
circulation (35).  However, visfatin’s peptide sequence does not have a typical signal 
sequence for secretion (102), and this has led researchers to question whether visfatin 
is a secreted protein or a substance released during cell death.  An early study by 
Kitani and colleagues suggested that visfatin was an intracellular rather than secreted 
protein with growth-phase dependent changes in subcellular localization (61).  
However, more recent studies have shown that visfatin occurs intracellularly and as 
an extracellular secreted protein (97).  Moreover, its release was found to occur via a 
non-classical pathway in adipocytes (97; 114).   





Visfatin, Obesity, & Glucose Metabolism 
Visfatin: Insulin-mimetic Effects 
Via a series of studies involving cell culture, rodent models, and humans, 
Fukuhara and colleagues extended the realm of visfatin to include obesity and glucose 
metabolism (35).   
With regards to adiposity, Fukuhara et al. found increased visfatin mRNA 
expression and protein secretion during 3T3-L1 adipocyte differentiation in vitro.  
Furthermore, in 101 men and women, plasma visfatin levels were positively and 
significantly correlated with visceral and subcutaneous fat content (r = 0.68 and 0.22, 
respectively).  In a mouse model of obesity and T2D (KKAy mice), plasma visfatin 
and visceral fat visfatin mRNA levels were found to increase during the growth 
period associated with obesity development in the mice.  Similar results were 
reported in c57BL/6J mice fed a high fat diet.  Thus, visfatin was related to adiposity.  
(35) 
Fukuhara and colleagues also investigated the biological and physiological 
effects of visfatin and found relationships with glucose regulation.  Acute 
administration of recombinant visfatin in c57BL/6J mice decreased fasting plasma 
glucose in a dose-dependent manner, independent of insulin changes.  Furthermore, 
injecting visfatin into obese, insulin resistant KKAy mice and into mice made insulin 
deficient via streptozotocin treatment decreased plasma glucose, effects similar to 
insulin injections in the mice.  Also, chronic administration of visfatin via an 
adenovirus vector increased visfatin levels and reduced glucose and insulin levels in 




Fukuhara’s group also studied visfatin transgenic mice.  Visfatin gene 
knockout mice were found to die during embryonic development, whereas visfatin 
heterozygous mice were viable, with plasma visfatin levels two-thirds those of 
wildtype mice.  In addition, visfatin heterozygotes were not significantly different 
from wildtype mice with regard to growth, food intake, body weight, organ and tissue 
weight, plasma insulin, or insulin sensitivity during an insulin tolerance test.  
However, plasma glucose levels under fasting and feeding conditions and after 60 and 
120 minutes of a glucose tolerance test were found to be elevated in the heterozygous 
mice as compared to wildtype mice.  Based on this work, visfatin was believed to 
have an insulin-like effect.  (35) 
Fukuhara’s group then further examined visfatin’s insulin-like actions.  
Similar to insulin treatment, visfatin treatment was found to increase glucose uptake 
in 3T3-L1 adipocytes and L6 myocytes and prevent glucose release from H4IIEC3 
hepatocytes.  Also similar to insulin, visfatin injection in mice and visfatin treatment 
in cultured 3T3-F442A adipocytes, L6 myocytes, and H4IIEC3 hepatocytes was 
found to induce phosphorylation of the insulin receptor, insulin receptor substrate 
(IRS)-1, and IRS-2.  Additionally, the cell culture studies detected 
phosphatidylinositol 3-kinase binding to IRS-1 and IRS-2 and phosphorylation of Akt 
and mitogen-activated protein kinase.  Further studies found that the binding 
dissociation constants for visfatin and insulin were similar, although insulin and 
visfatin were found to bind to the insulin receptor in slightly different ways.  The 
results of these studies again supported visfatin having insulin-like effects.  However, 




impact was likely to be small due to its low concentration (~ 10 % that of insulin).  
(35)      
Fukuhara and colleagues’ paper was considered seminal in this area, until its 
retraction in 2007.  In the retraction, the researchers indicated that questions raised by 
the Osaka University Graduate School of Medicine Committee for Research Integrity 
dealt with their experiments involving visfatin interactions with the insulin receptor.  
In brief, after publication of the original paper, the researchers later determined that 
not all of their visfatin preparations bound with or activated the insulin receptor.   
However, the researchers indicated that they believed in their earlier conclusions and 
cited a report by Xie and colleagues (126) which found that visfatin had insulin-
mimetic effects in cultured osteoblasts.  (36)  
An earlier article also indicated that the Osaka University Graduate School of 
Medicine questioned the exclusion of results that did not support the researchers’ 
conclusions.  Specifically, the researchers tried to create male and female visfatin 
heterozygous knockout mice.  The male transgenic mice were viable and had half of 
the visfatin found in a wildtype mouse; however, the females did not experience as 
much visfatin lowering.  Moreover, only the results from the male mice were 
included in the paper.  (82)  
Providing support to Fukuhara and colleagues’ report of visfatin’s insulin-
mimetic effects, Xie and colleagues studied the effects of visfatin on human primary 
osteoblasts.  First, they found that human osteoblasts did not express visfatin mRNA, 
but osteoblast lysates were found to express insulin receptor protein.   Next, the 




that visfatin treatment in human osteoblasts led to insulin receptor, IRS-1, and IRS-2 
tyrosine phosphorylation, effects similar to those of insulin treatment at the same 
concentrations.  Furthermore, pre-treatment with an inhibitor of insulin receptor 
tyrosine kinase activity inhibited visfatin and insulin activation of insulin signaling.  
The researchers then examined whether visfatin influenced glucose transport in 
osteoblasts and found that visfatin increased glucose uptake at concentrations of 10 
and 100 ng/mL, effects similar to those of 10 and 100 ng/mL of insulin.  Visfatin also 
increased osteoblast proliferation, type 1 collagen mRNA expression, type 1 collagen 
secretion, and osteoblast mineralization; effects similar to those of insulin.  (126) 
Although Xie and colleagues reported similar insulin-like visfatin effects 
(126), other researchers have not been able to replicate these findings (97).  
Furthermore, Revollo and colleagues have surmised that visfatin’s connection to 
obesity and glucose-related variables is via its role as the NAD biosynthetic enzyme 
Nampt (95; 97).  Moreover, the researchers proposed a mechanism linking Nampt to 
NAD biosynthesis and glucose metabolism via the maintenance of NMN and NAD 
levels.  Studies leading to a description of this mechanism will be briefly discussed 
next. 
Visfatin as Nampt: Linking NAD Biosynthesis & Glucose Metabolism 
 NAD is a coenzyme in oxidation/reduction reactions and its biosynthesis can 
be initiated 3 ways: the de-novo pathway from tryptophan, from nicotinic acid, or 
most commonly, from nicotinamide (95).  Moreover, nicotinamide is converted to 
NMN by Nampt and then into NAD by nicotinamide/nicotinic acid mononucleotide 




limiting enzyme in the NAD pathway starting from nicotinamide since Nampt had a 
higher affinity for nicotinamide and was less catalytically efficient than Nmnat (96).  
In addition, the researchers found that overexpressing Nampt in mouse cell lines 
increased total NAD levels, whereas overexpressing Nmnat did not increase NAD 
levels (96).   
Revollo and colleagues also characterized intracellular and extracellular 
Nampt using a series of in vitro and in vivo experiments.  They examined the 
production of intracellular and extracellular Nampt in pre-adipocytes during 
differentiation and found that the differentiation of both brown and white (3T3-L1) 
adipocytes increased intracellular and extracellular Nampt levels, with greater 
amounts produced by brown adipocytes.  Furthermore, they examined the production 
of extracellular Nampt by different cell types and found that COS-7 (a transformed 
monkey kidney cell line) and Chinese hamster ovary (CHO) cells produced detectable 
amounts of extracellular Nampt when Nampt was overexpressed.  However, COS-7, 
CHO, HEK293 (a human embryonic kidney cell line), and NIH3T3 (a mouse 
fibroblast cell line) cell lines did not naturally produce extracellular Nampt.  Next, 
they investigated the enzymatic activity of intracellular and extracellular Nampt and 
determined that both were highly active with dimerization necessary for Nampt’s 
activity.  (97)  
Then, the researchers tried to replicate the findings of Fukuhara and 
colleagues [i.e. insulin-mimetic effects (35)], but were unable to as they found that 
Nampt did not induce expression of adipocyte differentiation markers, did not affect 




did not reduce blood glucose levels.  The researchers also generated Nampt 
transgenic mice.  Similar to the results of Fukuhara and colleagues (35), Revollo’s 
group found that Nampt null mice were embryonically lethal, but that Nampt 
heterozygous mice were viable.  Moreover, the heterozygous mice had normal body 
weight, normal islet area, normal fasting glucose levels, reduced intracellular Nampt, 
reduced brown adipose tissue NAD levels, and normal liver NAD levels as compared 
to wild-type mice.  They also found that extracellular Nampt was reduced by ~ 50 % 
in female Nampt heterozygous knockout mice, but not in male mice.  As mentioned 
previously, Fukuhara and colleagues found ~ 50 % reduced levels of visfatin in male 
mice (35); furthermore, the possible difference may be because the researchers used 
different techniques and mouse strains to create the transgenic creatures.  Regardless, 
the female Nampt heterozygous mice had reduced insulin secretion and impaired 
glucose tolerance during intraperitoneal glucose tolerance tests (IPGTT), but no 
differences as compared to wild-type mice during insulin tolerance tests.  (97) 
Next, the researchers confirmed their in vivo results with in vitro studies of 
isolated islets.  They found that glucose-stimulated insulin secretion was reduced in 
isolated primary islets from Nampt heterozygous females, and that NAD levels also 
were ~ 40 % reduced in the animals when nicotinamide was added to the culture 
media overnight.  The researchers also found that the IPGTT glucose tolerance and 
insulin secretion defects in the heterozygous Nampt mice and isolated islets could be 
corrected by administering NMN, a product of the Nampt reaction.  Furthermore, the 
researchers found that NMN was also present in plasma, and reduced by ~ 35 % in 




Nampt inhibitor (FK866) and found that the inhibitor reduced NAD biosynthesis by ~ 
80 % and glucose-simulated insulin secretion by ~ 60 % in the isolated islets.  (97) 
These results suggest that Nampt is a NAD biosynthetic enzyme and that the 
NAD activity of Nampt is important for glucose regulation.  Furthermore, Nampt did 
not exert insulin-mimetic effects as reported previously by Fukuhara and colleagues.  
Thus, visfatin’s effects on glucose metabolism may be related to its function as 
Nampt, rather than its suggested function as an adipokine.  Moreover, the mechanism 
proposed by Revollo and colleagues, and outlined in Figure 6-1, links Nampt to 
metabolic processes via the regulation of NAD-dependent factors such as the sirtuin 
family.  First, nicotinamide absorbed from the diet undergoes distribution to the 
tissues via the circulation.  If taken up by cells, nicotinamide conversion to NMN 
would take place by intracellular Nampt.  If not removed from the circulation, 
extracellular Nampt could convert nicotinamide to NMN, which would then be 
transported to the tissues for uptake.  Once inside of cells, Nmnat would complete the 
reaction to produce NAD.  Then, via its involvement in transcriptional regulation, 
NAD could regulate metabolism.  (95; 97)  
One such target of NAD is the sirtuin family, as NAD cleavage is required for 
their deacetylase and ADP-ribosylation reactions.  Furthermore, Revollo and 
colleagues found that the Nampt-regulated NAD biosynthesis pathway regulated 
mammalian sirtuin activity (96).  In fact, the researchers found that increasing Nampt 
dosage led to increased transcriptional repressive activity of the mouse Sir2α catalytic 
domain (96).  Moreover, the sirtuin family has been implicated in the regulation of 




 There are 7 mammalian sirtuins (SIRT1-7); moreover, SIRT1 and SIRT3 have 
been implicated in metabolism via their deacetylase activity, whereas SIRT4 has been 
connected to metabolism via its role as an ADP-ribosyltransferase.  SIRT1 has been 
shown to regulate genes involved in pancreatic beta cell insulin secretion (14; 80), 
beta cell survival (60), adipogenesis (91), lipolysis (38; 91; 99), gluconeogenesis (98; 
99), and cholesterol degradation (99).  In contrast, Hallows and colleagues reported 
that SIRT3 activates acetyl-coenzyme A synthetase (47), an enzyme important in the 
formation of acetyl coenzyme A, which is involved in the citric acid cycle, 
cholesterol synthesis, and fatty acid synthesis.  Finally, Haigis and colleagues linked 
SIRT4 to amino acid-stimulated insulin secretion as it was shown to ADP-ribosylate 
and inhibit glutamate dehydrogenase (46).  Thus, the sirtuin family may help to 
connect Nampt, NAD biosynthesis, and metabolic function.  In addition, Nampt and 
the sirtuin family have been linked in studies involving stress resistance (128) and 
smooth muscle cell longevity (118).         
Figure 6-1. Mechanism linking Nampt, NAD biosynthesis, and physiological function 
as proposed by Revollo and colleagues (95; 97). 
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Visfatin Studies  
 Regardless of the mechanism, numerous investigators have examined 
visfatin’s potential role in glucose and obesity-related conditions.  The studies can be 
organized into those involving associations with circulating visfatin levels, visfatin 
mRNA expression, and visfatin gene polymorphisms.  Additionally, 1 study has 
examined the response of visfatin to acute exercise and 3 studies have assessed 
exercise training’s impact on visfatin. 
Circulating Visfatin Studies 
Type 1 Diabetes & Type 2 Diabetes  
Haider and colleagues compared fasting plasma visfatin levels in insulin 
dependent diabetes mellitus (T1D) patients (n = 18) and healthy individuals (n = 14).  
The groups differed in terms of age, fasting glucose, and visfatin levels.  Moreover, 
T1D patients had greater plasma visfatin levels than the healthy controls.  In addition, 
there were no correlations found between visfatin and body mass index (BMI) or age.  
Although the participants were comparable in terms of BMI, lipoprotein-lipid 
measures, and physical activity status, the researchers did not adjust for differences in 
age and gender.  In addition, some of the patients were receiving medications for co-
morbidities, including hypertension and cholesterol medication, and these were not 
taken into account in the analyses.  Last, the researchers did not assess diet, and 
differences in diet could potentially influence the outcome measures. (43)   
Lopez-Bermejo and colleagues investigated the relationship between serum 
visfatin and insulin secretion in 118 non-diabetic men, 64 men and women with type 




circulating visfatin was negatively correlated with the acute insulin response to 
glucose (i.e. insulin secretion, r = -0.27), fasting insulin (r = -0.20), and 30-minute 
oral glucose tolerance test (OGTT) insulin (r = -0.24), and positively correlated with 
insulin sensitivity (r = 0.19).  However, only the acute insulin response to glucose was 
found to be a significant predictor of serum visfatin in multiple linear regression 
analysis.  The researchers also found circulating levels of visfatin to be higher in T2D 
patients as compared to non-diabetic patients and highly correlated with glycosylated 
hemoglobin (r = 0.49).  However, when comparing newly diagnosed T2D patients to 
the non-diabetics, there was no difference in visfatin levels.  Last, visfatin levels were 
increased in the T1D patients as compared to both the T2D patients and the non-
diabetics.  Thus, this study suggests that T1D, and possibly beta-cell dysfunction, are 
associated with increased visfatin levels.  However, the study did not take the varying 
types of medication used by the T2D patients into account.  The study also did not 
account for the effects of diet, physical activity status, or female menopausal status, 
all of which may have influenced the outcome measures.  (74)  
Takebayashi and colleagues investigated the association between plasma 
visfatin and vascular endothelial function in patients with T2D.  Overall, the 
investigators reported no differences in the plasma visfatin concentration between 
healthy control individuals (n = 28) and diabetic patients (n = 80).  In addition, they 
found no differences in plasma visfatin between patients receiving and not receiving 
antihypertensive medications and between smokers and non-smokers.  The 
researchers also looked at the effects of 12 weeks of pioglitazone or insulin treatment 




investigators did however detect significant correlations between the visfatin 
concentration and creatinine clearance (r = -0.2750), aldosterone (r = -0.2432), flow-
mediated vasodilation (r = -0.2672), and urinary albumin excretion (r = 0.2305).  
(112) 
However, the results from the Takebayashi and colleagues study are 
somewhat difficult to interpret (especially in the diabetics) because of the varying co-
morbidities and therapies reported.  In addition, the diabetic patients were recruited 
after hospitalization for glycemic control and/or diabetes education, and these issues 
in these individuals (along with their duration of disease) could potentially influence 
the results.  Furthermore, the investigators provided very brief subject characteristic 
data in the form of a table and some of the data seems to be entered into the wrong 
columns.  For example, the non-diabetic subjects have significantly higher fasting 
plasma glucose, glycosylated hemoglobin (HbA1c), and BMI than the diabetic 
subjects.  Also, a dash (rather than a 0) is provided as to the number of smokers and 
antihypertensive medication takers in the control group.  Thus, the control group may 
not have been queried as to these variables.  Finally, there was no indication as to 
dietary or physical activity status differences in the groups.  However, the researchers 
indicated that 3 of the diabetic patients were using diet alone as their diabetic therapy.  
Thus, several extraneous factors may have affected the outcome variables.  (112)  
Dogru and colleagues reported higher levels of plasma visfatin in T2D 
patients (n = 22) as compared to healthy controls (n = 40).  However, no differences 
were detected between T2D patients and participants with impaired glucose tolerance 




there were no detectable differences in visfatin levels between men and women, and 
visfatin levels were not correlated significantly with BMI, blood pressure, insulin, C-
reactive protein (CRP), glucose, lipids, or homeostasis model assessment insulin 
resistance (HOMA-IR).  One of the positive aspects of this study was the detailed 
inclusion/exclusion criteria.  However, the researchers did not assess diet, physical 
activity status, or female menopausal status in the participants, all of which could 
have influenced the results.  (29)   
Chen and colleagues compared visfatin plasma concentrations in 61 Chinese 
T2D patients and 59 sex and age matched non-diabetic controls.  The researchers 
found that the visfatin concentration was independently and significantly associated 
with T2D.  Moreover, the plasma visfatin concentration was elevated in the T2D 
patients as compared to the healthy controls even after adjusting for age, gender, 
BMI, and smoking status.  Plasma visfatin was also found to be associated with age, 
waist-to-hip ratio (WHR), fasting plasma insulin, adiponectin, and HOMA-IR in 
simple regression models.  These results suggest that visfatin may play a role in T2D 
pathogenesis.  However, the researchers did not determine if differences existed with 
regard to diet, physical activity status, and female menopausal status among the 
participants, and these factors may have affected the measurements.  (22)  
Retnakaran and colleagues compared serum visfatin levels in Thai T2D 
outpatients (n = 50) and healthy controls (n = 79) using a new ELISA kit designed to 
target full-length visfatin (as opposed to using the C-terminal assay).  The researchers 
found that visfatin levels were significantly higher in the T2D patients as compared to 




systolic blood pressure, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting 
glucose, and HOMA-IR.  In addition, the researchers found that resistin was the only 
variable that correlated significantly with visfatin.  Although this study had very 
specific entrance criteria for the Thai T2D patients, the authors failed to assess and 
account for potential differences in diet, physical activity, and female menopausal 
status among the participants.  Furthermore, these factors may have affected the 
outcome variables and metabolic covariates.  (94)   
Sandeep and colleagues investigated relationships between serum visfatin and 
obesity and diabetes-related traits in 150 T2D (n = 75 men, n = 75 women) and 150 
non-diabetic (n = 75 men, n = 75 women) Asian Indians.  They found significantly 
higher levels of visfatin in T2D versus non-diabetic individuals, and this relationship 
remained significant after adjusting for age and gender, but was no longer significant 
after additionally adjusting for BMI (p = 0.067) or waist circumference (p = 0.057).  
Visfatin levels were also associated with obesity, visceral fat, and HOMA-IR, but not 
with subcutaneous fat.  Furthermore, the association between visfatin levels and 
obesity remained significant, with an odds ratio of 1.060, after adjusting for age, 
gender, and diabetes status.  The association between visfatin levels and visceral fat 
also remained significant after adjustment for age, gender, diabetes status, and BMI, 
and the relationship between visfatin levels and HOMA-IR remained significant after 
adjustment for age and gender, but not after additionally adjusting for diabetes status.  
This suggests that visfatin levels are associated with obesity and that associations 
with diabetes may occur via visfatin’s connection with obesity.  Besides this study’s 




differences in diet or physical activity levels between the groups.  In addition, no 
indication was made as to whether co-morbidities existed and were being treated in 
the diabetic patients.  (104)    
Fernandez-Real and colleagues assessed whether an interaction existed 
between visfatin and parameters of iron metabolism (ferritin and prohepcidin) in 95 
healthy Spanish men with normal glucose tolerance (NGT) and in 43 otherwise-
healthy Spanish men with altered glucose tolerance (IGT, impaired fasting glucose 
(IFG), or undiagnosed diabetes).  The researchers found that serum visfatin, ferritin, 
and prohepcidin were increased in men with previously undiagnosed diabetes as 
compared to the NGT or IGT/IFG groups of men.  In the entire group, relationships 
among visfatin, insulin sensitivity, and parameters of iron metabolism were 
modulated by the obesity status and glucose tolerance of the men.  Furthermore, in 
nonobese men, insulin sensitivity was found to contribute to visfatin variance, 
whereas only the serum soluble transferrin receptor contributed to visfatin variance in 
obese men after adjusting for BMI, age, prohepcidin, insulin sensitivity, and glucose 
tolerance.  The researchers concluded that these results may indicate that visfatin is 
upregulated in connection with increased iron stores and proposed a mechanism 
connecting oxidative stress with insulin, iron overload, and visfatin levels.  However, 
this study was cross-sectional in nature and both longitudinal and confirmatory 
studies are needed to validate many of the steps in the proposed mechanism.  This 
study also did not control for diet or physical activity status, both of which could 




Li and colleagues investigated plasma visfatin levels in NGT (n = 36), IGT (n 
= 26), and T2D (n = 30) patients and found lower fasting and 2-hour OGTT visfatin 
levels in T2D patients as compared to the NGT controls, even after adjustment for 
age, gender, and BMI.  Furthermore, fasting plasma visfatin was positively correlated 
with BMI (r = 0.27) and WHR (r = 0.42) and negatively correlated with 2-hour OGTT 
glucose levels (r = -0.33) and hemoglobin A(1c) (r = -0.25) (73).   Despite the 
positive findings, the researchers did not address whether the different treatments 
used in the T2D group affected visfatin levels.  The researchers also did not assess 
menopausal status or hormone replacement use in the female study participants, even 
though the average ages of the NGT, IGT, and T2D groups were 51 ± 9, 55 ± 9, and 
56 ± 10 yrs.  Last, diet and physical activity status differences were not accounted for, 
even though some of the T2D patients were reportedly using diet treatment.  (73)  
Jian and colleagues found that serum visfatin levels were similar in Chinese 
adults with NGT (n = 61), IGT (n = 65), and T2D (n = 115).  However, visfatin levels 
were significantly lower in obese (n = 43) versus normal weight (n = 93) individuals 
and obese (n = 43) versus overweight (n = 105) individuals.  Serum visfatin was also 
similar in males and females, and there were no significant correlations between 
visfatin and BMI, waist-to-hip ratio (WHR), or OGTT-related variables.  Since the 
group comparisons involved t-tests, adjustment was not made for the statistically 
significant differences in body composition between the NGT, IGT, and T2D groups.  
The researchers also did not assess diet, physical activity status, or menopausal status 




Tsiotra and colleagues compared visfatin expression in peripheral monocyte-
enhanced mononuclear cells from 24 women with T2D and 26 healthy women.  Both 
groups of women were further subdivided by BMI into lean or overweight, thus there 
were 4 subject groups.  All women were pre-menopausal and aged 21-48 years.  
Although plasma visfatin tended to be higher in the overweight T2D patients as 
compared to the other groups, it was not statistically significant.  Plasma TNF-α also 
did not differ, although plasma adiponectin was lower in the T2D women and IL-6 
was higher in the overweight T2D women.  There were also no significant 
correlations found for visfatin with BMI, waist circumference, fasting glucose, fasting 
insulin, HOMA-IR, triglycerides, or HDL-cholesterol.  Thus, this study suggests that 
circulating levels of visfatin are not elevated in mononuclear cells from diabetic 
women.  However, there were a few problematic aspects involving this study which 
may have impacted the results.  First, different treatments were being used in the T2D 
patients (15 were on special diets, 5 were on oral hypoglycemic agents, and 2 were on 
combined insulin and hypoglycemic therapy), and these were not examined as 
potential confounding variables.  In addition, the duration of diabetes, the physical 
activity status, and the average age for each of the groups were not provided and were 
not examined as potential confounding variables in the analyses.  Last, beyond 
fasting, there was no mention of the blood drawing conditions.  Thus, the time course 
of medication usage in the T2D participants was not provided.  (116)  
Gestational Diabetes Mellitus 
Lewandowski and colleagues examined the relationship between visfatin and 




their responses to a glucose challenge test (GCT) and OGTT.  Moreover, the control 
group (n = 20) responded normally to both tests, the intermediate group (n = 15) had 
an elevated GCT and normal OGTT, and the gestational diabetes (GDM) group (n = 
16) had elevated results for both tests.  Overall, the groups were similar in terms of 
age and BMI and had no pregnancy-related complications.  The researchers found 
that there was a statistically significant elevation in serum visfatin levels in the GDM 
group as compared to the control group and an almost significant increase in the 
intermediate group as compared to the control group (p = 0.07) and GDM group (p = 
0.08).  In addition, significant correlations were detected for visfatin and insulin (r = 
0.38), 120 minute insulin (r = 0.39), 120 minute glucose (r = 0.035), HOMA-IR (r = 
0.35), and an insulin sensitivity index (r = 0.32).  This suggests that visfatin is 
increased in pregnant women with abnormal glucose tolerance and may be related to 
insulin sensitivity.  However, weight gain, diet, and physical activity status were not 
examined in the study and differences in these factors may have influenced the 
results.  (72)  
In a study by Krzyzanowska and colleagues comparing women with GDM (n 
= 64) to healthy pregnant women (n = 30), GDM was associated with increased 
plasma visfatin levels.  No association was found for visfatin levels and fasting 
glucose, insulin, BMI, or HOMA-IR in the diabetic women.  Furthermore, in a 
subgroup of 24 women with GDM, visfatin levels were found to increase during 
pregnancy (comparing weeks 28-30 with weeks 38-40) and after delivery (comparing 
2 weeks after delivery with weeks 38-40).  One of the positive aspects of this study 




GDM.  However, diet was not examined in the healthy pregnant women, and physical 
activity status was not assessed in either group; moreover, these factors could have 
influenced the outcome variables.  (68)  
In contrast, Chan and colleagues reported decreased plasma visfatin levels in 
Chinese women with GDM (n = 20) as compared to healthy pregnant women (n = 20) 
(20).  Moreover, they detected significant correlations between visfatin levels and 
maternal age, first trimester body weight, and first trimester BMI (r = -0.399, -0.350, 
and -0.336, respectively).  The researchers assessed many potentially influential 
factors in the study including first trimester weight, first trimester BMI, GCT weight, 
GCT BMI, and gestational age at glucose challenge.  The researchers also excluded 
participants with multiple pregnancies, fetal abnormalities, chronic diseases, pre-
existing hypertension, or pre-existing diabetes.  However, the researchers did not 
assess diet or physical activity status in the subjects, and they did not mention 
whether cigarette smoking status was exclusionary.  These factors may have impacted 
the results.  (20)  
Haider and colleagues reported similar results when they compared plasma 
visfatin levels from OGTTs of 10 women with GDM to plasma visfatin levels from 
10 healthy pregnant, age-matched women.  Besides having lower fasting visfatin 
levels, the women with GDM also had higher fasting glucose and lower insulin 
sensitivity than the healthy controls.  However, fasting insulin and the insulin 
responses during the glucose challenge were similar in the groups.  In response to the 
glucose challenge, plasma levels of visfatin increased in both groups.  However, the 




lower in the GDM patients than in the controls.  This suggests that impaired glucose 
tolerance in women with GDM may contribute to a blunted oral glucose challenge 
visfatin response.  However, since glucose induces visfatin release (and the women 
with GDM had higher glucose levels), the lower visfatin levels in the women with 
GDM must be related to something other than glucose and insulin, and the 
researchers suggested cytokines.  Although the cause of the lower visfatin levels in 
the women with GDM was not determined, some of the positive aspects of this study 
were that none of the women were on a special diet, none were taking medication, all 
were in weeks 24-28 of pregnancy, and both groups had similar anthropometric and 
lipid measurements.  (40)  
Obesity, Body Composition, & Weight Loss 
Ingelsson and colleagues investigated whether plasma visfatin would be 
positively related to diabetes, obesity, and visceral adiposity in 374 participants from 
the Framingham Third Generation Cohort.  Participants with computer tomography 
scans were chosen randomly for inclusion in the study, with over-sampling of 
participants from low and high BMI quartiles.  Variables assessed included age, BMI, 
waist circumference, systolic blood pressure, diastolic blood pressure, total 
cholesterol, HDL-cholesterol, triglycerides, fasting glucose, visceral adipose tissue, 
subcutaneous adipose tissue, metabolic syndrome status, low LDL-cholesterol status, 
diabetes status (based on fasting glucose), and smoking status.  Thus, the researchers 
did not assess insulin sensitivity or perform an OGTT for determination of diabetes 
status.  When analyzed as continuous variables, age and triglyceride levels had 




categorically, hypertension was found to be associated with plasma visfatin; however, 
the presence of hypertension was found to be lower for both the lowest and highest 
quintiles of plasma visfatin as compared to the middle three quintiles.  This study 
suggests that plasma visfatin may not be a marker for metabolic traits.  Besides its 
cross-sectional nature, this study did not assess whether diet or physical activity status 
differed among the subject population.  In addition, the average age of the 
participants was 45 ± 6 yrs, and no indication was made as to the menopausal status 
of the female participants (53 % of the group).  These factors could have influenced 
the study’s major outcome variables.  (53)  
Choi and colleagues compared fasting plasma visfatin levels in healthy, non-
diabetic obese (n = 36) and overweight (n = 12) Korean women.  The women were 
30-55 yrs of age, sedentary (< 20 minutes of exercise twice per wk), free of 
cardiovascular disease, and not taking laboratory test result-altering medications.  
Overall, the obese women had higher plasma visfatin levels than the overweight 
women.  However, the researchers did not assess or account for differences in 
demographic variables or diet between the groups, and these factors may have 
influenced the outcome measures.  (25)  
In a study by Zahorska-Markiewicz and colleagues, serum levels of visfatin 
were determined in 21 obese, but otherwise healthy, women and compared with those 
of 16 normal weight women.  Overall, the obese women had significantly higher 
levels of serum visfatin and insulin than the normal weight women.  In addition, 
significant correlations were found for serum visfatin and insulin levels (r = 0.51) in 




women (r = 0.52).  However, no statistically significant correlations were detected 
between body composition measures and serum visfatin.  Overall, physical activity 
and diet were not considered in the experiment, which is a limitation of the study 
since these factors may have influenced the results.  Moreover, differences in physical 
activity and/or diet may explain why the normal weight women had significantly 
higher HDL-cholesterol levels than the obese women (61.2 ± 11.6 vs. 50.3 ± 8.5 
mg/dL), since all other lipid measures did not differ between the groups.  (131)  
Pagano and colleagues analyzed the plasma visfatin concentrations of 30 
normal weight and 39 obese men and women.  They also compared visfatin levels in 
subcutaneous and visceral fat and in free fatty acid-induced insulin resistance.  
Plasma visfatin levels were lower in obese individuals as compared to normal weight 
individuals; moreover, plasma visfatin correlated negatively with BMI in the obese 
participants (r2 = 0.14).  Plasma visfatin was also positively correlated with 
subcutaneous visfatin mRNA expression (r2 = 0.32).  Last, plasma levels of visfatin 
were not different between men and women and were not influenced by free fatty 
acid-induced insulin resistance.  Overall, the subjects had an unlimited diet and were 
recruited from hospital staff or outpatients.  However, this study did not address 
physical activity status, female menopausal status, or medication usage as potential 
influential factors.  (88)  
Jin and colleagues examined serum visfatin concentrations in generally 
healthy, obese (n = 72) and normal weight (n = 76) Chinese adolescents.  Even after 
adjustment for age, gender, and Tanner stage, the researchers found a higher median 




adolescents.  In obese adolescents, significant correlations were found for visfatin and 
age (r = -0.280), HDL-cholesterol (r = 0.251), Tanner stage (r = -0.298), and an early 
insulin secretion index (r = -0.284).  Furthermore, age and HDL-cholesterol were 
significant predictors of visfatin in multiple regression analysis.  Although the 
researchers excluded adolescents who were dieting, had secondary obesity, or IGT 
from study participation, they did not query participants on behavioral factors such as 
physical activity or cigarette smoking status.  Moreover, differences in these factors 
may have influenced the outcome variables.  (56)  
Haider and colleagues found almost 2-fold higher plasma visfatin levels in 83 
non-diabetic obese children as compared to 40 lean, healthy children.  However, there 
were no significant associations detected for visfatin with CRP, lipids, BMI, or age.  
Overall, the groups of children did not differ in terms of age, gender composition, or 
pubertal status.  However, the potential influence of diet or physical activity status on 
the outcome variables was not measured.  (41)  
Araki and colleagues also studied children and reported that plasma visfatin 
levels were a diagnostic marker for visceral fat accumulation in obese Japanese 
children.  The obese children (n = 56; 37 boys, 19 girls) were age-matched, but not 
pubertal status-matched, with non-obese children (n = 20; 12 boys, 8 girls), and no 
mention was made as to the dietary or physical activity status of the participants.  
Overall, visfatin levels were higher in the obese children as compared to the non-
obese children, but did not vary by gender.  In simple correlation analyses, age, 
height, weight, waist circumference, visceral adipose tissue, subcutaneous adipose 




correlated with plasma visfatin levels in the obese children.  However, after 
adjustment for age and gender, only visceral adipose tissue remained significantly 
correlated with visfatin levels (r = 0.347).  The researchers also grouped the children 
based on the presence of metabolic syndrome and found higher plasma visfatin levels 
in the obese children with metabolic syndrome (n = 7) as compared to both the obese 
children without metabolic syndrome (n = 49) and to the non-obese controls (n = 20).  
(7)  
Malavazos and colleagues studied epicardial fat in connection with visfatin 
levels.  Forty two obese but otherwise healthy women (n = 27 severely obese) and 15 
normal weight women had epicardial fat thickness measured via echocardiograph and 
circulating levels of visfatin, plasminogen activator inhibitor-1 (PAI-1), and other 
inflammatory markers assessed.  The obese women had thicker epicardial fat and 
higher visfatin and PAI-1 levels than the normal weight women.  In addition, visfatin 
was correlated with epicardial fat thickness, even after adjustment for body fat.  Thus, 
visfatin may be related to epicardial fat thickness, possibly via its role as an 
inflammatory adipokine.  (76)  
Korner and colleagues assayed visfatin levels in serum samples stored from a 
previous study (13) using a new ELISA.  They compared 10 subcutaneously obese, 
10 viscerally obese, and 10 lean controls and found no significant differences 
between the groups with regard to serum visfatin levels, although visfatin tended to 
be higher in the viscerally obese group.  The researchers also found no relationship 
between serum visfatin and BMI, waist circumference, hip circumference, waist-to-




OGTT blood glucose, plasma lipids, or visfatin mRNA expression.  Moreover, with 
the exception of BMI (which was shown as a scatterplot), no numerical correlations 
were presented for any of these measures.  It is also important to note that the 
participants chosen did not differ in terms of glucose tolerance, as there were no 
differences between the lean and obese groups with regard to fasting glucose or 120 
minute OGTT glucose.  Thus, this study did not address whether visfatin levels differ 
in those with varying degrees of glucose tolerance.  In addition, the statistical analysis 
involved t-tests, even though the gender composition of the groups was different (4 
females in the lean group, 8 females in the subcutaneous obese group, and 7 females 
in the visceral obese group).  (65) 
Garcia-Fuentes and colleagues investigated the change in plasma visfatin 
concentrations in severely obese patients (BMI = 54.4 ± 6.8 kg/m2) before and after 
weight loss due to bariatric surgery.  Plasma visfatin levels were higher in the 
severely obese individuals at baseline as compared to healthy individuals (BMI = 
26.8 ± 3.8 kg/m2) not undergoing surgery.  After grouping the severely obese 
individuals as normal, impaired, or diabetic based on fasting glucose levels, the 
researchers found that severely obese individuals in the IFG and T2D groups had 
significantly higher levels of plasma visfatin than the healthy controls.  Seven months 
after bariatric surgery, plasma visfatin levels were higher in the severely obese 
individuals as compared to their pre-operative values and as compared to the healthy 
controls.  Moreover, the increase in post-operative visfatin levels was not related to 
the type of bariatric surgery or to the pre-operative fasting glucose level.  However, 




operative leptin concentration (r = 0.39) and waist reduction percentage (r = -0.36).  
No statistically significant correlations were found with glucose or insulin sensitivity.  
These results suggest that visfatin is increased in severely obese individuals with IFG 
and T2D and increases after bariatric surgery regardless of surgery type or fasting 
glucose.  A major limitation of this study is that dietary and physical activity habits 
were not accounted for before or after the intervention, and both could have 
influenced the 7 month measurements of weight loss, waist circumference, lipids, and 
adipokines.  (37)  
Haider and colleagues found that plasma visfatin levels decreased in obese 
patients 6 months after gastric banding.  Thirty one participants (3 males, 28 females) 
who were overall healthy but had a BMI ≥ 40 kg/m2 were studied before and 6 
months after bariatric surgery.  Their data were compared to those of 14 healthy 
controls (7 males, 7 females) with a BMI < 25 kg/m2.  As compared to the healthy 
controls, visfatin and leptin concentrations were increased in the obese patients before 
surgery, whereas adiponectin was lower.  There were no significant correlations at 
baseline involving visfatin, although leptin and adiponectin were both positively 
correlated with HOMA-IR.  After surgery, 30 of the 31 patients lost weight.  Overall, 
weight decreased from 133 ± 20 kg to 116 ± 20 kg, and BMI decreased from 46 ± 5 
kg/m2 to 40 ± 5 kg/m2.  In addition, plasma visfatin and leptin levels decreased, 
whereas adiponectin levels increased.  In the surgery patients, changes in visfatin 
were found to correlate positively with changes in BMI (r = 0.69) and weight (r = 
0.64) and negatively with changes in waist circumference (r = -0.43), insulin (r = -




not correlated with any of the changes in body composition or glucose and insulin 
metabolism.  Of interest, fasting glucose levels, fasting insulin levels, and HOMA-IR 
were not statistically changed by the gastric banding.  Multiple linear regression 
analysis indicated that the best predictors of change in visfatin were change in insulin, 
change in BMI, and change in HOMA-IR.  There are several limitations in this study 
which could have influenced the results including non-assessment of diet, physical 
activity status, and female menopausal status.  In addition, gender and age were not 
considered as possible influential factors in the statistical analyses.  (45)  
In contrast, Krzyzanowska and colleagues found that plasma visfatin levels 
increased in obese patients 14 months after gastroplastic surgery.  Thirty six 
participants (28 females, 8 males) who were overall healthy but had a BMI > 40 
kg/m2 were studied before and 14 months after gastroplastic surgery with vertical 
banded gastroplasty.  After the surgery, weight decreased from 128 kg to 94 kg, and 
BMI decreased from 44.3 kg/m2 to 31.9 kg/m2.  Furthermore, fasting insulin, fasting 
glucose, interleukin-6, CRP, and HOMA-IR decreased, whereas visfatin changes 
were variable with an increase occurring in most patients.  Prior to the surgery, 
fasting insulin, HOMA-IR, and triglycerides were found to be correlated with visfatin 
concentration (r = -0.35, -0.36, and -0.33, respectively).  After the surgery, changes in 
visfatin concentration were negatively correlated with changes in insulin (r = -0.35) 
and HOMA-IR (r = -0.45).  Moreover, HOMA-IR was an independent predictor of 
pre-surgery visfatin concentration, but not visfatin concentration after the surgery.  
One of the many positive aspects of this study was its analysis of diet, which was 




Botella-Carretero and colleagues conducted a study that also examined 
morbidly obese women undergoing bariatric surgery (n = 41; 28 premenopausal, 12 
postmenopausal).  The researchers reported that the women had increased levels of 
serum visfatin post-surgery, measured after attainment of weight loss of at least 15% 
of initial weight (14 ± 9 months post-surgery).  Overall, there were no differences in 
serum visfatin between the different surgery types (biliopancreatic diversion or 
laparoscopic gastric bypass), between premenopausal and postmenopausal women, 
and between hyperandrogenic and non-hyperandrogenic premenopausal women.  A 
multiple regression model indicated that weight loss, previous diabetic status, and 
change in waist circumference were the main predictors of the change in visfatin 
following bariatric surgery.  Although this study did account for the reproductive and 
diabetic status of the participants, it did not examine diet and physical activity status, 
and both of these factors could have influenced many of the variables measured.  (15)    
Manco and colleagues detected a slight decrease in visfatin levels 24 or 36 
months (the abstract and methods differ) after bilio-pancreatic diversion in women 
losing > 20 % of their initial BMI (n = 9), but not in the total study population of 
women undergoing bilio-pancreatic diversion (n = 10).  This study had the most 
specific subject inclusion criteria, including no medication usage, no alcohol 
consumption, overall healthiness, and no regular physical activity.  The study also 
required measurement during the same menstrual phases.  However, these specifics 
make the study participants far from representative of the general population.  (77)  
Varma and colleagues investigated the relationships between visfatin and 




subjects undergoing elective abdominal surgery and in 75 healthy subjects willing to 
undergo muscle and adipose tissue biopsies.  Considerable variation existed within 
the groups; moreover, age (24-62 yrs), BMI (29-76 kg/m2), and type of surgery 
(gastric bypass, gastric restriction, cholecystectomy, hysterectomy, hernia repair, etc.) 
were wide-ranging in the surgery group and BMI (19-55 kg/m2), percent body fat 
(15.5-54.1 %), and insulin sensitivity (0.62-26.8 x 10-5 x min-1/pM) were variable 
among the biopsy participants.  Plasma visfatin levels were not correlated with BMI, 
insulin sensitivity, or intramyocellular lipid levels.  In a subgroup of BMI-matched 
IGT and NGT women, plasma visfatin was not related to insulin sensitivity.  
Moreover, the researchers surmised that visfatin plasma levels may not reflect 
differences in body composition or insulin sensitivity, possibly because adipose tissue 
is only one source of circulating visfatin.  However, diet and physical activity status 
were not assessed in the groups, and both of these factors could have influenced many 
of the assessed variables.  (119)  
Berndt and colleagues found that plasma visfatin concentration correlated 
positively with visceral visfatin mRNA expression (r2 = 0.17), BMI (r2 = 0.04), 
percent body fat (r2 = 0.04), and negatively with subcutaneous visceral fat mRNA 
expression (r2 = 0.19) in 163 men and women with a range of body fat and glucose 
tolerance.  However, the researchers detected no relationship between plasma visfatin 
concentration and fasting insulin levels, fasting plasma glucose levels, glucose 
infusion rate during a euglycemic-hyperinsulinemic clamp, 2-hour OGTT plasma 
glucose, or computed tomography measures of visceral fat mass.  Overall, the 




were undergoing abdominal surgery for gastric banding, cholecystectomy, 
appendectomy, weight reduction surgery, injury, or laparotomy.  Although sex, BMI, 
and WHR subgroups were analyzed separately, age and surgery-type groups were 
not.  In addition, diet, physical activity status, and female menopausal status were not 
assessed.  Thus, these factors could have influenced the results.  (13)  
Polycystic Ovary Syndrome 
Chan and colleagues compared plasma visfatin levels in 26 Chinese women 
with PCOS and 26 healthy Chinese women.  They found that women with PCOS had 
higher fasting plasma visfatin levels than healthy women, and that plasma visfatin 
was positively correlated with BMI in the PCOS patients (r = 0.396).  However, 
plasma visfatin was not correlated with age, fasting insulin, thyroid hormones, or 
reproductive hormones in either group.  Thus, this study suggests that women with 
PCOS have higher visfatin levels than healthy women.  Although the PCOS and 
healthy women were similar in age and BMI, and the researchers excluded those with 
other various metabolic and chronic diseases, the researchers did not assess diet or 
physical activity status.  Differences in either of these variables could have influenced 
visfatin levels.  (19)  
Kowalska and colleagues examined visfatin levels in women with PCOS.  
Seventy (23 lean and 47 obese) women with PCOS were compared to 45 (25 lean and 
20 obese) healthy women.  The women with PCOS had lower insulin sensitivity and 
higher serum visfatin levels as compared to the healthy women.  However, when 
compared separately, only the lean PCOS patients were found to have increased 




0.23), waist girth (r = 0.24), insulin sensitivity (r = -0.27), 120 minute glucose (r = 
0.20), free fatty acid levels (r = 0.20), HDL-cholesterol (r = -0.27), and numerous 
gender-related hormone levels.  Thus, visfatin levels in lean PCOS patients appear to 
be related to insulin sensitivity and hyperandrogenism-related variables.  Although 
participants in the study were non-smokers and taking no anti-inflammatory or 
carbohydrate and lipid affecting medications, diet and physical activity status were 
not assessed.  Moreover, these factors may have influenced the results.  (66)  
Tan and colleagues compared visfatin levels in 8 women with PCOS to 8 
healthy women with unexplained infertility.  Visfatin mRNA expression in 
subcutaneous and omental adipose tissue and in subcutaneous adipocytes was greater 
in the PCOS patients than in the controls.  In addition, visfatin mRNA expression in 
the PCOS patients was higher in omental fat than in subcutaneous fat.  Similar 
findings were reported for visfatin protein and visfatin plasma levels.  Furthermore, 
plasma visfatin levels were positively correlated with visfatin protein levels, visfatin 
mRNA levels, insulin, HOMA-IR, testosterone, 17-beta estradiol, and negatively 
correlated with sex hormone binding globulin in the total study population.  However, 
plasma visfatin was not correlated with BMI or WHR, and visfatin protein levels 
were not correlated with BMI or WHR.  Some of the more important findings from 
this study indicate that visfatin plasma levels are related to adipose tissue visfatin 
protein levels and mRNA levels and that visfatin plasma levels are elevated in women 
with PCOS.  Unfortunately, correlation coefficients were not reported for the 
associated variables in this study, just probability values.  In addition, diet and 




variables.  However, medication usage, cigarette smoking, and the presence of 
additional metabolic and cardiovascular diseases were taken into account as 
exclusionary criteria.  (113)  
Chronic Kidney Disease 
Axelsson and colleagues found that serum visfatin levels were higher in stage 
5 chronic kidney disease (CKD) patients (n = 149) than in stage 3-4 patients (n = 40) 
or healthy controls (n = 30).  Univariate analyses also indicated differences in visfatin 
levels in patients with versus without diabetes and in patients with versus without 
cardiovascular disease.  Furthermore, visfatin was negatively correlated with 
glomerular filtration rate (r = -0.22), apolipoprotein B (r = -0.15), and serum albumin 
(r = -0.28) and positively correlated with IL-6 (r = 0.17), CRP (r = 0.14), and soluble 
vascular cell adhesion molecule 1 (r = 0.39), but not with fat mass or markers of 
insulin resistance.  Although the researchers did adjust some of their analyses for age, 
gender, and factors significantly associated with visfatin, and they assessed nutritional 
status, they did not account for female menopausal status, medication usage 
differences, or physical activity status.  Moreover, these factors could have influenced 
the outcomes.  (9)  
Yilmaz and colleagues compared the serum visfatin concentration in 406 non-
diabetic patients with different stages of CKD to those of 80 healthy controls. 
Overall, visfatin levels were increased in all but stages 1 and 2 of CKD.  In addition, 
visfatin was positively correlated with HOMA-IR (r = 0.11) and CRP (r = 0.56) and 
negatively correlated with estimated glomerular filtration rate (r = -0.62), flow-




Interestingly, similar correlations were reported for adiponectin.  Thus, visfatin levels 
may be related to endothelial dysfunction in non-diabetic CKD patients.  Although 
the groups were similar in terms of age, gender composition, and BMI, the 
researchers did not account for female menopausal status, length of disease, or dietary 
differences in their analyses.  Furthermore, these variables may have influenced 
several of the outcome measures.  (130)  
Metabolic Syndrome 
Filippatos and colleagues examined whether visfatin levels in obese and 
overweight individuals with metabolic syndrome varied from obese and overweight 
individuals without metabolic syndrome.  Twenty-eight individuals with metabolic 
syndrome and 28 age- and gender-matched individuals without metabolic syndrome 
served as the study population.  All participants were free of cardiovascular disease, 
T2D, impaired renal function, impaired hepatic function, and elevated thyroid 
stimulating hormone levels.  In addition, any lipid-lowering medications were 
discontinued for at least 6 weeks prior to the start of the study.  However, 
antihypertensive medications were permitted, and there was no mention of or 
correction for diet, physical activity status, and hormone replacement therapy status 
differences.  Despite these limitations, after adjustment for age, gender, and BMI, the 
researchers found that overweight and obese individuals with metabolic syndrome 
had significantly higher plasma visfatin levels than individuals without metabolic 
syndrome.  Significant correlations were found for plasma visfatin and age (r = 0.32), 




cholesterol (r = -0.38).   This work suggests that plasma visfatin levels are elevated in 
those with the metabolic syndrome.  (32)  
Chen and colleagues investigated the relationships between visfatin and 
parameters of metabolic syndrome.  Study participants were 244 males and 256 
females from a community-based metabolic syndrome study in Taiwan.  Overall, 
there was no significant difference in visfatin levels between males and females.  
Furthermore, in males, the researchers found no significant relationships between 
visfatin and age, waist circumference, hip circumference, WHR, blood pressure, 
fasting plasma glucose, fasting serum insulin, HOMA-IR, total cholesterol, 
triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol to HDL-cholesterol 
ratio, and uric acid.  However, visfatin was negatively and significantly correlated 
with BMI (r = -0.128).  Results were slightly different in women; moreover, total 
cholesterol (r = -0.132), HDL-cholesterol (r = 0.170), LDL-cholesterol (r = -0.146), 
and the total cholesterol to HDL-cholesterol ratio (r = -0.260) were found to be 
statistically correlated with visfatin.  The correlations remained significant after 
adjustment for waist circumference and after adjustment for age plus waist 
circumference.  However, this cross-sectional study did not take into account 
potential confounding variables such as diet and physical activity status.  Moreover, 
the reported age range of the participants was 39.89 to 85.17 yrs and menopausal 
status and hormone replacement therapy use were not reported for the female 
participants, which could have confounded some of the results.  (21)  
Zhong and colleagues compared visfatin levels in 139 metabolic syndrome 




characterized the metabolic syndrome cohort as to the presence or absence of carotid 
plaques.  Regardless of carotid plaque status, serum visfatin levels were higher in 
those with metabolic syndrome than in the healthy controls.  In addition, visfatin 
levels were higher in metabolic syndrome patients with carotid plaques as compared 
to those without carotid plaques.   However, within the metabolic syndrome group, 
there were no differences in visfatin levels between men and women or between those 
with 3 versus 4 metabolic syndrome components.  Last, visfatin was correlated with 
total cholesterol (r = 0.192) and LDL-cholesterol (r = 0.219) in the metabolic 
syndrome cohort, and remained associated with LDL-cholesterol in multiple 
regression analysis.  Despite the significant findings, this study did not account for 
potential differences in diet, physical activity, or female menopausal status among the 
participants.  Moreover, these factors may have influenced several of the metabolic 
and outcome variables.  (133)  
Cholesterol, Hypertension, & Coronary Heart Disease     
Wang and colleagues assessed plasma visfatin levels in relation to adiposity, 
insulin resistance, and lipids in 40 non-diabetic Caucasian males (n = 21) and females 
(n = 19) from the familial combined hyperlipidemia (FCHL) spouses databank versus 
35 non-diabetic Caucasian male (n = 15) and female (n = 20) FCHL family members.  
Visfatin did not differ between the groups.  It also did not differ by gender.  
Furthermore, in both groups and in the entire study population, visfatin was not 
related to BMI, percent body fat, subcutaneous fat, total cholesterol, LDL-cholesterol, 
or ApoB.  However, visfatin was negatively correlated with visceral fat size in the 




HOMA-IR score in the total study population (r = -0.245), with triglyceride levels in 
all groups (r = -0.402, -0.465, and -0.408, respectively) and positively correlated with 
HDL-cholesterol in all groups (r = 0.469, 0.403, and 0.439, respectively).   Multiple 
linear regression modeling determined that HDL-cholesterol and group identity were 
predictors of plasma visfatin.  Thus, this work suggests a possible connection between 
visfatin and lipid metabolism.  Limitations of this study include its cross-sectional 
nature, lack of dietary control, lack of information regarding hormone replacement 
therapy status in women, and lack of information regarding physical activity status.  
These factors could significantly influence lipid levels and potentially visfatin levels.  
(120)  
Dogru and colleagues reported that plasma visfatin levels did not differ (p = 
0.06) in young, newly diagnosed, male hypertensive patients (n = 33) as compared to 
healthy males (n = 33) (30).  In addition, plasma visfatin levels were not correlated 
with blood pressure, BMI, lipid levels, fasting glucose, fasting insulin, CRP, or 
HOMA-IR in either group of males.  This study was cross-sectional in nature with the 
diagnosis of hypertension preceding the measurement of visfatin.  In addition, diet 
and physical activity status were not examined in this study, which may have 
influenced the results.  (30)  
Choi and colleagues compared visfatin levels in 49 patients with coronary 
heart disease (CHD) to 42 age- and gender-matched, healthy controls.  The 
researchers reported no difference in visfatin between the groups; however, lipocalin-
2 levels were higher in the CHD patients.  Furthermore, there were no significant 




systolic blood pressure, diastolic blood pressure, HDL-cholesterol, triglycerides, 
fasting glucose, fasting insulin, or HOMA-IR.  Thus, this study suggests that visfatin 
may not be related to metabolic traits.  However, the authors failed to account for 
potential subject differences in diet, physical activity, and female menopausal status, 
which may have affected several of the metabolic and outcome variables.  (26)  
Inflammation, Arthritis, & Bone Turnover 
Moschen and colleagues compared visfatin levels in human inflammatory 
conditions to test whether their in vitro proinflammatory results applied in vivo.  They 
found that patients with ulcerative colitis or inflammatory bowel disease had higher 
visfatin serum levels than those of healthy controls.  Thus, in vitro and in vivo 
evidence suggests that visfatin is a proinflammatory adipokine.  (79)   
Oki and colleagues investigated the associations between serum visfatin and 
markers of systemic inflammation (IL-6 and CRP) and insulin resistance (HOMA-IR) 
in Japanese Americans (126 men, 169 women) living in Hawaii.  The participants 
were part of an epidemiological study started in 2002 which looked at risk factors for 
diabetes, hypertension, and atherosclerosis.  The average age of the participants was 
68.7 ± 14.9 years, and no additional demographic information was provided in the 
paper.  The researchers found positive correlations between visfatin and IL-6 and 
CRP.  Furthermore, visfatin was significantly correlated with IL-6 in both men (r = 
0.303) and women (r = 0.265), but with CRP only in men (r = 0.232).  After adjusting 
for age, gender, BMI, percent body fat, and waist girth, visfatin was still correlated 
with IL-6 and CRP.  No significant trend was found for tertiles of visfatin and 




However, diet and physical activity status were not taken into account in this study 
and neither was hormone replacement therapy status.  These factors may have 
influenced measurement of visfatin and the markers of inflammation and insulin 
resistance.  (86)  
Otero and colleagues examined adipokine levels, including visfatin, in 
rheumatoid arthritis patients (n = 31) as compared to healthy people (n = 18).  Higher 
plasma levels of adiponectin, leptin, and visfatin were detected in the rheumatoid 
arthritis patients as compared to the healthy controls, but no difference was found for 
resistin levels.  Furthermore, CRP was significantly correlated with adiponectin, 
leptin, and visfatin (r = 0.59, r = 0.71, and r = 0.63, respectively), but not with 
resistin.  This suggests that adipokines, including visfatin, may influence 
inflammation in rheumatoid arthritis patients.  However, this study did not examine 
whether the type of medication the patients were taking influenced the measurement 
outcomes.  It also did not mention the sampling conditions for measurement of the 
adipokines.  Other factors that were not examined in the study which could also have 
influenced the results include diet, physical activity status, and menopausal status in 
the females.  (87)  
Brentano and colleagues examined visfatin’s relationship with rheumatoid 
arthritis using synovial fibroblasts, monocytes, synovial fluid, and serum.  They 
found that administration of rheumatoid arthritis-related cytokines to fibroblasts 
increased visfatin expression, whereas visfatin administration activated cytokines and 
matrix metalloproteinases (MMP).  Synovial fluid and serum visfatin levels were also 




correlated with CRP levels (r = 0.92 and 0.73, respectively) and disease severity (r = 
0.73 and r = 0.74, respectively).  Thus, visfatin may be a proinflammatory factor in 
rheumatoid arthritis.  (18)  
Peng and colleagues examined relationships between adipocytokines, 
including visfatin, and bone mineral density and bone turnover markers in 232 
healthy Chinese men aged 20-80 years.  They found no relationship between serum 
visfatin and fat mass, bone mineral density, or bone turnover markers in the men 
(adjusted for age and BMI).  The study had strict inclusion/exclusion criteria, 
resulting in a population with very little variability in terms of body composition.  
The other major variables also may not have varied enough for relationships to be 
detected, but means were not provided for any of the bone-related variables to assess 
this.  Furthermore, diet could impact body composition and bone-related variables.  
However, dietary information was not examined in the study.  Interestingly, smoking 
status was not an exclusionary factor in the study, but was instead used as a potential 
predictor of bone mineral density in the multivariate analyses.  Last, on a positive 
note, habitual physical activity level was recorded and used as a potential predictor in 
the multivariate analyses.  (89)  
Medication Treatment 
Hsieh and colleagues reported that neither slow-release nor regular-form 
metformin treatment altered insulin resistance, adipokine levels (including visfatin), 
or inflammatory markers in individuals with T2D taking part in a 12 week, 




Hammarstedt and colleagues found that circulating levels of visfatin did not 
change in response to 3 weeks of thiazolidinedione treatment in newly diagnosed, 
untreated T2D patients (n = 2 males, n = 5 females) or in non-diabetic males (n = 6) 
with reduced insulin sensitivity.  Unfortunately, diet, physical activity status, female 
menopausal status, and the presence of co-morbidities were not assessed in this study, 
and these factors may have affected the results.  (48)  
Pfutzner and colleagues assessed whether 3 months of pioglitazone, 
simvastatin, or combined pioglitazone and simvastatin treatment affected adiponectin 
and visfatin levels in non-diabetic patients with metabolic syndrome.  Seventy eight 
females and 47 males took part in the prospective, randomized clinical trial.  
Although pioglitazone and the combined treatment improved insulin sensitivity and 
increased adiponectin levels, simvastatin treatment decreased adiponectin levels.  In 
contrast, visfatin levels did not change with any of the treatments.  After adjusting for 
differences in insulin levels, glucose levels, and BMI, the results did not change.  
Furthermore, baseline visfatin levels were not correlated with fasting glucose or 
insulin levels and the change in visfatin levels was not correlated with the change in 
HOMA-IR.    Thus, visfatin levels are not influenced by pioglitazone or simvastatin 
treatment.  However, the researchers did not report female menopausal status, 
hormone replacement therapy usage, physical activity status, or diet, and these factors 
may have influenced several of the outcome variables.  (90)    
Last, Haider and colleagues gave 16 healthy young males thiazolidinedione 





Haider and colleagues found that plasma visfatin concentrations increased in 
response to glucose infusion in healthy men (n = 9).  Glucose concentrations of both 
8.3 and 11.2 mmol/L were found to significantly increase baseline levels of visfatin.  
Moreover, insulin co-infusion prevented the increase in visfatin concentration.  
Similar increases in visfatin were found in subcutaneous and visceral adipocytes 
exposed to glucose in vitro.  (44)  
Sun and colleagues found baseline serum visfatin levels to be positively 
correlated with baseline serum triglycerides (r = 0.36) in healthy young men (n = 61).  
Furthermore, after short-term overfeeding, serum visfatin decreased by an average of 
19 % in the men.  Diet and physical activity levels were both assessed in this study; 
moreover, physical activity levels could not vary by more than 15 % from baseline 
during the overfeeding component of the study.  In addition, participants had to be 
healthy, weight stable for 6 months, and not taking lipid lowering medication.  (110)  
Gender, Age, & Race 
Seo and colleagues found that visfatin levels correlated positively with percent 
body fat (r = 0.206), IL-6 (r = 0.269), CRP (r = 0.233), triglycerides (r = 0.192), total 
cholesterol (r = 0.199), and diastolic blood pressure (r = 0.273) in non-diabetic 
Korean women.  However, none of these variables were significantly associated with 
visfatin levels in Korean men.  In multiple stepwise regression analyses, only 
diastolic blood pressure and IL-6 were related to visfatin levels in Korean women.  




reported, and these factors could have affected measurement of the outcome 
variables. (106)  
Kanda and colleagues assessed plasma visfatin levels in 154 bedridden 
geriatric and nursing home patients (n = 39 males, n = 115 females) from Osaka, 
Japan.  The average age of the participants was 80.3 ± 13.6 yrs, and the average bed 
confinement period was 45.5 ± 40.3 months.  A variety of clinical characteristics 
were assessed for characterization of potential relationships with plasma visfatin, 
including blood pressure, total cholesterol, adiponectin, and health complications 
(pneumonia, asthma, diabetes, dementia, renal failure, etc.).  The researchers found 
that plasma visfatin levels were associated with diastolic blood pressure, adiponectin, 
and CRP in the elderly subjects.  No other clinical parameters were associated with 
visfatin, thus the results suggest that visfatin may be a marker of inflammation in 
elderly bedridden patients.  However, only univariate analyses were used to assess 
relationships between the variables, and information such as means and counts were 
not provided for any of the clinical characteristics that were analyzed.  As the results 
were presented in the form of a letter, detailed information regarding other important 
information such as medication usage was also not provided.  (57)  
Smith and colleagues compared serum visfatin levels in Asian Indians and 
Caucasians living in Canada.  They detected no differences in visfatin levels between 
the races, although the difference between Asian Indian and Caucasian women neared 
significance (p = 0.07).   In the Asian Indian men, serum visfatin was positively 
correlated with HDL-cholesterol (r = 0.41) and apo A1 (r = 0.41).  Similar results 




had significant correlations with percent body fat (r = 0.58) and BMI (r = 0.52).  
However, there were no significant correlations involving visfatin in the Caucasian 
men and women.  This study did not take any of the significant differences between 
the groups (including smoking status and body composition) into account in the 
analyses.  In addition, factors like diet, physical activity status, and female 
menopausal status were also not considered.  Moreover, these factors could have 
influenced many of the outcome measures.  (107)        
Summary: Circulating Visfatin Studies 
Tables 1-1 and 1-2 (pages 12 and 13) summarize the results of studies 
comparing circulating visfatin levels in disease conditions.  Although the results have 
not been entirely consistent, most studies have found increased circulating levels of 
visfatin in T1D (43; 74), T2D (22; 29; 31; 74; 94; 104), GDM (68; 72), obesity (7; 25; 
37; 41; 45; 56; 76; 131), PCOS (19; 66; 113), CKD (9; 130), and metabolic syndrome 
(7; 32; 133) patients as compared to healthy or less-diseased individuals. 
As detailed in Table 6-1, the majority of studies investigating changes in 
visfatin levels with various diabetes treatments, in response to OGTTs, and in 
response to weight loss surgery have found no statistical differences or no consistent 
differences.  In addition, no differences in visfatin levels were reported in studies 
comparing men and women (13; 21; 88; 112; 120) or Asian Indians and Caucasians 
(107). 
As shown in Table 1-3 (page 14), several studies have also found significant 
correlations between circulating visfatin and glucose and obesity-related variables 




homeostasis model assessment-insulin resistance; HOMA-IR; (69; 113; 120)], fasting 
glucose (32; 131) visceral fat (7; 120), body mass index [BMI; (13; 19; 22; 73; 88)], 
and triglyceride levels (32; 69; 120).  There have also been correlations reported 
between the surgical weight loss-related change in visfatin levels and the change in 
fasting insulin (45; 69) and insulin sensitivity (45; 69).  However, these relationships 
have not always been consistent (Table 1-3). 
Part of the disparity in the results may be due to a lack of dietary and/or 
physical activity control in the studies.  Moreover, only 10 studies assessing visfatin 
levels also mentioned some sort of subject diet and/or physical activity status criteria; 
moreover, 5 of these studies included diet information (17; 40; 56; 69; 88), 4 included 
physical activity information (25; 43; 77; 89), and 1 study included both diet and 
physical activity information (110).  In addition, few of the studies involving women 
reported menopausal status or hormone replacement therapy usage, either of which 
could also have influenced many of the variables.  Thus, studies assessing visfatin 
levels that account for diet, physical activity status, and menopausal status would be 
useful.   
Taken together, the results of plasma and serum visfatin studies support a 









Table 6-1.  Circulating visfatin in intervention studies. 
  Result Comparison Sample Source 
NC 12 wks pioglitazone in T2D vs baseline plasma (112) 
NC T2D after 12 wks insulin vs baseline plasma (112)  
NC T2D after metformin vs baseline serum (51)  
NC T2D w/4 wks pioglitazone vs baseline plasma? (48)  
ND T2D w/hypertension medication vs w/o plasma (112)  
NC 
Pioglitazone, simvastatin, or combined 
therapy vs baseline ? (90)  







↑ NGT w/3 wks rosiglitazone vs baseline plasma (42)  
↓ T2D vs NGT plasma (73)  





↓ GDM vs healthy pregnant plasma (40)  
↑ 
Severely obese after bariatric surgery vs 
healthy plasma (37)  
↓ Obese after bariatric surgery vs baseline plasma (45)  
↑ 
Severely obese after bariatric surgery vs 
baseline plasma (37)  
↑ 
Severely obese after bariatric surgery vs 
baseline serum (15)  
↑ 
Obese after gastroplastic surgery vs 








After bilio-pancreatic diversion in 
women losing > 20 % BMI vs baseline serum? (77) 
NC Healthy w/acute exercise vs baseline plasma (34) 
↓ Healthy w/12 wks training vs baseline plasma (25) 
↓ T1D w/2 months training vs baseline plasma (43) 
↓ T1D w/4 months training vs baseline plasma (43) 





↓ Obese w/12wks training vs baseline plasma (17) 
↑ Glucose infusion vs baseline plasma (42) 
NC FFA-induced IR in healthy vs baseline plasma (88) 




↓ Short term overfeeding vs baseline serum (110) 
OGTT, oral glucose tolerance test; T2D, type 2 diabetes; wks, weeks; vs, 
versus; w/, with; w/o, without; NGT, normal glucose tolerance; IGT, impaired 
glucose tolerance; GDM, gestational diabetes mellitus; FFA, free fatty acid; 
IR, insulin resistance; NC, no change; ND, no difference; ↑, increased; ↓, 





Visfatin mRNA & Gene Expression Studies  
In contrast to Fukuhara’s rodent visfatin mRNA expression studies (described 
earlier) (35), Kloting and Kloting found no differences in visfatin gene expression in 
adipocytes from WOKW rats, a model of metabolic syndrome, as compared to 
control strains of rats (62).  
Pagano and colleagues investigated visfatin mRNA expression in 30 normal 
weight and 39 obese men and women.  Subcutaneous adipose tissue visfatin mRNA 
expression was reduced in obese subjects as compared to normal weight controls; 
however, the visceral adipose tissue of obese participants had higher visfatin mRNA 
expression than the healthy controls.  Furthermore, BMI was positively correlated 
with visceral adipose tissue visfatin mRNA expression (r2 = 0.35). Overall, the 
subjects had an unlimited diet and were recruited from the hospital staff or 
outpatients.  However, this study did not address physical activity status, female 
menopausal status, or medication usage as potential influential factors.  (88)  
Varma and colleagues investigated the relationships between visfatin and 
insulin sensitivity, obesity, intramyocellular lipid levels, and inflammation in 15 
subjects undergoing elective abdominal surgery and in 75 healthy subjects willing to 
undergo muscle and adipose tissue biopsies.  Substantial variation existed within the 
groups, with age (24-62 yrs), BMI (29-76 kg/m2), and type of surgery (gastric bypass, 
gastric restriction, cholecystectomy, hysterectomy, hernia repair, etc.) ranging in the 
surgery group and BMI (19-55 kg/m2), percent body fat (15.5-54.1 %), and insulin 
sensitivity (0.62-26.8 x 10-5 x min-1/pM) variable among the biopsy participants.  




tissue visfatin mRNA expression, although visceral visfatin mRNA expression was 
positively associated with BMI (r = 0.75), whereas subcutaneous visfatin mRNA 
expression was negatively associated with BMI (r = -0.48).  Furthermore, 
subcutaneous visfatin mRNA expression correlated with insulin sensitivity (r = 0.50), 
type I and type II intramyocellular lipid levels (r = -0.58 and -0.66, respectively), and 
markers of inflammation, such as tumor necrosis factor-alpha (r = -0.62).  In contrast, 
skeletal muscle visfatin mRNA expression was not correlated with BMI, insulin 
sensitivity, or intramyocellular lipid levels.  In a subgroup of BMI-matched IGT and 
NGT women, visfatin expression was found to be lower in the IGT participants.  
These findings suggest that visfatin may play a role in obesity and insulin resistance.  
However, diet and physical activity status were not assessed in the groups, and both 
of these factors could have influenced many of the assessed variables.  (119)   
Berndt and colleagues found that plasma visfatin concentration correlated 
positively with visceral visfatin mRNA expression (r2 = 0.17) and negatively with 
subcutaneous visfatin mRNA expression (r2 = 0.19) in 163 men and women with a 
range of body fat and glucose tolerance.  Furthermore, in 189 participants there were 
no differences in visfatin gene expression between visceral and subcutaneous adipose 
tissue; however, visceral visfatin gene expression was positively correlated with BMI 
(r2 = 0.09) and percent body fat (r2 = 0.06) in women.  Overall, this study was a 
retrospective cross-sectional study involving subjects who were undergoing 
abdominal surgery for gastric banding, cholecystectomy, appendectomy, weight 
reduction surgery, injury, or laparotomy.  Besides the aforementioned metabolic and 




Moreover, sex, BMI, and WHR subgroups were analyzed separately, but age and 
surgery-type groups were not.  In addition, diet, physical activity status, and female 
menopausal status were not assessed.  Thus, these factors could also have influenced 
the results. (13)  
Tsiotra and colleagues compared visfatin expression in peripheral monocyte-
enhanced mononuclear cells from 24 women with T2D and 26 healthy women.  Both 
groups of women were further subdivided by BMI into lean or overweight, thus there 
were 4 subject groups.  All women were pre-menopausal and aged 21-48 years. 
Visfatin mRNA levels were found to be almost 3-fold higher in both the lean and 
overweight T2D patients than in the healthy women.  Thus, this study suggests that 
mRNA expression of visfatin is elevated in mononuclear cells from diabetic women.  
However, there were a few problematic aspects involving this study which may have 
impacted the results.  First, differing treatments were being used to treat T2D (15 
were on special diets, 5 were on oral hypoglycemic agents, and 2 were on combined 
insulin and hypoglycemic therapy), and these were not examined as potential 
confounding variables.  In addition, the duration of diabetes, the physical activity 
status, and the average age for each of the groups were not provided and were not 
examined as potential confounding variables in the analyses.  Last, beyond fasting, 
there was no mention of the blood drawing conditions.  Thus, the time course of 
medication usage in the T2D participants was not provided.  (116)  
Poulain-Godefroy and colleagues examined the expression of inflammation 
and adipocyte differentiation-related genes in omental and subcutaneous adipose 




surgery.  Furthermore, the obese women were having bariatric surgery, whereas the 
lean women were having surgery for benign diseases.  The obese group was further 
subdivided by glucose tolerance status into normoglycemic, IGT, or T2D groups for 
analysis.  Overall, there were no differences in PBEF1 expression in omental versus 
subcutaneous fat or between any of the groups.  (92)  
Tan and colleagues compared visfatin levels in 8 women with PCOS to 8 
healthy women with unexplained infertility.  They looked at the mRNA expression of 
visfatin in subcutaneous and omental adipose tissue and subcutaneous adipocytes, 
visfatin protein levels in adipose tissue, and visfatin plasma levels.  Visfatin mRNA 
expression in subcutaneous and omental adipose tissue and in subcutaneous 
adipocytes was greater in the PCOS patients than in the controls.  In addition, visfatin 
mRNA expression in the PCOS patients was higher in omental fat than in 
subcutaneous fat.  Furthermore, subcutaneous and omental fat visfatin mRNA levels 
were correlated positively with BMI and WHR, and they were also correlated with 
each other.  Last, visfatin mRNA levels did not correlate with visfatin protein levels 
in either subcutaneous or omental fat.  Some of the more important findings from this 
study indicate that visfatin plasma levels are related to adipose tissue visfatin protein 
levels and mRNA levels and that visfatin mRNA, protein, and plasma levels are 
elevated in women with PCOS.  Unfortunately, correlation coefficients were not 
reported for the associated variables in this study, just probability values.  In addition, 
diet and physical activity status were not examined for their potential influence on the 




additional metabolic and cardiovascular diseases were taken into account as 
exclusionary criteria.  (113)   
In contrast to the plasma results of Haider and colleagues (42), Hammarstedt 
and colleagues found that visfatin mRNA expression did not increase in response to 3 
weeks of thiazolidinedione (TZD) treatment in newly diagnosed, untreated T2D 
patients (n = 2 males, n = 5 females) or in non-diabetic males (n = 6) with reduced 
insulin sensitivity (48).  They did however confirm visfatin’s role as an adipokine, 
with mRNA expression in both adipose tissue and isolated adipocytes.  
Unfortunately, diet, physical activity status, female menopausal status, and the 
presence of co-morbidities were not assessed in this study, and these factors may have 
affected the results.  (48)  
Using microarray, Dahl and colleagues found that visfatin gene expression 
was increased ~ 2-3 fold in carotid plaques from symptomatic (n = 14) as compared 
to asymptomatic (n = 7) endarterectomy patients.  Moreover, they confirmed their 
results by finding increased visfatin mRNA levels and increased visfatin protein 
levels in samples from the symptomatic patients.  The researchers also localized 
visfatin to the plaque’s lipid-rich core in symptomatic patients and to lipid-rich 
regions of the lesion in asymptomatic patients.   The group also examined visfatin 
expression during plaque rupture in coronary artery disease patients and found results 
similar to those of the endarterectomy patients.  Visfatin gene expression was also 
found to be significantly increased in the THP-1 monocytic cell line following 
stimulation with or 6 and 24 hour incubation with oxidized LDL, tumor necrosis 




human visfatin to the THP-1 monocytes and to peripheral blood mononuclear cells 
was found to significantly increase levels of matrix metalloproteinase-9 in the 
monocytes and TNF-α and IL-8 in the peripheral blood mononuclear cells, effects 
that were abolished with the addition of an inhibitor of insulin receptor signaling.  
This work supports a role of visfatin as an inflammatory mediator.  (27)   
Building on the work of Dahl et al., Adya and colleagues examined whether 
visfatin could activate nuclear factor-κB (NF-κB).  In human vascular endothelial 
cells transfected with a plasmid containing 5 NF-κB binding sites connected to a 
luciferase reporter gene, visfatin increased the transcriptional activity of NF-κB.  
Addition of a NF-κB inhibitor reduced visfatin’s induction of MMP-2 and MMP-9 
mRNA, protein levels, and activity.  Thus, visfatin may be involved in the process of 
vascular inflammation.  (4)  
Ognjanovic and colleagues found that visfatin mRNA levels were increased in 
fetal membranes from patients with severe infection-related pre-term labor as 
compared to controls.  Treatment of amniotic epithelial cells with various cytokines, 
including IL-6, TNF-α, and IL-1β, was also found to increase PBEF expression.  
Thus, these lines of evidence suggest cytokine-like properties for visfatin.  (85)  
Hufton and colleagues reported that the visfatin gene was one of the genes 
overexpressed in primary colorectal cancer (52).  Koczan and colleagues found 
similar results in psoriasis patients (63).  Turpaev and colleagues found similar results 
in nitric-oxide exposed monocytic cells (117). 
Kralisch and colleagues examined the hormonal regulation of visfatin in 3T3-




in vitro was increased 6-fold in 3T3-L1 adipocytes and 3-fold during adipogenesis.  
Kralisch et al. also found that hormones known to induce insulin resistance in vitro 
and in vivo affected visfatin levels.  Moreover, dexamethasone treatment upregulated 
visfatin mRNA expression, whereas growth hormone, TNF-α, and isoproterenol 
treatments downregulated visfatin mRNA expression.  Insulin did not affect visfatin 
mRNA expression.   These results suggest that the differential hormonal regulation of 
visfatin may influence the pathogenesis of obesity and insulin resistance.  (67)  
MacLaren and colleagues investigated factors that regulated visfatin mRNA 
expression in adipocytes and pre-adipocytes.  Visfatin mRNA expression increased 
during 3T3-L1 adipocyte differentiation and during dexamethasone treatment in pre-
adipocytes and adipocytes.  In contrast, treatment of pre-adipocytes with insulin, 
progesterone, testosterone, palmitate, and oleate decreased mRNA expression.  In 
adipocytes, insulin, TNF-α, and TZD treatment decreased mRNA expression.  Thus, 
multiple hormones regulate visfatin mRNA expression in adipocytes and pre-
adipocytes, which suggests a physiological role for visfatin.  (75)    
Wen and colleagues determined the effects of oleate [monounsaturated free 
fatty acid (FFA)] and palmitate (saturated FFA) on adipocyte visfatin mRNA 
expression and glucose transport in an attempt to examine the role of visfatin in FFA-
induced insulin resistance.  Cultured 3T3-L1 adipocytes and pre-adipocytes were 
incubated overnight with 0.125, 0.5, or 1.0 mmol/L of either oleate or palmitate.  
Basal glucose transport was not affected by oleate or palmitate, but insulin-stimulated 
glucose transport was inhibited in both cases.  Furthermore, the inhibition was dose-




differentiation, but was significantly decreased with oleate or palmitate.  Again, this 
decrease was dose-dependent.  The researchers concluded that FFA-induced glucose 
transport/insulin sensitivity reductions in adipocytes may be a consequence of 
oleate’s and palmitate’s ability to decrease visfatin mRNA expression.  (123)  
Hector and colleagues incubated visceral adipose tissue from lean non-
diabetic patients undergoing abdominal surgery with TNF-α for 24, 48, and 72 hours.  
They reported a significant reduction in the mRNA expression (97 %, 91 %, and 96 
%, respectively) and protein expression (42 %, 28 %, and 39 %, respectively) of 
adiponectin (n = 4), whereas the mRNA level of visfatin (n = 6) increased 
dramatically (255 %, 335 %, and 341 %, respectively).  This suggests that the 
increased expression of TNF-α, common in obesity and insulin resistance, may 
contribute to the increased levels of visfatin often reported in conditions of obesity 
and/or insulin resistance.  (49)  
Choi and colleagues examined the effects of peroxisome proliferator activated 
receptor (PPAR)-α and PPAR-γ agonists (fenofibrate and rosiglitazone, respectively) 
on visfatin expression in male Otsuka Long-Evans Tokushima fatty (OLETF) rats 
during the early to advanced diabetic stages.  As compared to rats without treatment, 
rats receiving the fenofibrate or rosiglitazone treatment had lower glucose and insulin 
levels and higher visceral fat visfatin mRNA expression.  Thus, PPAR-α and PPAR-
γ agonists improve glucose homeostasis in OLETF rats, results which may be related 





Choi and colleagues examined whether a PPAR-δ agonist affected adipokine 
gene expression levels in rat visceral adipose tissue and in cultured adipocytes, since 
activation of PPAR-δ has been shown to improve metabolic derangements in animal 
models.  Although body weight was similar at the start of the study (6 weeks of age in 
the rats), rats fed a high-fat diet plus a PPAR-δ agonist for 4 weeks gained 
significantly less weight than rats fed a high-fat diet for 4 weeks.   In addition, 
visceral adipose tissue from rats fed both the high fat diet and PPAR-δ agonist had 
significantly greater mRNA levels of visfatin, adiponectin, and PPAR-δ as compared 
to rats not receiving the agonist.  Similar results were found in cultured 3T3-L1 
adipocytes having PPAR-δ agonist added to their differentiation medium.  Thus, the 
addition of a PPAR-δ agonist helped to prevent weight gain in rats fed a high fat diet 
and increased the gene expression of adipokines, including visfatin, in rats and 
cultured adipocytes.  (23)  
Yang and colleagues found that cell stress and nutrient restriction increased 
visfatin/Nampt expression.  Furthermore, visfatin/Nampt levels were 1.5-fold to 2-
fold higher than controls in human fibrosarcoma HT1080 cells exposed to serum-free 
media, livers from rats fasted for 48 hours, cardiomyocytes exposed to hypoxia, and 
cardiomyocytes exposed to serum-free media.  The researchers also found that 
visfatin/Nampt protected against genotoxic stress-induced cell death since cells 
overexpressing it were more resistant to methylmethane sulfonate, and cells with less 
of it were more sensitive to methylmethane sulfonate.  Thus, this work suggests that 




Summary: Visfatin mRNA & Gene Expression Studies 
Overall, the results of these studies suggest that no differences exist in visfatin 
mRNA expression in visceral and subcutaneous fat depots (13; 119), although this 
may not be the case in obese individuals (88), individuals with altered glucose 
tolerance (116; 119), or PCOS patients (113).  Moreover, visceral visfatin mRNA 
expression has been positively correlated with BMI (13; 88; 113; 119), percent body 
fat (13), and plasma visfatin (13), whereas subcutaneous visfatin mRNA expression 
has been negatively correlated with markers of inflammation (119) and plasma 
visfatin (13) and positively correlated with insulin sensitivity (119).  Lastly, visfatin 
mRNA expression has been found to increase during adipogenesis (67; 75) and to be 
influenced by hormones and other factors known to influence insulin sensitivity (23; 
24; 49; 67; 75; 123).  Thus, the results of visfatin mRNA studies support a connection 
to glucose and obesity-related phenotypes.  
Visfatin Polymorphism Studies 
The human visfatin protein reportedly shares over 95 % sequence homology 
with rat and mice visfatin (11).  Besides its high degree of conservation, an important 
functional role for visfatin may be inferred from the finding that visfatin gene 
homozygous knockout mice die during embryonic development (35).   
Ognjanovic and colleagues reported on the organization of the visfatin gene 
(PBEF1) and found that it had 11 exons, 10 introns, putative regulatory elements, and 
no sequence homology with any known cytokines (85).  Furthermore, its transcription 
factor binding sites were suggested to include locations for Sp1, activator protein-1 




releasing factor, cyclic adenosine monophosphate (cAMP) response element binding 
protein, nuclear factors (NF-1, NF-IL6, and NF-κB), hepatic nuclear factors, and liver 
factor-1 (85).  
PBEF1 is located on chromosome 7q22.  This chromosomal region has 
previously been reported to have linkage with the insulin response to aerobic exercise 
training in Caucasians (70), insulin resistance syndrome phenotypes in Mexican-
Americans (8), and BMI in the National Heart, Lung, and Blood Institute’s Family 
Blood Pressure Program (125).  Thus, based on its chromosomal location, the visfatin 
gene may be a candidate for glucose and obesity-related phenotypes.  
Over 52 single nucleotide polymorphisms (SNPs) have been reported in 
PBEF1, with several studies conducting genotype and haplotype association studies.  
This brief review will focus on polymorphisms and haplotypes with reported 
frequencies > 0.05.    
PBEF1 Promoter Polymorphisms 
 
-4689 G>T (rs2110385), -4191 A>G (rs1737358), & -3186 C>T (rs11977021) 
 Bailey and colleagues examined the -4689 G>T, -4191 A>G, and -3186 C>T 
polymorphisms with obesity and glucose-related phenotypes in participants from the 
Quebec Family Study.  Overall, no associations were significant at the p < 0.05 level 
for the -4689 and -4191 polymorphisms, although fat mass (p = 0.062), total apoB (p 
= 0.067), LDL apoB (p = 0.074), and LDL cholesterol (p = 0.092) neared significance 
for the -4689 polymorphism.  In contrast, total cholesterol (p = 0.03) and LDL 
cholesterol (p = 0.049) were significantly associated with the -3186 polymorphism, 




reported as 0.41, 0.42, and 0.17, respectively.  Positive features of this study include 
its large sample size (n = 136 male founders, n = 173 female founders, n = 261 male 
nonfounders, n = 348 female nonfounders) and outcome measurements.  In addition, 
the analyses accounted for the influence of age, gender, relatedness (identity by 
descent probabilities), and mode of inheritance.  However, there was no mention of 
menopausal status for the female participants or medication usage, diet, or physical 
activity status for the entire group of participants.  Moreover, these factors could have 
influenced the obesity and glucose-related outcomes.  (11) 
 Concerning function, promoter region polymorphisms can conceivably alter 
transcription factor activity and visfatin gene expression.  Although no information 
was provided for the -4689 G>T or -4191 A>G polymorphisms, the -3186 C>T 
polymorphism is reportedly located in a nuclear hormone response element binding 
sequence (11). 
-2657 G>A 
 In single SNP analyses, Zhang and colleagues found that the -2657 G>A 
polymorphism was not significantly associated with T2D.  Their study compared 2 
different sets of T2D patients [n = 479 (cardiovascular complications of diabetes 
study) and n = 335 (randomly selected Joslin Clinic patients)] with non-diabetic 
controls (n = 320; unrelated non-diabetic spouses or parents of T1D patients), all 
recruited from the Boston, MA area by the Joslin Clinic.  Unfortunately, no subject 
characteristic data pertaining to co-morbidities, medication usage, diet, physical 
activity status, or female menopausal status was provided.  Furthermore, all of the 




determined to be haplotype-tagging.  The minor allele frequency was reported as 
0.06.  (132)  
-2423 A>G (rs7789066) 
Bailey and colleagues also examined the -2423 variant in the Quebec Family 
Study and found that it was significantly associated with HDL triglycerides (p = 
0.032) and very low density lipoprotein (VLDL) apoB (p = 0.032) using a dominance 
parameter.  Moreover, VLDL apoB remained significant in an additive model (p = 
0.012), whereas HDL triglycerides and VLDL triglycerides neared significance (both 
p < 0.07).  The minor allele frequency was reported as 0.08.  (11)    
Zhang and colleagues also examined the rs7789066 variant (labeling it -2422 
A>G) as a haplotype tagging SNP and found no association with T2D in their case-
control study involving patients from the Boston Joslin Diabetes Center (132).  The 
minor allele frequency was reported as 0.09 (132). 
With regard to function, this polymorphism is reportedly located within a 
nuclear factor of activated-T cells (NFAT) binding sequence (11).  Thus, a possible 
functional effect could occur via NFAT’s postulated involvement in adipogenesis 
(50) and insulin gene transcription (71).   
-1543 C>T (also known as -1535 C>T) 
 Ye and colleagues conducted a case-control SNP association study in white 
patients with sepsis-associated acute lung injury and severe sepsis.  The frequency of 
the T allele was significantly lower in the acute lung injury group (n = 8; 20 %) as 
compared to the healthy control subjects (n = 8; 31 %).  However, only a weak 




injury after controlling for age, gender, and co-morbidities in multiple logistic 
regression analysis.  Furthermore, the researchers reported a ~ 1.8-fold decrease in 
luciferase reporter gene expression in human lung microvascular endothelial cells 
with the T allele as compared to the C allele.  Unfortunately, no subject 
characteristics were provided in the paper besides disease status and race.  Thus, 
group comparability is impossible to ascertain.  It is interesting that significant and 
nearly significant findings were detected with such small sample sizes, and the 
reduction in transcription does suggest a potential functional effect for this variant.  It 
is also important to note that the polymorphism designated by Ye and colleagues as -
1543 is actually located 1535 basepairs upstream of the PBEF1 ATG site.  (129)  
 Bajwa and colleagues investigated the -1543 polymorphism in 375 acute 
respiratory distress syndrome patients and 787 at-risk controls.  They found that the 
polymorphism did not increase the risk of acute respiratory distress syndrome, but 
that it was associated with a reduced risk of acute respiratory distress syndrome in 
septic shock patients.  In the acute respiratory distress syndrome patients, the -1543 T 
allele was also associated with better mortality and ventilation outcomes.  (12) 
 Jian and colleagues examined the PBEF -1535 C>T SNP and glucose and 
obesity-related variables in NGT (19 men, 42 women), IGT (26 men, 39 women), and 
newly diagnosed T2D (66 men, 49 women) patients in China.  The -1535 C>T SNP 
was not associated with T2D, fasting glucose, 120 minute OGTT glucose, glucose 
AUC, total cholesterol, triglycerides, HDL-cholesterol, or LDL-cholesterol.  
Moreover, the T allele frequency was reported as 0.53 in the NGT participants.  




participants were > 40 years of age and were taking no lipid- or glucose-altering 
medications.  However, cigarette smoking status, female menopausal status, diet, and 
physical activity status were not reported; moreover, all of these factors could have 
affected measurement of the outcome variables.  (55)  
 Axelsson and colleagues investigated the polymorphism in stage 5 chronic 
kidney disease patients (n = 135) and reported no differences in visfatin levels.  The 
minor allele frequency was ~ 0.258.  In addition, the researchers reported that the 
polymorphism was in linkage disequilibrium with the -1001 and -423 variants (both r2 
= 0.11).  (9)  
Tokunaga and colleagues studied the -1535 SNP in healthy, non-diabetic (191 
men, 142 women) and T2D (245 men, 203 women) Japanese individuals.   They 
reported that it was the only promoter polymorphism detected in their cohort.  In the 
case-control portion of their study, the frequency of the C allele did not differ 
between the non-diabetic and T2D groups (0.44 vs. 0.45).  In genetic association 
studies involving the non-diabetic participants, there were no differences reported for 
BMI, fasting glucose, fasting insulin, or HOMA-IR by -1535 genotype group.  
However, the -1535 polymorphism was associated with triglyceride and HDL-
cholesterol levels.  Moreover, the TT group had lower triglycerides and higher HDL-
cholesterol levels than the CC group.  In the group with T2D, there were no 
significant genotype effects found for the lipid measures, and there was no mention of 
the glucose and insulin-related variables.  The researchers also conducted a reporter 




activity for the C versus T promoters, in contrast to the Ye et al. study (129) 
involving human lung microvascular endothelial cells.  (115) 
It is important to note that menopausal status, hormone therapy usage, diet, 
and physical activity status were not accounted for in the study by Tokunaga and 
colleagues.  Furthermore, these factors could have influenced many of the outcome 
variables.  In addition, the age and gender make-up of the genotype groups was not 
reported, and one-way ANOVA was used to compare differences in the genotype 
groups.  Thus, adjustment for the possible influence of age and gender on the 
outcome variables did not take place.  (115)  
-1001 T>G (rs9770242) 
  Bailey and colleagues reported that the -1001 T>G polymorphism was 
associated with glucose and insulin phenotypes in the Quebec Family Study 
population (11).  Moreover, the G allele was associated with lower fasting insulin and 
glucose levels and occurred at a frequency of 0.26 (11). 
Bottcher and colleagues studied the -1001 polymorphism in Germans and 
found that it was not associated with T2D in a case-control study.  Moreover, in 626 
non-diabetics, the polymorphism was also not associated with body composition or 
glucose-related variables.  It was also not associated with plasma visfatin, 
subcutaneous fat visfatin mRNA expression, and visceral fat mRNA expression in a 
subgroup of abdominal surgery patients.  However, the -1001 polymorphism was 
associated with a lower ratio of visceral to subcutaneous visfatin mRNA expression in 
the surgery patients.  The case-control study involved 503 T2D patients (250 men, 




for age, gender, and BMI differences between the groups.  The subgroup of non-
diabetics consisted of 308 men and 318 women.  However, no information regarding 
overall characteristics, diet, physical activity status, medication usage, or female 
menopausal status was provided.  Thus, these factors may have affected the outcome 
variables.  Last, the subgroup of 189 individuals (95 men, 94 women) with abdominal 
tissue samples were undergoing surgery for weight loss, explorative laparotomy, or 
abdominal injury repair.  In addition, these individuals varied in terms of age, BMI, 
and insulin sensitivity.  Although analyses accounted for age, gender, and body 
composition differences, no information regarding other co-morbidities, diet, physical 
activity status, medication usage, or female menopausal status was provided.  
Moreover, these factors could have influenced measurement of visfatin levels.  Last, 
the G allele frequency was reported as 0.31.  (16)  
Axelsson and colleagues found significant -1001 genotype effects for visfatin 
levels in stage 5 chronic kidney disease patients, but after adjusting for age, sex, 
glomerular filtration rate, and serum albumin the visfatin differences in the stage 5 
chronic kidney disease patients were no longer significant.  However, the -1001 
polymorphism was found to be a significant predictor of visfatin levels in stage 5 
chronic kidney disease patients in multivariate regression models, accounting for 4 % 
of the variation.  The minor allele frequency was ~ 0.25.  (9)    
Korner and colleagues examined the -1001 polymorphism in connection with 
obesity and insulin resistance in children.  The researchers studied 167 (89 boys, 78 
girls) obese and 508 (243 boys, 265 girls) healthy German children.  In the healthy 




GT heterozygotes and G homozygotes after adjustment for age and gender.  However, 
pubertal status was not taken into account in the single SNP analyses.  Diet and 
physical activity levels also were not assessed in the study, and these factors could 
also have influenced many of the metabolic outcomes.  The frequency of the G allele 
was 0.25 in the school children.  (64)   
Last, in case-control studies, the G allele was associated with increased odds 
of acute respiratory distress syndrome (12), acute lung injury (129), and sepsis (129).     
With regard to functional significance, a luciferase reporter gene assay found 
that the -1001 G allele did not significantly alter PBEF gene expression in lung 
microvascular endothelial cells (129).  However, the -1001 polymorphism is in 
complete linkage disequilibrium with rs1319501, another PBEF1 promoter SNP.  
Thus, it has been suggested that the functional variant may actually be rs1319501 
(11).  Furthermore, since the -1001 polymorphism is reportedly in moderate linkage 
disequilibrium (r2 = 0.47) and proximity (53 basepairs) with the -948 polymorphism, 
the 2 may be acting as a functional SNP’s marker (132).   Bottcher and colleagues 
also reported moderate linkage disequilibrium for the -1001 polymorphism with the 
rs4730153 (r2 = 0.53) and rs11553095 (r2 = 0.52) polymorphisms (16).  Finally, 
Axelsson and colleagues reported that the polymorphism was in linkage 
disequilibrium with the -1535 polymorphism (r2 = 0.11), too (9). 
-948 G>T (also known as C>A) 
In case-control studies, Zhang and colleagues found that the -948 T allele was 
significantly associated with T2D (132), whereas Bottcher and colleagues did not find 




reported as 0.12 (132) and 0.19 (16), respectively.  A possible difference between 
these studies involves subject characteristics.  For example, in the Zhang et al. study, 
the non-diabetic cases and T2D controls were of similar age (61 ± 15 yrs versus 63 ± 
7 yrs) and from the Boston, MA area, whereas the non-diabetic controls and T2D 
cases in the Bottcher et al. study varied in terms of age (47 ± 0.7 yrs versus 59 ± 0.4 
yrs) and were German. 
Zhang and colleagues also conducted a study in 630 healthy Italians and 
reported a significant association for the -948 T allele with higher plasma CRP and 
fibrinogen levels, suggesting a possible connection with low-grade inflammation.  
However, no associations were detected with fasting glucose or insulin levels.  
Moreover, the researchers suggested that the healthy, young, lean participants in the 
study were likely not ideal subjects for studies of insulin resistance.  Although the 
participants were not taking medication, the researchers did not provide information 
regarding diet or physical activity status, and differences in these 2 factors could have 
influenced the outcome variables.  The T allele frequency was ~ 0.13.  (132)  
In contrast, the -948 G>T polymorphism was associated with fasting insulin, 
total apoB, and LDL apoB in the Quebec Family Study’s French-Canadian population 
(11), and the G allele was associated with increased diastolic blood pressure in obese 
children (64).  Furthermore, non-diabetic German PBEF1 -948 T allele carriers had 
significantly lower OGTT 2-hour plasma glucose and fasting insulin levels than GG 
homozygotes, and TT homozygotes tended to have a lower percent body fat (p = 
0.06) and higher clamp glucose infusion rate (p = 0.09) than G allele carriers (16).   




because of subject differences.  Last, in 189 Caucasians undergoing abdominal 
surgery, a lower ratio of visceral to subcutaneous visfatin mRNA expression was 
found for the -948 T allele (16).  The frequency of the T allele was reported as 0.14 
(11; 64) and 0.19 (16) in these studies, respectively. 
The -948 G>T polymorphism is located in the promoter region of PBEF1 and 
may influence gene expression via altering transcription factor activity.  
Alternatively, the -948 G>T polymorphism may be in linkage disequilibrium with a 
functional SNP.  Bottcher and colleagues reported moderate linkage disequilibrium 
values for the -948 G>T polymorphism and -1001 T>G (D’ = 0.99, r2 = 0.51) and -
423 A>G (D’ = 0.99, r2 = 0.53) polymorphisms (16).  In addition, Zhang and 
colleagues reported moderate linkage disequilibrium for the SNP with -1001 T>G (r2 
= 0.47), rs6971643 (r2 = 0.42) and rs17314507 (r2 = 0.69) (132).   
-423 A>G (rs1319501) 
 Bailey and colleagues found significant associations for the -423 A>G 
polymorphism and fasting glucose and fasting insulin levels in the Quebec Family 
Study participants.  Moreover, GG homozygotes had lower fasting glucose and 
insulin values.  In addition, the variant showed complete linkage disequilibrium with 
the -1001 T>G polymorphism.  The frequency of the G allele was 0.26.  (11)  
 Axelsson and colleagues also reported that this polymorphism was in 
complete linkage disequilibrium with the -1001 polymorphism.  Moreover, they 
found significant -423 genotype effects on visfatin levels until adjustment for age, 
gender, glomerular filtration rate, and serum albumin level in stage 5 chronic kidney 




 Rs1319501 is located within a nuclear hormone response element recognized 
by the nuclear receptor family that includes peroxisome proliferator-activated 
receptors and the vitamin D receptor (11; 39).     
PBEF1 Intronic & Exonic Polymorphisms 
rs1319313, rs6947766, rs3801268, & rs3801272 
 Zhang and colleagues examined the rs1319313 (position 2807, G>A), 
rs6947766 (position 14664, C>T), rs3801268 (position 26700, G>C), and rs3801272 
(position 28803, G>A) polymorphisms individually and as part of a haplotype 
analysis in a case-control study involving T2D patients.  There were no associations 
with T2D for any of the individual polymorphisms.  Moreover, the minor allele 
frequencies were 0.27, 0.24, 0.42, and 0.35, respectively.   The polymorphism 
locations were reported as intron 1 for rs1319313, intron 4 for rs6947766, intron 8 for 
rs3801268, and intron 8 for rs3801272.  (132)  
rs10953502 & rs2058539 
Jian and colleagues examined the rs10953502 (T>C) and rs2058539 (A>C) 
SNPs in connection with glucose and lipid variables in NGT, IGT, and T2D Chinese 
individuals.  Individuals homozygous for the rs10953502 C allele had higher fasting 
plasma glucose, OGTT 2-hour glucose, and glucose AUC values than individuals 
homozygous for the T allele.  The researchers also found that individuals 
homozygous for the rs2058539 A allele had higher fasting glucose and glucose AUC 
values than rs2058539 CC homozygotes.  All of the significant findings were 
adjusted for participant age, gender, and glucose tolerance status.  In addition, all 




medications.  However, cigarette smoking status, female menopausal status, diet, and 
physical activity status were not reported; moreover, all of these factors could have 
affected measurement of the outcome variables.  The rs10953502 C allele frequency 
was ~ 0.20 in the NGT participants, and the rs2058539 C allele frequency was ~ 0.39.  
The polymorphisms are reportedly located in intron 1 and intron 9, respectively.  (55)  
rs4730153 
The A allele of the rs4730153 (c. 744 -87 G>A) polymorphism was associated 
with a lower ratio of visceral to subcutaneous visfatin mRNA expression in Germans 
and had a frequency of 0.48 (16).  This intron 6 SNP also had strong linkage 
disequilibrium with rs11553095 (r2 = 0.80) and moderate linkage disequilibrium with 
the -423 A>G (r2 = 0.5) and -1001 T>G (r2 = 0.53) polymorphisms (16).   
rs2302559 
 This polymorphism (C>T) is located in exon 7 of the visfatin gene and results 
in a synonymous amino acid change at position 301 (SER301SER).  It has not been 
examined previously in association studies, but has a reported minor allele frequency 
of ~ 0.41 (132).   
PBEF1 Haplotypes 
 Results from 4 PBEF1 haplotype association studies have been published.  
Moreover, 2 studies investigated haplotypes derived from the rs9770242 (-1001), -
948, and rs4730153 polymorphisms (16; 64), 1 study looked at haplotypes created 
from the -2647, rs7789066, -948, rs1319313, rs6947766, rs3801268, and rs3801271 
polymorphisms (132), and 1 study examined haplotypes constructed from the 




Bottcher and colleagues examined haplotypes derived from the -1001 T>G 
polymorphism, -948 G>T polymorphism, and rs4730153 G>A polymorphism.  The 
researchers examined 4 commonly occurring haplotypes in their study population of 
non-diabetic Germans (n = 626), the TGG, TGA, GGA, and GTA haplotypes.  
Furthermore, carriers of the TGA haplotype had higher 2-hour OGTT glucose levels 
and higher glucose infusion rates during euglycemic, hyperinsulinemic clamps than 
haplotype non-carriers.   The researchers also found that non-carriers of the GTA 
haplotype had higher fasting plasma insulin levels and higher 2-hour glucose levels 
than individuals with 1 or 2 copies of the GTA haplotype.  Interestingly, the GTA 
haplotype was the only commonly occurring haplotype containing the -948 T allele, 
and similar results were found in this same study for single SNP analyses involving 
the -948 polymorphism.  (16)  
Korner and colleagues also examined haplotypes from the -1001 T>G 
polymorphism, -948 G>T polymorphism, and rs4730153 G>A polymorphism.  They 
studied 2 different cohorts of children, obese children and school children, and found 
no haplotype associations with BMI, WHR, glucose, insulin, or lipid measures.  
However, the TGA haplotype was associated with increased diastolic blood pressure 
in both the school children and obese children.  (64)  
Zhang and colleagues examined 8 common PBEF1 haplotypes, tagged by 7 
SNPs, in a case-control study involving T2D patients.  The 7 SNPs were the -2657 
G>A, rs7789066 A>G, -948 G>T, rs1319313 G>A, rs6947766 C>T, rs3801268 G>C, 
and rs3801271 T>C.  The GATACGT haplotype, the only commonly occurring 




= 2.365, p = 0.018), whereas the GAGACGT haplotype was associated with a 
decreased risk of T2D (Haploscore = -2.61, p = 0.009).  (132)  
Finally, Ye and colleagues examined haplotypes composed of the -1001 T>G 
and -1543 C>T polymorphisms in a case-control study involving patients with sepsis-
associated acute lung injury and severe sepsis.  They found that the GC haplotype 
significantly increased the risk of acute lung injury 7.7-fold and the risk of sepsis 4.8-
fold.  The researchers also found that the TT haplotype was protective, reducing the 
risk of acute lung injury 0.8-fold; however, this reduction in risk was not significant.  
There were no differences in risk found for the GT or TC haplotypes.  (129)  
 
Summary: Visfatin Polymorphism & Haplotype Studies 
Tables 6-2 and 6-3 summarize the results from association studies involving 
PBEF1 polymorphisms.  Taken together, the results of genetic association studies 
suggest a possible role for visfatin gene polymorphisms and haplotypes in glucose 





















Table 6-2. Results from PBEF1 intronic and exonic polymorphism 
studies. 











Fasting plasma glucose 
Glucose area under the curve 
AA ↑ 




Not independently with type 2 
diabetes  (132)  




(16)  Rs4730153 Intron 6 
c.744 
-87 G>A 




Not independently with type 2 




Not independently with type 2 




Fasting plasma glucose 
OGTT 120 minute glucose 





Genotype associations are significant unless indicated otherwise.  Log, 
common logarithm; vis, visceral fat; subcut, subcutaneous fat; mRNA, 





Table 6-3. Results from PBEF1 promoter polymorphism studies. 
SNP Genotype Associations Other Source 
Rs2110385 
-4689 G>T Fat mass, total apoB (p < 0.07)  (11) 
Rs1737358 
-4191 A>G No glucose or obesity-related traits  (11) 
Rs11977021 
-3186 C>T Total cholesterol, LDL-cholesterol  (11)  
-2657 G>A Not independently with type 2 diabetes  (132)  
VLDL apoB 
VLDL triglycerides (p = 0.067; 0.069) 
HDL triglycerides ( p = 0.061; 0.032) 
Additive; 
dominant (11)  Rs7789066 -2423 A>G 
Not independently with type 2 diabetes  (132)  
Acute lung injury (p = 0.059) 
Luciferase reporter/promoter activity 
T ↓ risk 
T ↓ (129)  
Acute respiratory distress syndrome T ↓ risk (12)  
No glucose or lipid-related traits  (55)  




-1535 C>T Not with glucose, insulin, or BMI 
HDL-cholesterol 
Triglycerides 






Fasting glucose, fasting insulin GG ↓ (11)  
Acute lung injury, sepsis 
Luciferase reporter/promoter activity 
G ↑ risk 
= (129)  
Log vis/subcut visfatin mRNA 
No glucose or obesity-related traits 
Not with visfatin levels 
G ↓ (16)  
Not with visfatin levels in CKD  (9)  




Acute respiratory distress syndrome G ↑ risk (12)  
Fasting insulin, total apoB, LDL apoB  (11)  
Fasting insulin, 2-hour OGTT glucose 
Log vis/subcut visfatin mRNA 





Type 2 diabetes 
C-reactive protein, fibrinogen levels 
A ↑ risk 




Diastolic blood pressure G carrier ↑ (64)  
Fasting glucose, fasting insulin GG ↓ (11)  Rs1319501 
-423 A>G Not with visfatin levels  (9)  
Genotype associations are significant unless indicated otherwise.  Apo, 
apolipoprotein; OGTT, oral glucose tolerance test; log, logarithm; vis, visceral 
fat; subcut, subcutaneous fat; mRNA, messenger RNA; CKD, chronic kidney 




Visfatin & Exercise 
Many beneficial physiological changes occur with aerobic exercise training, 
including improvements in glucose tolerance and insulin sensitivity.  Furthermore, 
adipokines such as adiponectin are responsive to exercise training.  However, the 




 Only 1 study, thus far, has examined visfatin’s response to acute exercise in 
humans.  Frydelund-Larsen and colleagues studied visfatin mRNA expression in 15 
healthy men, approximately 25 yrs of age, with a BMI of ~ 25 kg/m2.  The 15 men 
were divided into an exercise group (n = 8) and a control group (n = 7).  The exercise 
group cycled on a cycle ergometer for 3 hours at 60 % of their maximal oxygen 
consumption (VO2max) and then underwent 6 hours of recovery.  In contrast, the 
control group rested for 9 hours.  Muscle and adipose tissue biopsies were taken 
immediately before exercise (0 hour), immediately after the exercise bout (3 hours), 
and during the recovery period (4.5 hours, 6 hours, 9 hours, 24 hours) in the 
exercisers, with similarly timed biopsies taken in the control subjects.  Venous blood 
samples were drawn at time points 0, 1, 2, 3, 4.5, 6, 9, and 24 hours, respectively.  
The researchers found that as compared to the control participants and as compared to 
baseline, abdominal adipose tissue visfatin mRNA expression increased 3-fold in 
response to exercise, with significant increases at the 3, 4.5, and 6 hour time points.  
However, skeletal muscle visfatin mRNA expression and plasma visfatin levels did 




Aerobic Exercise Training 
 
Only 3 studies, thus far, have examined visfatin’s response to aerobic exercise 
training in humans.  Haider and colleagues examined the effects of aerobic exercise 
training on plasma visfatin levels in 18 (11 women and 7 men, 42 ± 10 yrs of age) 
T1D patients.  The participants were compared to healthy, non-exercising controls (7 
women and 7 men, 29 ± 5 yrs of age).  The exercise training program consisted of 4 
months of stationary cycling for 1 hour, at an intensity of 60-70 % of heart rate 
reserve.  For the initial 2 weeks of the program, exercise sessions took place twice a 
week, and then for the remainder of the program exercise sessions were held 3 times 
per week.  At baseline, the T1D patients had greater fasting plasma glucose and 
visfatin levels than the controls.  Moreover, there was no correlation between visfatin 
and BMI or age at baseline.  After both 2 and 4 months of exercise training, visfatin 
levels decreased significantly in the T1D patients (from 64.1 ± 12 ng/mL to 27.8 ± 
2.6 ng/mL and 17.5 ± 3.4 ng/mL, respectively) and remained lower 8 months after the 
cessation of exercise training.  However, BMI, fasting glucose, glycosylated 
hemoglobin, and lipoprotein-lipids were unchanged with the exercise training.  In 
addition, the researchers did not measure VO2max or a similar training effect 
variable, and to be included in the study, participants only had to attend > 60 % of the 
exercise sessions.  Thus, it is difficult to determine if an actual aerobic exercise 
training effect occurred.  Furthermore, some of the patients were receiving 
medications for co-morbidities, including hypertension and cholesterol medication, 




assess diet, and differences in diet could potentially influence the outcome measures.  
(43)  
Choi and colleagues evaluated the effect of a combined aerobic and resistance 
exercise training program on plasma visfatin levels in non-diabetic Korean women.  
Healthy, overweight or obese women (n = 48) aged 30-55 yrs were recruited for the 
study.  The participants had to be sedentary (< 20 minutes of exercise twice per week) 
and underwent a graded exercise test to screen for cardiovascular disease.  In 
addition, to be eligible for the study, participants could not be taking laboratory test 
result-altering medications.  The 12 week exercise training intervention consisted of 
approximately 45 minutes of aerobic exercise and 20 minutes of resistance exercise, 5 
times per week.  The intensity of the aerobic exercise started at 40 % of age-predicted 
maximal heart rate and progressed to 60-75 % of age-predicted maximal heart rate by 
week 12.  All but 2 of the women were premenopausal, and 36 of the women were 
obese.  At baseline, the obese women had higher plasma visfatin levels than the 
overweight women.  Plasma visfatin levels were associated with body weight, BMI, 
and waist circumference in simple regression analyses and BMI in multiple 
regression analyses.  After 12 weeks of exercise training, the participants had lost ~ 4-
5 kg of weight, decreased BMI, waist circumference, blood pressure, percent body 
fat, fasting glucose, HOMA-IR, and visfatin levels.  Thus, a combined aerobic and 
resistance exercise training program and weight loss significantly decreased plasma 
visfatin levels in healthy, overweight or obese Korean women.  (25) 
Although, Choi and colleagues did not measure VO2max or a similar training 




the other variables measured may be consistent with a training effect.  However, diet 
was not assessed in the study and part of the weight loss was likely due to dietary 
changes since the caloric cost of the exercise training was estimated by the 
researchers as ~ 400 kcal per session.  In addition, there is no indication that the 
training changes were adjusted for age within the obese and overweight groups or for 
age and obesity status within the combined group.  Moreover, a graph showing 
visfatin changes with aerobic exercise training depicts a high degree of variability.  
Furthermore, data from several subjects appears to have been excluded as outliers.  
Also, it appears that participants in the overweight group may not have changed their 
visfatin levels with exercise training, but raw data is only provided for the total group.  
Thus, it is difficult to assess whether changes in visfatin levels occurred in non-obese 
individuals with exercise training and whether the exercise training or weight loss 
caused the reported differences.  (25)  
Finally, Brema and colleagues compared plasma visfatin levels in 15-30 yr old 
Caucasian age- and BMI-matched obese and T2D patients before and after the 
completion of an aerobic exercise training intervention.  The training program lasted 
12 weeks and consisted of 4 supervised sessions per week at an intensity of 75 % 
VO2max and a duration of 1 hour.  Dietary intake reportedly remained unchanged 
during the program, as did nearly every physiological variable measured, with the 
exception of waist circumference in the T2D group and VO2max in the obese group.  
Furthermore, visfatin levels were comparable in the obese and T2D patients before 
the intervention and decreased in both groups with training, with a greater decrease 




percent body fat (r = -0.933) and HDL-cholesterol (r = -0.893) at baseline.  As 
VO2max did not change in the T2D patients and most outcomes did not change with 
the program, it is difficult to assess if a training effect occurred.  Furthermore, there 
was no indication made as to whether the participants were sedentary before the 
program started.  In addition, gender was not accounted for and differences between 
the groups could have affected many of the outcome variables.  (17)  
Summary: Visfatin & Exercise   
Thus, acute exercise seems to increase visfatin mRNA expression but not 
visfatin plasma levels in healthy, young men.  In contrast, plasma visfatin levels seem 
to be responsive to exercise training.  However, no research has been reported 
regarding the independent effects of 6 months of aerobic exercise training on plasma 
visfatin levels in NGT and IGT individuals.  In addition, previous studies in T1D 
patients and non-diabetic Korean women have not controlled for the effects of diet, 
and all 3 previous studies have not provided evidence that an actual training effect 
occurred.  Thus, studies taking these factors into account would help to further 
elucidate the effects of aerobic exercise training on plasma visfatin levels. 
Aerobic Exercise Training Responses & Their Genetic Link 
Coincidentally, the response of many variables to aerobic exercise training 
tends to be highly variable.  In fact, part of the variation in the response of glucose 
and obesity-related phenotypes to aerobic exercise training has been attributed to 
common genetic polymorphisms (93).  With its links to glucose and obesity-related 
phenotypes, its polymorphisms associated with glucose and obesity-related 















Appendix A: Delimitations & Limitations 
  Delimitations 
1. Subjects in this study took part in the Gene Exercise Research Study (GERS) 
at the University of Maryland, College Park, MD. 
2. As members of the GERS, the subjects were recruited from the University of 
Maryland and Washington D.C. metropolitan areas. 
3. As participants of the GERS, the subjects had to meet specific study inclusion 
criteria.  Briefly, the participants had to be 50-75 yrs of age, non-smoking, 
non-diabetic, sedentary, healthy (with the exception of having a National 
Cholesterol Education Program lipid abnormality and/or elevated blood 
pressure), not taking medications known to affect glucose levels, 
postmenopausal (if female), and have a BMI < 37 kg/m2.  The results, 
therefore, are most applicable to populations with similar characteristics. 
Limitations 
1. The participants were recruited as part of the GERS and may not be 
representative of the general population. 
2. The GERS participants self-reported many initial health and lifestyle factors 
such as physical activity habits, dietary habits, and medication regimens.  
Thus, it is possible that inaccurate self-reports may affect the results of the 
proposed study. 




4. The frequencies of genotypes were not controlled, so rare allele carriers were 
grouped together in the analyses when sample sizes were inadequate. 
5. Due to a lack of available data and differences in allele and genotype 
frequencies between ethnic groups, only data from GERS Caucasian 
participants was examined in this project. 
6. Due to the lack of existing data, some of the hypotheses were not directional 
in nature. 
7. This study involved a retrospective analysis of data and used banked plasma 




Appendix B: Definitions 
Adipokine – A substance (hormone, cytokine, etc.) produced by adipose 
tissue. 
Allele – An alternative form of a gene. 
Diabetes mellitus – A group of diseases resulting from defects in insulin 
action and/or insulin secretion which affect the maintenance of appropriate glycemia. 
Genotype – The genetic make-up of an individual. 
Glucose – A monosaccharide containing six-carbon atoms that is used as a 
major energy substrate in the body. 
Haplotype – A set of closely linked genetic markers present on 1 
chromosome that tend to be inherited together. 
Impaired fasting glucose – An intermediate stage in the pathogenesis of type 
2 diabetes where glucose levels are above normal but below the diagnostic level for 
diabetes.  In this case, the plasma glucose level is 100-125 mg/dL (5.6-6.9 mmol).  
Impaired glucose tolerance – An intermediate stage in the pathogenesis of 
type 2 diabetes where glucose levels are above normal but below the diagnostic level 
for diabetes.  In this case, plasma glucose concentration is 140-199 mg/dL (7.8-11.0 
mmol) after a 2-hour, 75-gram oral glucose tolerance test. 
Insulin – A hormone secreted by the islets of Langerhans involved in the 
control of blood glucose levels by promoting the uptake and storage of glucose in the 
body.  
Insulin resistance – A condition in which the body has a reduced 




Linkage disequilibrium – The nonrandom association of 2 or more alleles; 
the occurrence of alleles at 2 or more loci more frequently than expected.   
Nicotinamide adenine dinucleotide – A coenzyme that functions as a carrier 
of hydrogen atoms in oxidation-reduction reactions. 
Nicotinamide – A form of nicotinic acid (vitamin B3). 
Obesity – Excess body fat; often defined as body mass index ≥ 30 kg/m2.   
Oral glucose tolerance test – A diagnostic assessment measuring the ability 
of the body to maintain euglycemia in response to a glycemic challenge. 
Polymorphism – A base or section of DNA that is variable among 
individuals.  
Promoter – A nucleotide sequence in DNA to which transcription factors and 
RNA polymerase bind to initiate transcription. 
Sedentary – A term used to describe individuals who are not physically 
active.  In this project, individuals who, on average, complete less than 20 minutes of 
aerobic exercise less than twice per week.  
Single nucleotide polymorphism – DNA sequence variation involving the 
substitution of 1 purine or pyrimidine base (A, T, G, or C) by another purine or 
pyrimidine base (A, T, G, or C).  
TaqMan – A high through-put method for genotyping single nucleotide 
polymorphisms. 
Transcription – A process where the genetic information in 1 strand of DNA 
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